Cancer Drug Discovery and Development Series Editor: Beverly A. Teicher
For further volumes: http://www.springer.com/series/7625
Rebecca G. Bagley Editor
The Tumor Microenvironment
Editor Rebecca G. Bagley Genzyme Corporation Framingham MA, USA
[email protected]
ISBN 978-1-4419-6614-8 e-ISBN 978-1-4419-6615-5 DOI 10.1007/978-1-4419-6615-5 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010934382 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer soft-ware, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pericytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bystanders to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer regulators was the recognition that lymphocytes can participate in what was termed “immune surveillance” in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies showing the potential use of immune-based therapies in cancer treatment. The role of tumor infiltrating lymphocytes is nicely discussed here in the chapter by Fu and Yu, with a special emphasis on the potential prognostic implications of the presence of these cells at a tumor site. Natural killer cells, first shown to be involved in tumor surveillance by Herlyn in the 1980s, also have multiple effects on tumors as discussed in the chapter by Arai. Additional immune and inflammatory cells are also discussed. These include macrophages, which have effects on both tumor cells and blood vessels, and mast cells, which have a potent and somewhat underappreciated effect on tumor growth that is clarified in the chapter by Angelidou and Zhang. A picture emerges of the tumor as a city filled with diverse cellular inhabitants who operate in the role of a “zoning board” in telling the tumor how fast it can expand and into what spaces it can grow. An extremely important regulator of tumor growth and metastasis is the tumor vasculature. Again, tumors were known to be filled with functional blood vessels for many decades before Judah Folkman explained how they might influence tumor v
vi
Preface
growth. His theory of tumor angiogenesis predicted that anti-angiogenic agents might be developed to combat cancer and this prediction has been borne out. In many cases, the predominant signal for angiogenesis is tissue hypoxia and a very strong section of this book deals with the effects of hypoxia on the tumor and on the vascular components of the tumor. The potential translational aspects of this field is just emerging and a compelling discussion of the novel therapies that target the hypoxia induced transcription factor, HIF-1-alpha can be found in the book’s opening chapter by Rapisarda and Melillo. Along with the immune cells, inflammatory cells, and vascular cells, the tumor surrounds stromal cells including fibroblasts and other mesenchymal cells. The interplay between stromal cells and tumor cells is an extremely vibrant area of study and is nicely discussed in the chapter by Orimo. Of course, a principal function of these cells is to produce and remodel the elements of the extracellular matrix as described in the contribution by DeClerck. These proteins can present a barrier to tumor invasion and metastasis. Excellent and comprehensive discussions of the role of collagens and of fibronectin as well as their binding partners the integrins and tetraspanins can be found in the section on the extracellular matrix. The modulation of the matrix by cancer cells is discussed in detail in the chapter on matrix metalloproteases and cancer cell invasion by Zucker and Cao. The interplay of tumor cells and the microenvironment is mirrored in the complex interactions of tumor cells, fibroblasts, matrix elements, and the various cells that produce either matrix metalloproteases or their natural inhibitors. No contemporary discussion of the role of the tumor microenvironment could be complete without an in-depth examination of the existence and potential role of stem cells in the establishment of human tumors and in their metastatic dissemination. This is a relatively new field and comes with the attendant controversies that often characterize new areas of investigation. This can make for very exciting reading, as it does in the chapters on cancer stem cells by Giordano, on endothelial cell precursors by Shaked and on mesenchymal stem cells by Banerjee. It is safe to say that the exact contribution of all of these progenitor, precursor and stem cell populations to cancer is an emerging and truly important field of inquiry. These chapters beautifully capture the scientific foment that characterizes the study of these cells and their role in cancer. Perhaps, the most exciting aspect of the increased attention paid to the tumor microenvironment is the promise that new approaches to cancer therapy can be derived from our paying attention to these non-tumor elements and to their interactions with the tumor cells. This is beautifully captured throughout this book. One senses an emerging optimism that the tumor microenvironment is not only important, but that it represents a treasure trove of potential therapeutic opportunities such as the ones described in the chapter on secreted growth factors as therapeutic targets by Teicher. Whether one starts out as a skeptic, or as a devotee, this excellent and comprehensive compilation will educate the reader and stimulate new ideas about tumors as an integrated combination of cellular, secreted, stromal, and matrix elements that each represents a potential therapeutic target. Boston, MA
Bruce Zetter
Contents
Part I: Physiological Parameters 1 Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy.................................................... Annamaria Rapisarda and Giovanni Melillo
3
2 The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases.............................. Pawel Swietach, Adrian L. Harris, and Richard D. Vaughan-Jones
23
3 Hypoxia, Gene Expression, and Metastasis........................................... Olga V. Razorenova and Amato J. Giaccia 4 Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX..................... Jaromir Pastorek and Silvia Pastorekova 5 Glycolytic Pathway as a Target for Tumor Inhibition.......................... Weiqin Lu and Peng Huang
43
59 91
Part II: Malignant Cells 6 Aberrant DNA Methylation in Cancer Cells......................................... Toshikazu Ushijima
121
7 DNA Repair and Redox Signaling.......................................................... Mark R. Kelley, Millie M. Georgiadis, and Melissa L. Fishel
133
8 Cancer Stem Cells and Microenvironment............................................ Mario Federico and Antonio Giordano
169
9 Epithelial–Mesenchymal Transition in Development and Diseases...................................................................... Yadi Wu and Binhua P. Zhou
187 vii
viii
Contents
10 Invasion and Metastasis......................................................................... Douglas M. Noonan, Giuseppina Pennesi, and Adriana Albini 11 Dormancy of Disseminated Tumor Cells: Reciprocal Crosstalk with the Microenvironment.................................................. Paloma Bragado, Aparna C. Ranganathan, and Julio A. Aguirre-Ghiso
213
229
Part III: Vasculature and Stroma 12 Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy.................................... Robert S. Kerbel, Francesco Bertolini, and Yuval Shaked 13 Bone Marrow Derived Mesenchymal Stem/Stromal Cells and Tumor Growth....................................................................... Pravin J. Mishra and Debabrata Banerjee 14 Integrin Signaling in Lymphangiogenesis............................................ Barbara Garmy-Susini 15 Role of Pericytes in Resistance to Antiangiogenic Therapy................................................................................................... Koji Matsuo, Chunhua Lu, Mian M.K. Shazad, Robert L. Coleman, and Anil K. Sood 16 Tumour-Promoting Stromal Myofibroblasts in Human Carcinomas........................................................................... Urszula M. Polanska, Kieran T. Mellody, and Akira Orimo
257
275 289
311
325
Part IV: Immune-Mediated Cells 17 Mast Cells and Tumor Microenvironment.......................................... Theoharis C. Theoharides, Konstantinos-Dionysios Alysandratos, Asimenia Angelidou, and Bodi Zhang
353
18 Macrophages in the Tumor Microenvironment.................................. Monica Escorcio-Correia and Thorsten Hagemann
371
19 The Prognostic Significance of Tumor-Infiltrating Lymphocytes........................................................................................... Ping Yu and Yang-Xin Fu
385
Contents
20 The Pro-inflammatory Milieu and Its Role in Malignant Epithelial Initiation................................................................................ Adam Yagui-Beltrán, Qizhi Tang, and David M. Jablons 21 Natural Killer Cells for Adoptive Immunotherapy............................ Jonathan E. Benjamin and Sally Arai
ix
409 431
Part V: Extracellular Matrix 22 Fibronectin.............................................................................................. Andreas Menrad
457
23 Collagen in Cancer................................................................................. Janelle L. Lauer and Gregg B. Fields
477
24 Integrins and Cancer............................................................................. Laurie G. Hudson and M. Sharon Stack
509
25 Matrix Metalloproteinases and Cancer Cell Invasion/Metastasis................................................................................ Stanley Zucker and Jian Cao 26 Tetraspanins and Cancer Metastasis.................................................... Margot Zöller
531 555
Part VI: Secreted Proteins 27 Chemokines and Metastasis.................................................................. Kalyan C. Nannuru, Seema Singh, and Rakesh K. Singh
601
28 Transforming Growth Factor-b in Lung Cancer, Carcinogenesis, and Metastasis............................................................ Sonia B. Jakowlew
633
29 Cooperative Interactions Between Integrins and Growth Factor Signaling in Pathological Angiogenesis.................................... Jennifer Roth, Eric Tweedie, and Peter C. Brooks
673
30 The Extracellular Matrix and the Growth and Survival of Tumors......................................................................... Yves A. DeClerck
695
x
Contents
31 Secreted Growth Factors as Therapeutic Targets............................... Beverly A. Teicher
711
32 Adrenomedullin...................................................................................... Rebecca G. Bagley
733
Index................................................................................................................
749
Contributors
Julio A. Aguirre-Ghiso Division of Hematology and Oncology, Departments of Medicine and Department of Otolaryngology, Tisch Cancer Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA Adriana Albini IRCCS Multimedica, Via Fantoli 16/15, 20138 Milano, Italy Konstantinos-Dionysios Alysandratos, MD Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Asimenia Angelidou, MD Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Sally Arai, MD Division of Blood and Marrow Transplantation, Stanford School of Medicine, 300 Pasteur Drive, H3249 MC 5623, Stanford, CA 94305, USA, Rebecca G. Bagley Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA Debabrata Banerjee Department of Medicine and Pharmacology, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA Jonathan E. Benjamin Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
xi
xii
Contributors
Francesco Bertolini, MD/PhD Department of Hematology-Oncology, European Institute of Oncology, Milan, Italy Paloma Bragado, PhD Division of Hematology and Oncology, Department of Medicine and Department of Otolaryngology, Mount Sinai School of Medicine – NYU, New York, NY 10029, USA Peter C. Brooks Maine Medical Center Research Institute, Center for Molecular Medicine, 81 Research Drive, Scarborough, ME, USA Jian Cao, PhD Stony Brook University, Room 004, Life Sciences Building, Stony Brook, NY 11794-5200, USA Robert L. Coleman, MD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, University of Texas, Houston, TX, USA Yves A. DeClerck Departments of Pediatrics and Biochemistry and Molecular Biology, University of Southern California and The Saban Research Institute of Childrens Hospital Los Angeles, Los Angeles, CA 20027, USA Monica Escorcio-Correia, PhD Barts and The London School of Medicine and Dentistry, Institute of Cancer, Charterhouse Square, London, UK EC1M 6BQ Mario Federico, MD Sbarro Health Research Organization, Temple University, BioLife Science Building, Suite 333, 1900 N. 12th Street, Philadelphia, PA 19122, USA; Section of Clinical Oncology, University of Palermo, Palermo, Italy Gregg B. Fields Department of Biochemistry, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA Melissa L. Fishel, PhD Herman B. Wells Center for Pediatric Research, Indiana University, 980 W. Walnut Street, Indianapolis, IN 46202, USA
Contributors
Yang-Xin Fu, MD/PhD Department of Pathology and Section of Dermatology/ Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 3083, Chicago, IL 60637, USA Barbara Garmy-Susini Unité mixte Inserm U858, Institut de Médecine Moléculaire de Rangueil, IFR 150, 1, Avenue Jean Poulhès, BP 84225 31432, Toulouse Cedex 4, France Millie M. Georgiadis, PhD Herman B. Wells Center for Pediatric Research, Indiana University, 980 W. Walnut Street, Indianapolis, IN 46202, USA Amato J. Giaccia Division of Radiation and Cancer Biology, Stanford University, Stanford, CA 94305, USA Antonio Giordano Biology Department, Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA Thorsten Hagemann Barts and The London School of Medicine and Dentistry, Institute of Cancer, Charterhouse Square, London, EC1M 6BQ, UK Adrian L. Harris Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK Peng Huang Department of Molecular Pathology, The University of Texas MD, Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Laurie G. Hudson, PhD University of New Mexico College of Pharmacy, Albuquerque, NM, USA David Jablons, MD Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA Sonia B. Jakowlew National Cancer Institute, Center for Cancer Training, Cancer Training Branch, Bethesda, MD 20892, USA
xiii
xiv
Contributors
Mark R. Kelley Department of Pediatrics, Section of Hematology/Oncology, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN 46202, USA Robert S. Kerbel, PhD Department of Cellular and Molecular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada Janelle L. Lauer, PhD The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA Chunhua Lu, MD/PhD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Weiqin Lu, PhD MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Koji Matsuo, MD Department of Gynecologic Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Giovanni Melillo SAIC-Frederick, Inc., DTP-Tumor Hypoxia Laboratory, Developmental Therapeutics Program, National Cancer Institute – Frederick, Building 432, Room 218, Frederick, MD 21702, USA Kieran T. Mellody, BSc./MPhil Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, England M20 4BX Andreas Menrad Antibody Therapeutics Genzyme Europe Research, 310 Cambridge Science Park, Milton Road, Cambridge, CB4 OWG, UK Pravin J. Mishra, MS Department of Medicine, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 195 Little Albany St, New Brunswick, NJ 08901, USA Kalyan C. Nannuru, PhD Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA
Contributors
xv
Douglas M. Noonan, PhD Universita degli Studi dell’Insubria, Varese, Italy Akira Orimo CR-UK Stromal-Tumour Interaction Group, Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, M20 4BX, UK Jaromir Pastorek Centre of Molecular Medicine, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic Silvia Pastorekova Centre of Molecular Medicine, Slovak Academy of Sciences, Dubravask cesta 9, Bratislava 845 05, Slovak Republic Giuseppina Pennesi, MD IRCCS Multimedica, Via Fantoli 16/15, 20138 Milano, Italy Urszula M. Polanska, Msc/PhD Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Manchester, England M20 4BX Aparna C. Ranganathan, PhD Division of Hematology and Oncology, Department of Medicine and Department of Otolaryngology, Mount Sinai School of Medicine – NYU, New York, NY 10029, USA Annamaria Rapisarda, PhD SAIC-Frederick, Inc., DTP-Tumor Hypoxia Laboratory, Developmental Therapeutics Program, National Cancer Institute – Frederick, Building 432, Room 218, Frederick, MD 21702, USA Olga V. Razorenova, PhD Division of Radiation and Cancer Biology, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305, USA Jennifer M. Roth, MS Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA Yuval Shaked Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
xvi
Contributors
M. Sharon Stack University of Missouri School of Medicine, M214C Medical Sciences Building, 1 Hospital Drive, Columbia, MO 65212, USA Mian M. K. Shazad, MS/MD Department of Gynecologic Oncology, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA Rakesh K. Singh Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA Seema Singh, PhD Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA Anil K. Sood Department of Gynecologic Oncology, Cancer Biology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA Center for RNA Interference and Non-Coding RNA, University of Texas, Houston, TX, USA Pawel Swietach, DPhil Deparment of Physiology, Anatomy & Genetics, Oxford University, Oxford OX1 3PT, UK Qizi Tang, PhD Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA Beverly A. Teicher Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA
[email protected] Theoharis C. Theoharides Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Eric Tweedie, BS Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA
Contributors
xvii
Toshikazu Ushijima National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan Richard D. Vaughan-Jones, PhD Deparment of Physiology, Anatomy & Genetics, Oxford University, Oxford OX1 3PT, UK Yadi Wu, PhD Department of Molecular and Biomedical Pharmacology, Markey Cancer Center and University of Kentucky School of Medicine, BBSRB room B336, 741 South Limestone, Lexington, KY 40506-0509, USA Adam Yagui-Beltrán Department of Surgery, Division of Adult Thoracic Surgery, The Helen Diller Family Comprehensive Cancer Center Thoracic Surgery, University of California San Francisco, 1600 Divisadero, Room A-743, San Francisco, CA 94143-1724, USA Ping Yu The Committee on Immunology and Department of Pathology and Section of Dermatology/Department of Medicine, University of Chicago, 5841 S. Maryland Ave, Chicago, IL 60637, USA Bruce Zettler, PhD Childrens’s Hospital, Boston Harvarel Medical School, 300 Lougwood Ave., Boston, MA 02115, USA Bodi Zhang, MD/MPH Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111, USA Binhua P. Zhou Markey Cancer Center, University of Kentucky School of Medicine, Lexington, KY, USA and Department of Molecular and Cellular Biochemistry, University of Kentucky School of Medicine, Lexington, KY, USA
xviii
Margot Zöller Department of Tumor Cell Biology, University Hospital of Surgery, Im Neuenheimer Feld 365, D-69120, Heidelberg, Germany and Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg, Germany and Department of Applied Genetics, University of Karlsruhe, Karlsruhe, Germany Stanley Zucker Veterans Affairs Medical Center, Northport, NY 11768, USA and Stony Brook University, Stony Brook, NY 11794, USA
Contributors
Part I
Physiological Parameters
Chapter 1
Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy Annamaria Rapisarda and Giovanni Melillo
Abstract Solid tumors often present regions of decreased oxygen levels (hypoxia) due to an imbalance between increased oxygen consumption and insufficient oxygen delivery from the aberrant tumor vasculature. Intratumor hypoxia is associated with altered cellular metabolism, an invasive and metastatic phenotype, as well as resistance to radiation and chemotherapy. The discovery of Hypoxia Inducible Factor-1 (HIF-1), a transcription factor critically involved in cellular responses to hypoxia and tumor progression, has provided evidence of a potential molecular target of intratumor hypoxia that could be exploited for the development of novel cancer therapeutics. A growing number of small molecule inhibitors of HIF-1, which act by distinct molecular mechanisms, have been described so far. However, HIF-1 expression in human cancers is focal and heterogeneous, consistent with the possibility that single agent HIF-1 inhibitors may have limited clinical activity. It is then plausible that combination strategies aimed at maximizing the clinical potential of HIF-1 inhibition may be more effective. We will discuss current approaches used for targeting HIF-1, emphasizing in particular opportunities for rationally designed combination strategies aimed at exploiting vulnerable features of the tumor microenvironment.
Introduction Whereas each tumor type reflects a heterogeneous collection of genetic and epigenetic alterations, hypoxia represents a unifying characteristic of human tumors, being a widely represented feature of the tumor microenvironment. Intratumor hypoxia not only affects cells that are located far from a functional blood vessel but also originates from an imbalance between increased oxygen consumption of rapidly G. Melillo (*) DTP-Tumor Hypoxia Laboratory, Bldg. 432, Room 218, SAIC – Frederick, Inc., NCI at Frederick, Frederick, MD 21702, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_1, © Springer Science+Business Media, LLC 2010
3
4
A. Rapisarda and G. Melillo
growing tumor cells and inadequate oxygen supply from a structurally and functionally abnormal tumor vasculature. The fluctuation of oxygen levels in the tumor microenvironment results in the induction of an array of responses in tumor cells, such as inactivation of apoptotic pathways and activation of pro-survival pathways, induction of a more invasive and metastatic phenotype, switch to a glycolytic metabolism and induction of angiogenesis, responses aimed at providing adaptation to, or escape from, the hypoxic microenvironment. Clinically, hypoxia is associated with resistance to standard treatment, including chemotherapy and radiation therapy, and is predictive of metastasis and poor outcome in a variety of tumor types (Hockel and Vaupel 2001; Brown and Giaccia 1998; Brizel et al. 1996; Semenza 2007). Hypoxia controls the expression of hundreds of genes, many of which are regulated by Hypoxia Inducible Factor-1 (HIF-1), a master regulator of the transcriptional response to oxygen deprivation (Semenza 2007; Manalo et al. 2005). HIF-1 is a heterodimeric protein comprised of a constitutively expressed HIF-1b (also known as aryl hydrocarbon receptor nuclear translocator, ARNT) subunit and a HIF-a subunit, which is regulated by oxygen concentrations (Wang et al. 1995; Wang and Semenza 1995). Under normoxic onditions, HIF-a is rapidly hydroxylated on two proline residues by oxygen-dependent prolyl hydroxylases (PHDs) and targeted for ubiquitylation and proteasomal degradation in a VHL-dependent fashion. In addition, HIF-1a can be hydroxylated on an asparagine residue (Asn803) by Factor Inhibiting HIF-1 (FIH), hence inhibiting the recruitment of the co-activator p300/CBP and transcriptional activity. In contrast, under hypoxic conditions the HIF-a subunit is stabilized and translocates to the nucleus where it dimerizes with HIF-1b and, by binding to hypoxia responsive elements (HREs), activates transcription of hundreds of target genes involved in key steps of tumorigenesis, including angiogenesis, metabolism, proliferation, metastasis, and differentiation (Semenza 2008) (Fig. 1.1). Overwhelming evidence indicates that HIF-a (HIF-1a and/or HIF2a) is indeed over-expressed in the majority of human cancers (Zhong et al. 1999; Talks et al. 2000; Bos et al. 2001), where it is associated with patient mortality and poor response to treatment (Table 1.1) (Aebersold et al. 2001; Birner et al. 2000, 2001b; Bos et al. 2003; Koukourakis et al. 2006). Notably, increased HIF-1a expression is associated with a variety of genetic alterations frequently detected in human cancers, including loss of function of tumor suppressor genes, such as VHL, PTEN, and CDKN2A (which encodes ARF) or oncogenic gain of function, such as RAS, SRC, and BCR-ABL (Semenza 2003). In addition, the involvement of receptor tyrosine kinase-dependent signaling pathways, including EGFR, HER2/Neu, and the PI3K/AKT/mTOR and MAPK pathways, in the induction of HIF-1a expression also suggests that many of these pathways converge on or implicate HIF-1 in mediating cell survival and growth (Pouyssegur et al. 2006; Majumder et al. 2004; Pore et al. 2006; Hudson et al. 2002). Therefore, HIF-1 has become an attractive target for the development of novel cancer therapeutics and despite the challenges associated with the discovery and development of small molecule inhibitors of transcription factors, many HIF-1 inhibitors which may potentially be useful for cancer therapy have been described so far (Onnis et al. 2009; Melillo 2007; Welsh et al. 2006; Melillo 2006).
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
5
Angiogenic factors
(VEGF, FGF2, PDGF, PIGF, Tie2)
VHL binding Proteosomal degradation
Inhibition of transcriptional activity
P402 OH
Drug resistance
(Telomerase, Oct4)
(MDR1/ABCB-1, ABCG-2)
Glycolitic metabolism, pH regulation
HIF- α P564 OH HIF- α N803OH PHDs
RTKs/mTOR
(GLUT1, PDK1, PGK1, HK2, LDH-A, CA9, MCT4)
FIH
Survival, Proliferation
HIF- α
HIF-1 translation
mRNA transcription
O2 concentration
Immortalization and stem cells
β
α
Dimerization Cofactors recruitment DNA binding
(Cyclin D1, VEGF, IGF2, TGF-α)
Migration (CXCR4, SDF-1 α)
Invasion Metastasis (UPAR, Met, LOX)
Fig. 1.1 Regulation of Hypoxia Inducible factor-a (HIF-a) and HIF-1 dependent gene expression. Under normal oxygen conditions, HIF-a is continuously translated and rapidly degraded through the VHL-proteasome pathway following hydroxylation of proline residues by PHDs. Factor inhibiting HIF-1 mediates the hydroxylation of an asparagine residue, thus inhibiting the recruitment of the co-activator p300/CBP and HIF-1 transcriptional activity. All these processes are inhibited when oxygen concentration decreases, hence the HIF-a subunit is stabilized, translocates to the nucleus where it dimerizes with HIF-1b and induces the transcription of a large number of genes involved in crucial aspects of tumorigenesis. In addition, receptor tyrosine kinase-dependent signaling pathways can increase the rate of HIF-1a translation, at least in part, through the activation of mTOR
Small Molecule Inhibitors of HIF-1 The approach most widely used so far to identify HIF-1 inhibitors has been cell-based high throughput screens (HTS) using reporter gene assays (Rapisarda et al. 2002). The main advantage of cell-based HTS is the potential for the identification of unrecognized pathways associated with the activation of the target being investigated. However, determining the mechanism of action of active “hits” may be time consuming and chances to identify highly specific inhibitors is very low. Indeed, the majority of HIF-1 inhibitors described so far lack specificity, which complicates the pharmacological validation of HIF-1 inhibitors for cancer therapy, and either target signaling pathways that are involved in HIF-1 regulation or inhibit HIF-1a protein accumulation and/or transcriptional activity. Examples of agents that target signaling pathways implicated in the HIF-1a expression include
6
A. Rapisarda and G. Melillo
Table 1.1 Human cancers in which HIF-1a over-expression has been associated with patient mortality Cancer type
Reference
Astrocytoma (diffuse) Bladder (superficial urothelial)a Bladder (transitional cells) Breast Breast (c-Erb2 positive) Breast (positive linfonode) Breast (negative linfonode) Cervix (early stage) Cervix (radiation therapy) Cervix (grade IB-IIIB, radiation therapy) Endometrial Gastric Gastrointestinal stromal tumor (stomach) Lung (nonsmall cell lung carcinoma) Melanoma (malignant)b Oligodendrioglioma Oropharynx-squamous cell carcinoma Ovariana Pancreas
Korkolopoulou et al. (2004) Theodoropoulos et al. (2004) Theodoropoulos et al. (2005) Vleugel et al. (2005) and Dales et al. (2005) Giatromanolaki et al. (2007) Schindl et al. (2002) Bos et al. (2003) Birner et al. (2000) Burri et al. (2003) Bachtiary et al. (2003) Sivridis et al. (2002) Griffiths et al. (2007) Takahashi et al. (2003) Swinson et al. (2004) Giatromanolaki et al. (2003) Birner et al. (2001a) Aebersold et al. (2001) Birner et al. (2001b) Sun et al. (2007)
Combination of HIF-1a over-expression and mutant p53 HIF-2a over-expression
a
b
inhibitors of mTOR (Majumder et al. 2004; Hudson et al. 2002), AKT (Tan et al. 2005), Her2/Neu (Laughner et al. 2001), EGFR (Pore et al. 2006; Koukourakis et al. 2003; Zhong et al. 2000), and Bcr-Abl (Mayerhofer et al. 2002) (Fig. 1.2). Since HIF-1a accumulation is controlled primarily at the level of protein translation or protein degradation, many of the HIF-1 inhibitors identified thus far do indeed decrease HIF-1a protein levels by a number of distinct molecular mechanisms. HIF-1 inhibitors that affect protein translation, although by mechanisms not always clearly elucidated, include topoisomerase I (topotecan and EZN-2208, a pegylated form of SN38) (Rapisarda et al. 2004a, b; Sapra et al. 2008) and topoisomerase II inhibitors (NSC644221) (Creighton-Gutteridge et al. 2007), microtubule stabilizing (taxanes and epothilones) and destabilizing agents (Mabjeesh et al. 2003; Escuin et al. 2005), cardiac glycosides (Zhang et al. 2008), PX-478, which also increases HIF-1a degradation (Koh et al. 2008) and farnesyltransferase inhibitors (Han et al. 2005). Agents that appear to affect primarily HIF-1a degradation include inhibitors of the chaperon protein Hsp90 (17-AAG, 17-DMAG) (Isaacs et al. 2002; Mabjeesh et al. 2002), and HDAC inhibitors (vorinostat, LAQ824, FK228) (Ellis et al. 2009), which may also block HIF-1a transcriptional activity (Kong et al. 2006), and YC-1, which activates soluble guanylate cyclase (sGC) (Kim et al. 2006a). Another mechanism by which HIF-1 may be inhibited is at the level of transactivation. In addition to chetomin (Kung et al. 2004), which
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
HIF-1 β
α
Co-factors Recruitment Transcriptional activity DNA binding
NSC50352
7 Chetomin Bortezomib Vorinostat Amphotericin
HIF-1-dependent gene expression
Echinomycin Polyamides Doxorubicin
Dimerization
HIF-1 β 17AAG,17DMAG YC-1, SCH66336 NS398, ibuprofen celecoxib
HIF-1 α
RTKs/mTOR
Translation Degradation
Temsirolimus Everolimus Gefitinib Erlotinib Cetuximab Herceptin
TPT,SN38 NSC644221, Digoxin Candidaspongiolide PX478, 2ME2
Proteasome HIF-1 α mRNA
HIF-1 α antisense RNA Aminoflavone
Fig. 1.2 Signaling pathways targeted by small molecule inhibitors of HIF-1
was originally identified as a small molecule that interferes with the interaction between HIF-1a C-TAD and p300/CBP, inhibition of the proteasome (bortezomib, Velcade®) has also been associated with blockade of HIF-1 transcriptional activity, despite the paradoxical increase of HIF-1a protein, although the exact mechanism of action remains to be fully elucidated (Shin et al. 2008; Kaluz et al. 2008). Finally, modulation of HIF-1a mRNA levels using antisense oligonucleotides (EZN-2968) (Greenberger et al. 2008) or the AhR ligand aminoflavone (Terzuoli et al. submitted) also leads to inhibition of HIF-1 expression. However, in order to identify HIF-1 small molecule inhibitors with a higher degree of selectivity, efforts are ongoing to target protein–protein interaction, a challenging yet potentially highly rewarding strategy, in an attempt to interfere with HIF-a/HIF-1b dimerization (Yang et al. 2005; Park et al. 2006; Scheuermann et al. 2009). In addition, examples of HIF-1 inhibitors that affect HIF-1 DNA binding to the HRE have been provided, including synthetic polyamides (Olenyuk et al. 2004), echinomycin (Kong et al. 2005), and anthracyclines (Lee et al. 2009), which represent a conceptually attractive strategy to inhibit HIF-1. Many of the HIF-1 inhibitors described above are either FDA approved or are in early clinical development (Table 1.2). Results of ongoing clinical trials of HIF-1 inhibitors in patients with cancer will provide information regarding both inhibition of HIF-1 and potential clinical activity of this emerging therapeutic approach.
8
A. Rapisarda and G. Melillo
Table 1.2 HIF-1 inhibitors FDA approved or in clinical development with potential mechanism of action Agent
Target
Mechanism
Reference
EZN-2968 Aminoflavone
HIF-1a mRNA AhR
Greenberger et al. (2008) Terzuoli, submitted
Topotecan EZN-2208 PX-478 Erlotinib, gefitinib, cetuximab Trastuzumab Temsirolimus, everolimus 17AAG, 17DMAG
Topoisomerase 1 Topoisomerase 1 unknown EGFR
Degradation HIF-1a mRNA processing Translation Translation Translation Signaling
Her2/Neu mTOR
Translation Translation
HSP90
Degradation
Doxorubicin Bortezomib
DNA Proteasome
Vorinostat, LAQ824, FK228
HDAC
DNA binding Transcriptional activity Degradation, transcriptional activity
Rapisarda et al. (2004b) Sapra et al. (2008) Welsh et al. (2004) Pore et al. (2006) and Luwor et al. (2005) Koukourakis et al. (2003) Del et al. (2006) and Wan et al. (2006) Isaacs et al. (2002) and Mabjeesh et al. (2002) Lee et al. (2009) Kaluz et al. (2006) Kong et al. (2006), Mie et al. (2003), and Qian et al. (2006)
Targeting HIF-1: Single Agent or Combination? The potential therapeutic benefit of HIF-1 inhibition has been extensively documented in preclinical models using both genetic and pharmacological tools, and consistent inhibition of tumor growth and angiogenesis has been demonstrated in different tumor types (Semenza 2003; Melillo 2006). However, the lack of selective HIF-1 inhibitors and reliable biomarkers associated with HIF-1 inhibition in tumor tissue, associated with the hardly predictive nature of results obtained in xenograft models, have significantly hampered the validation of HIF-1 as a target in human cancers. For instance, it is still largely unclear whether tumor regression should be an expected, although desirable, outcome of single agent HIF-1 inhibition. Evidence has been provided that HIF-1 inhibition might be most effective when used in early, rather than late, stages of tumor progression (Li et al. 2005), a situation rarely encountered in clinical oncology practice, where the majority of patients present with metastatic disease. In addition, even conceptually, inhibition of HIF-1 expressing cells, as a single agent strategy, may not be particularly effective for a number of reasons, including the focal and heterogeneous expression of HIF-1a in solid tumors, the reliance of cancer cells on HIF-1-independent pathways in oxygenated areas of the tumor, and the overall well-established redundancy of oncogenic signaling pathways that may be hardly affected by single agent strategies. In addition, the broad involvement of HIF-1 in a number of biological pathways that are
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
9
relevant for tumorigenesis provides unique opportunities for combination therapies that may take advantage of the different approaches available in the current therapeutic armamentarium. A better understanding of the role that HIF-1 plays in the biology of human cancers and in the context of available therapeutic strategies will provide valuable information for the design of rational combinations that may target vulnerable aspects of the tumor microenvironment.
Molecularly Targeted Agents and HIF-1 Inhibition Combination strategies aimed at targeting multiple and redundant signaling pathways that contribute to oncogenesis are a mainstay of current therapeutic efforts in oncology for the potential to both prevent the emergence of resistant clones and translate in a better therapeutic outcome. Indeed, combinations of molecularly targeted agents, with or without chemotherapy, are currently being tested in virtually any tumor type with the goal of assessing safety of administration and potential therapeutic efficacy. As mentioned above, several novel targeted agents currently in clinical development or FDA approved also inhibit HIF-1, raising the possibility that combination strategies incorporating these agents may already provide examples in which inhibition of HIF-1 may potentially contribute to the therapeutic efficacy. Experimental evidence in support of this conclusion has been provided by combination of the mTOR inhibitor rapamycin with the HDAC inhibitor LBH589, which showed increased antitumor activity in prostate and renal cell cancer xenografts models (Verheul et al. 2008). Interestingly, the concomitant inhibition of HDACs and mTOR resulted in a greater inhibition of HIF-1a protein levels relative to what was achieved by each agent alone, possibly due to the activity of these inhibitors at different levels of HIF-1a regulation including translation, protein stability, and transcriptional activity. In addition, experiments conducted in colon cancer xenograft models using low doses of rapamycin in combination with the camptothecin analog irinotecan (a topoisomerase I inhibitor) showed a marked increase in antitumor activity associated with a profound inhibition of HIF-1a protein accumulation that was not observed with either agent alone (Pencreach et al. 2009). Interestingly, previous studies in a human glioma xenograft model had suggested that daily, but not intermittent, administration of single agent topotecan, a topoisomerase I HIF-1 inhibitor, downregulated HIF-1a expression in tumor tissue and caused inhibition of tumor growth and angiogenesis (Rapisarda et al. 2004c). These examples emphasize how HIF-1 inhibition may be an underappreciated therapeutic consequence of molecularly targeted agents currently in clinical development. A better understanding of the potential contribution of HIF-1 inhibition to therapeutic activity of these combinations may help in selecting patients more likely to respond and in designing optimal schedules of administration to maximize inhibition of HIF-1-dependent responses.
10
A. Rapisarda and G. Melillo
Hypoxic Cells Are More Resistant to Chemotherapy and Radiation Therapy It has long been recognized that hypoxic cells are more resistant to conventional therapeutic approaches, including chemotherapy and radiation therapy. Likewise, it is well appreciated that resistant hypoxic cells may contribute to treatment failure and poor prognosis of patients whose cancers are more hypoxic. Resistance to radiotherapy and chemotherapy in hypoxic tumors has been attributed to a multitude of mechanisms, including direct effects (decreased generation of oxygendependent radical formation or decreased drug accessibility to the more distant hypoxic cells) and indirect effects (clonal selection of cells adapted to hypoxia) (Brown and Giaccia 1998; Vaupel et al. 2001). Hypoxia exerts selective pressure on cells for loss of p53, regulates the transcription of several genes pivotal for the selection of a resistant phenotype, such as multidrug resistance gene 1 (MDR-1) and ABCG-2 and ABCB-1 (ABC transporters), induces expression of VEGF and other pro-angiogenic factors (important for the survival of endothelial cells following radiation), downregulates genes involved in DNA mismatch repair (MSH2, MSH6, NSB1, and BRCA1) leading to increased genomic instability (Huang 2008), and finally induces genes important for survival of cancer cells (Bertout et al. 2008; Huang 2008). Many of the effects described above are mediated by HIF-1; therefore, it is conceivable that inhibition of HIF-1 may contribute in a number of ways to combination therapies by counteracting mechanisms that are activated in the tumor microenvironment to generate resistance and by sensitizing cancer cells to available therapeutic strategies.
Combination of HIF-1 Inhibitors with Chemotherapy The potential contribution of HIF-1a to cellular resistance to chemotherapy has been suggested by evidence in both experimental models and the clinical setting. Initial clinical observations indicated that high levels of HIF-1a expression were associated with incomplete responses to radiation and chemotherapy in patients with head and neck squamous cancers (Aebersold et al. 2001; Koukourakis et al. 2003). Formal evidence that HIF-1a may be implicated in mediating resistance to conventional chemotherapeutic agents was provided by studies showing that MDR-1, one of the most widely expressed efflux pumps that mediate resistance to chemotherapy, is a direct HIF-1 target gene (Comerford et al. 2002). In addition, it was shown that HIF-1a deficient mouse embryonic fibroblasts were more sensitive to carboplatin, etoposide (a topoisomerase II inhibitor), and irradiation (agents that cause double-strand DNA breaks) but not to the topoisomerase 1 inhibitor SN38 (that generates single-strand DNA breaks) (Unruh et al. 2003), suggesting that HIF-1-mediated resistance to chemotherapy cannot simply be explained by upregulation of MDR-1. Resistance to etoposide, a
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
11
topoisomerase II inhibitor, also appears to correlate with HIF-1-dependent induction of anti-apoptotic genes and downregulation of topoisomerase IIa (Sermeus et al. 2008; Sullivan and Graham 2009). The potential synergistic activity of HIF-1 inhibition in combination with chemotherapy has been formally tested in a glioma xenograft model in which HIF-1a expression was downregulated by an inducible shRNA system (Li et al. 2006). Earlier evidence had indicated that HIF-1a downregulation by shRNA effectively inhibited tumor growth, although the effect was more pronounced in early rather than late stages of tumor progression (Li et al. 2005). The combination of the cytotoxic drug temozolomide with HIF-1a knockdown exhibited a super-additive therapeutic effect compared with either approach alone, demonstrating that HIF-1 inhibition impacted on sensitivity to chemotherapy (Li et al. 2006). However, the same authors showed no benefit of a combination between HIF-1 inhibition and the angiogenesis inhibitor ABT-869 (a multitargeted receptor tyrosine kinase inhibitor). It is interesting to note that following treatment with ABT-869, large tumors that are less likely to be responsive to HIF-1a inhibition became sensitive to HIF-1a knockdown, suggesting that anti-angiogenic treatment might partially alleviate the “resistance” of large tumors to HIF-1a knockdown and sensitize tumors to HIF-1 inhibition. Further studies in preclinical models, ultimately with validation in clinical trials, are required to fully explore the potential of HIF-1 inhibition to modulate cellular sensitivity to chemotherapeutic agents and to block stress pathways induced by chemotherapy in the tumor microenvironment. Combination of HIF-1 Inhibitors with Radiation Therapy Hypoxia is an important factor contributing to tumor radioresistance, a phenomenon initially explained by the reduced generation of oxygen radicals in hypoxic tissues and consequent decrease in radiation-induced DNA damage (Moeller et al. 2007). In reality, more complex biological pathways are implicated in the effects of radiation therapy on hypoxic tumors. Clinical studies have suggested that high levels of HIF-1a expression correlate with poor local control in patients with oropharyngeal cancers (Aebersold et al. 2001) and evidence from preclinical studies has indicated that HIF-1 deficient tumors are more radiosensitive than their wild-type counterpart (Zhang et al. 2004; Moeller et al. 2005; Williams et al. 2005). Moreover, it has been shown that radiation increases HIF-1a levels and induces the expression of HIF-1-dependent genes in tumors (Moeller et al. 2004), consistent with the possibility that HIF-1 activation may be part of compensatory pathways that might mediate resistance to radiation therapy. However, further studies have shown that HIF-1 may have divergent effects on radiosensitivity. On the one hand, HIF-1 might be involved in the induction of apoptosis by increasing p53 phosphorylation following radiation treatment, thus sensitizing cancer cells to radiation (Moeller et al. 2005). On the other side, it is well appreciated that the tumor vasculature is an important target of radiation therapy and a major determinant of response
12
A. Rapisarda and G. Melillo
(Garcia-Barros et al. 2003), thus the induction of angiogenic factors, including VEGF, by HIF-1 may actually protect endothelial cells from radiation-induced apoptosis (Gupta et al. 2002). Indeed, combination of the HIF-1 inhibitor YC-1 with radiation blocked radiation induced HIF-1 upregulation and resulted in significant vascular destruction, suggesting that combining HIF-1 blockade with radiation may increase antitumor efficacy (Moeller et al. 2004). In addition, the HIF-1 inhibitor PX-478 increased therapeutic efficacy of radiation by blocking HIF-1-dependent effects on the tumor microenvironment in addition to a direct effect on tumor cell survival (Schwartz et al. 2009). Finally, recent evidence also suggests that HIF-2a inhibition sensitizes renal cancer cells to radiation therapy by increasing p53 activity and inducing apoptosis (Bertout et al. 2009). Given the complexity of the role that HIF signaling may play in the response of tumor tissue to radiation therapy, careful consideration should be given to the identification of tumor types and features of the tumor microenvironment that may predict for or be associated with a positive interaction between radiation therapy and HIF-1 inhibition.
Intratumor Hypoxia as a Potential Mechanism of Resistance to Anti-angiogenic Therapies The excitement associated with the introduction of anti-angiogenic agents for cancer therapy has been partially blunted by the limited single agent activity of this therapeutic strategy and by the development of resistance, a phenomenon originally unanticipated for an approach targeted to “normal,” genetically stable endothelial cells. While anti-angiogenic therapies have shown clinical benefit in combination with chemotherapy in metastatic colorectal cancer, advanced nonsmall cell lung cancer, and metastatic breast cancer (Ferrara 2005; Shojaei and Ferrara 2007; Ellis and Hicklin 2008), the single agent activity has been well below expectations and has been demonstrated only in few tumor types, including in renal cell carcinoma and more recently gliomas. More importantly, clinical benefit has only been transient and most tumors eventually become resistant and relapse. In addition to “intrinsic” resistance in patients who do not respond to anti-angiogenic agents, several mechanisms of “acquired” resistance have been proposed, including upregulation of alternative pro-angiogenic signals, production of pro-angiogenic factors by stromal cells, recruitment of bone marrow derived pro-angiogenic cells, increased pericyte coverage of the vasculature, and activation of invasive phenotypes (Rapisarda and Mellilo 2009). Interestingly, many of the responses implicated in resistance to anti-angiogenic therapy may be mediated by the products of genes induced by HIF-1. The consequences of effective anti-angiogenic therapy on the tumor microenvironment are still poorly understood and partly controversial, which limits our ability to develop rational combination therapies. On the one hand, “normalization” of tumor vasculature has been proposed, with consequent decrease in interstitial pressure and
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
13
better delivery of chemotherapy (Jain 2005); on the other hand, vascular “regression” has been demonstrated in several experimental models and appears to be a logical consequence of effective inhibition of tumor vasculature (Kerbel and Folkman 2002). The latter scenario is associated with an increase in intratumor hypoxia, which not only might be mechanistically involved in mediating resistance to anti-angiogenic therapies but also might provide unique opportunities for combination strategies (Paez-Ribes et al. 2009; Loges et al. 2009). Indeed, while expression of HIF-1a in solid tumors is focal and heterogeneous, detected predominantly in perinecrotic areas, “therapy-induced” hypoxia, which may be associated with the administration of antiangiogenic therapies, will lead to a more persistent and protracted expression of HIF-1a. Higher levels of HIF-1 in the tumor microenvironment may not only contribute to drug resistance in general, but also provide a mechanism of “escape” for tumor cells overcoming the potential therapeutic effects of anti-angiogenic agents. Thus, it is conceivable that combination of anti-angiogenic therapy with HIF-1 inhibition may have synergistic therapeutic activity by targeting HIF-1 in the context of a “hypoxic stressed” tumor microenvironment. Combination of Anti-angiogenic Therapies and HIF-1 Inhibitors To test the hypothesis that anti-angiogenic therapies may be more efficacious in combination with HIF-1 inhibition, we combined topotecan, a topoisomerase I inhibitor that downregulates HIF-1a protein in vitro and in vivo (Rapisarda et al. 2004b, c), with the anti-VEGF antibody bevacizumab in a glioma xenograft model. Indeed, we found that inhibition of HIF-1a by topotecan in a hypoxic stressed tumor microenvironment resulted in a more pronounced antitumor effect, relative to either agent alone. The effects on tumor growth were associated with significantly decreased HIF-1 transcriptional activity and reduced tumor cell proliferation (Rapisarda et al. 2009), consistent with the hypothesis that targeting HIF-1a activity may abrogate compensatory pathways required for cancer cell survival. Moreover, recent studies showed that genetic disruption of both HIF-1a and HIF-2a expression in colon cancer xenografts improves tumor response to sunitinib (a multitargeted receptor tyrosine kinase inhibitor) (Burkitt et al. 2009). This effect was mediated by a marked decrease in tumor angiogenesis and perfusion, through inhibition of multiple pro-angiogenic factors, as well as a marked decrease in tumor cells proliferation. To further support the role that HIF-1 inhibition might play in combination with anti-angiogenic therapies, it is interesting to point out that the combination of bevacizumab and irinotecan (another topoisomerase I inhibitor that also inhibits HIF-1) has shown clinical benefit in glioblastoma patients with a six-month overall survival of 62–77% (Vredenburgh et al. 2007; Chen et al. 2007). Further studies are required to better define the patient population that may benefit from these combination approaches, in particular by better understanding when and to what extent anti-angiogenic therapy is indeed associated with increased intratumor hypoxia and HIF-1a expression.
14
A. Rapisarda and G. Melillo
Cancer Cell Metabolism and the Hypoxic Tumor Microenvironment More than 80 years ago, Otto Warburg observed that cancer cells avidly take up glucose and produce lactic acid under aerobic conditions, a process subsequently referred to as the Warburg effect or aerobic glycolysis. The exact molecular mechanism(s) regulating cancer cells dependence on glycolysis remain unclear, but it is likely that a combination of effects due to oncogenic alterations and the hypoxic tumor microenvironment play a role. Many genetic alterations associated with the cancer phenotype promote glycolysis and, at the same time, suppress oxidative phosphorylation. For instance, p53 plays an important role in regulating both “aerobic” and “anaerobic” respiration, while c-Myc expression activates the transcription of several glycolytic enzymes (Kroemer and Pouyssegur 2008). The largest functional group of genes consistently upregulated by HIF-1 in a number of cell types is associated with glucose metabolism. HIF-1 increases the expression of the transporters necessary for the entry of glucose into the cell, the genes involved in the enzymatic breakdown of glucose to pyruvate and the enzymes involved in the metabolism of pyruvate. In hypoxic cells, pyruvate is converted by lactate dehydrogenase (LDH) to lactate, which is then released into the extracellular space. HIF-1 also controls cellular oxygen consumption by (a) inducing the expression of PDH kinase 1 (PDK1), which inhibits pyruvate dehydrogenase (PDH) and the conversion of pyruvate to acetyl-CoA, ultimately decreasing mitochondrial respiration (Papandreou et al. 2006; Kim et al. 2006b) and (b) reducing mitochondrial mass, by counteracting the stimulatory action of c-Myc on mitochondrial biogenesis (Zhang et al. 2007). It is conceivable then that these metabolic changes utilized by cancer cells to survive in a hypoxic, nutrient deprived tumor microenvironment might also offer therapeutic opportunities to selectively target hypoxic cells and spare normal tissues.
HIF-1 Inhibitors in Combination Strategies Targeting Tumor Metabolism Cancer cells, but not normal cells, are thought to be “addicted” to glycolysis and attempts are being pursued to explore the possibility to target glycolysis for cancer therapy. However, the activity of 2-deoxyglucose (2-DG, a competitive inhibitor of glucose), as single agent, has been limited by evidence of toxicities in clinical trials (Denko 2008). Interestingly, genetic knockdown of HIF-1a, as well as treatment with CCI-779 (an inhibitor of mTOR that decreases HIF-1 activity), sensitizes cancer cells in vitro to 2-DG (Maher et al. 2007; Wangpaichitr et al. 2008), suggesting that HIF-1 inhibitors might be used to increase the therapeutic efficacy of 2-DG. An original approach has been proposed to increase oxygen consumption in cancer cells by reversing the inhibition of mitochondrial function using either the HIF-1 inhibitor echinomycin or the PDK-1 inhibitor dichloroacetate (DCA) (Cairns et al. 2007). The pharmacological induced increase in oxygen consumption, associated
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
15
with the limited oxygen supply due to the dysfunctional tumor vasculature, made the tumors more hypoxic and sensitized cancer cells to the hypoxic cytotoxin tirapazamine. These data suggest that HIF-1 inhibitors might have a potential role in combination strategies aimed at targeting tumor metabolism or oxygen consumption.
Conclusion In the complex biology of human cancers, HIF-1 is yet another attractive target for the development of cancer therapeutics. The role of HIF-1 in human cancers has been extensively investigated and accumulating evidence implicates HIF-1 in a number of biological processes associated with resistance to therapy and tumor progression. Hence, HIF-1 inhibition appears as a logical therapeutic strategy and many small molecule inhibitors of HIF-1 have been described, several of which are validated in preclinical models. However, we have still limited understanding of when and to what extent inhibition of HIF-1 in cancer patients may be effective. Single agent studies are required to have a better appreciation of the biological consequence associated with HIF-1 inhibition in human cancers, yet the lack of selective pharmacological inhibitors of HIF-1 significantly hinders this task. On the other hand, we have learned over the last few years that targeting multiple signaling pathways deregulated in cancer cells may be a more effective therapeutic strategy. The broad involvement of HIF-1 in many biological processes associated with and required for tumor progression provides unique opportunities for the development of combination therapies. A better understanding of the role played by HIF-1 in pathways associated with the administration of chemotherapy, radiation and anti-angiogenic therapies may unveil vulnerable aspects of the tumor microenvironment that could be exploited for the rational design of combination strategies. Acknowledgments The authors would like to thank members of the Tumor Hypoxia Laboratory and Dr. R. H. Shoemaker for helpful discussion. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government. This research was supported in part by the Developmental Therapeutics Program, DCTD, of the National Cancer Institute, NIH.
References Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916.
16
A. Rapisarda and G. Melillo
Bachtiary B, Schindl M, Potter R et al (2003) Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234–2240. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967–975. Bertout JA, Majmundar AJ, Gordan JD et al (2009) HIF2{alpha} inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 106:14391–14396. Birner P, Schindl M, Obermair A et al (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60:4693–4696. Birner P, Gatterbauer B, Oberhuber G et al (2001a) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165–171. Birner P, Schindl M, Obermair A et al (2001b) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661–1668. Bos R, Zhong H, Hanrahan CF et al (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314. Bos R, van der GP, Greijer AE et al (2003) Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97:1573–1581. Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941–943. Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416. Burkitt K, Chun SY, Dang DT et al (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 8(5):1148–1156. Burri P, Djonov V, Aebersold DM et al (2003) Significant correlation of hypoxia-inducible factor1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494–501. Cairns RA, Papandreou I, Sutphin PD et al (2007) Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci USA 104:9445–9450. Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714–4721. Comerford KM, Wallace TJ, Karhausen J et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62:3387–3394. Creighton-Gutteridge M, Cardellina JH, Stephen AG et al (2007) Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 13:1010–1018. Dales JP, Garcia S, Meunier-Carpentier S et al (2005) Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 116:734–739. Del BD, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549–5554. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713. Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factortargeted therapy. Clin Cancer Res 14:6371–6375. Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145–153. Escuin D, Kline ER, Giannakakou P (2005) Both microtubule-stabilizing and microtubuledestabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65:9021–9028.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
17
Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3):11–16. Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159. Giatromanolaki A, Sivridis E, Kouskoukis C et al (2003) Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493–501. Giatromanolaki A, Koukourakis MI, Simopoulos C et al (2007) Metastatic cancer cells from c-erbB-2 negative primary breast cancer maintain the original c-erbB-2/HIF1alpha phenotype. Cancer Biol Ther 6:153–155. Greenberger LM, Horak ID, Filpula D et al (2008) A RNA antagonist of hypoxia-inducible factor1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 7:3598–3608. Griffiths EA, Pritchard SA, Valentine HR et al (2007) Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 96:95–103. Gupta VK, Jaskowiak NT, Beckett MA et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8:47–54. Han JY, Oh SH, Morgillo F et al (2005) Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 97:1272–1286. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276. Huang LE (2008) Carrot and stick: HIF-alpha engages c-Myc in hypoxic adaptation. Cell Death Differ 15:672–677. Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014. Isaacs JS, Jung YJ, Mimnaugh EG et al (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936–29944. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19:7–16. Kaluz S, Kaluzova M, Stanbridge EJ (2006) Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol 26:5895–5907. Kaluz S, Kaluzova M, Stanbridge EJ (2008) Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood 111:5258–5259. Kerbel R and Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739. Kim HL, Yeo EJ, Chun YS et al (2006a) A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol 29:255–260. Kim JW, Tchernyshyov I, Semenza GL et al (2006b) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177–185. Koh MY, Spivak-Kroizman T, Venturini S et al (2008) Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 7:90–100. Kong D, Park EJ, Stephen AG et al (2005) Echinomycin, a small-molecule inhibitor of hypoxiainducible factor-1 DNA-binding activity. Cancer Res 65:9047–9055. Kong X, Lin Z, Liang D et al (2006) Histone deacetylase inhibitors induce VHL and ubiquitinindependent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26:2019–2028. Koukourakis MI, Simopoulos C, Polychronidis A et al (2003) The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/ VEGF pre-treatment status? Anticancer Res 23:1673–1680.
18
A. Rapisarda and G. Melillo
Korkolopoulou P, Patsouris E, Konstantinidou AE et al (2004) Hypoxia-inducible factor 1alpha/ vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30:267–278. Koukourakis MI, Bentzen SM, Giatromanolaki A et al (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727–735. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482. Kung AL, Zabludoff SD, France DS et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33–43. Laughner E, Taghavi P, Chiles K et al (2001) HER2 (neu) signaling increases the rate of hypoxiainducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004. Lee K, Qian DZ, Rey S et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106:2353–2358. Li L, Lin X, Staver M et al (2005) Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 65:7249–7258. Li L, Lin X, Shoemaker AR et al (2006) Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 12:4747–4754. Loges S, Mazzone M, Hohensinner P et al (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167–170. Luwor RB, Lu Y, Li X et al (2005) The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24:4433–4441. Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxiainducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478–2482. Mabjeesh NJ, Escuin D, LaVallee TM et al (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3:363–375. Maher JC, Wangpaichitr M, Savaraj N et al (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6:732–741. Majumder PK, Febbo PG, Bikoff R et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594–601. Manalo DJ, Rowan A, Lavoie T et al (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659–669. Mayerhofer M, Valent P, Sperr WR et al (2002) BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100:3767–3775. Melillo G (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4:601–605. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26:341–352. Mie LY, Kim SH, Kim HS et al (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300:241–246. Moeller BJ, Cao Y, Li CY et al (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441. Moeller BJ, Dreher MR, Rabbani ZN et al (2005) Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99–110.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
19
Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26:241–248. Olenyuk BZ, Zhang GJ, Klco JM et al (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA 101: 16768–16773. Onnis B, Rapisarda A, Melillo G (2009) Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med in press.. Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231. Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197. Park EJ, Kong D, Fisher R et al (2006) Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5:1847–1853. Pencreach E, Guerin E, Nicolet C et al (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 15:1297–1307. Pore N, Jiang Z, Gupta A et al (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66:3197–3204. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443. Qian DZ, Kachhap SK, Collis SJ et al (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 66:8814–8821. Rapisarda A, Melillo G (2009) Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12:74–80. Rapisarda A, Uranchimeg B, Scudiero DA et al (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62:4316–4324. Rapisarda A, Shoemaker RH, Melillo G (2004a) Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 3:172–175. Rapisarda A, Uranchimeg B, Sordet O et al (2004b) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475–1482. Rapisarda A, Zalek J, Hollingshead M et al (2004c) Schedule-dependent inhibition of hypoxiainducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64:6845–6848. Rapisarda A, Hollingshead M, Uranchimeg B et al (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8:1867–1877. Sapra P, Zhao H, Mehlig M et al (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888–1896. Scheuermann TH, Tomchick DR, Machius M et al (2009) Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 106:450–455. Schindl M, Schoppmann SF, Samonigg H et al (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8:1831–1837. Schwartz DL, Powis G, Thitai-Kumar A et al (2009) The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 8:947–958. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. Semenza GL (2007) Hypoxia and cancer. Cancer Metastasis Rev 26:223–224. Semenza GL (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60:591–597.
20
A. Rapisarda and G. Melillo
Sermeus A, Cosse JP, Crespin M et al (2008) Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 7:27. Shin DH, Chun YS, Lee DS et al (2008) Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111:3131–3136. Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345–348. Sivridis E, Giatromanolaki A, Gatter KC et al (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055–1063. Sullivan R, Graham CH (2009) Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 8:1702–1713. Sun HC, Qiu ZJ, Liu J et al (2007) Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol 30: 1359–1367. Swinson DE, Jones JL, Cox G et al (2004) Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111:43–50. Takahashi R, Tanaka S, Hiyama T et al (2003) Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep 10:797–802. Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxiainducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 157:411–421. Tan C, de Noronha RG, Roecker AJ et al (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65:605–612. Theodoropoulos VE, Lazaris AC, Sofras F et al (2004) Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200–208. Theodoropoulos VE, Lazaris AC, Kastriotis I et al (2005) Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 95:425–431. Unruh A, Ressel A, Mohamed HG et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22:3213–3220. Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29–35. Verheul HM, Salumbides B, van EK et al (2008) Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589–3597. Vleugel MM, Greijer AE, Shvarts A et al (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58:172–177. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. Wan X, Shen N, Mendoza A et al (2006) CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8:394–401. Wang GL and Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230–1237. Wang GL, Jiang BH, Rue EA et al (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helixPAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510–5514. Wangpaichitr M, Savaraj N, Maher J et al (2008) Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 7:1506–1513. Welsh S, Williams R, Kirkpatrick L et al (2004) Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 3:233–244.
1 Combination Strategies Targeting Hypoxia Inducible Factor 1
21
Welsh SJ, Koh MY, Powis G (2006) The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 33:486–497. Williams KJ, Telfer BA, Xenaki D et al (2005) Enhanced response to radiotherapy in tumors deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 75:89–98. Yang J, Zhang L, Erbel PJ et al (2005) Functions of the Per/ARNT/Sim domains of the hypoxiainducible factor. J Biol Chem 280:36047–36054. Zhang X, Kon T, Wang H et al (2004) Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 64:8139–8142. Zhang H, Gao P, Fukuda R et al (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11:407–420. Zhang H, Qian DZ, Tan YS et al (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 105:19579–19586. Zhong H, De Marzo AM, Laughner E et al (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835. Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545.
Chapter 2
The Tumor Microenvironment: New Insights into Regulation of Tumor pH by Carbonic Anhydrases Pawel Swietach, Adrian L. Harris, and Richard D. Vaughan-Jones
Abstract Intracellular pH (pHi) is a powerful modulator of cell function. There is a narrow range of pHi, usually between 7.0 and 7.5, over which cell growth and development is optimal. Metabolism, particularly cellular respiration, tends to disturb this favorable steady state. The survival of cells undergoing such an acid challenge relies on efficient mechanisms for regulating pHi. In solid tumors, pHi regulation is challenged by their heavy demand for energy and poor blood supply. Inadequately perfused cancer cells deprive the milieu of oxygen, forcing a switchover to the less energy efficient, anaerobic mode of respiration. To meet energy demands, cells upregulate respiration and excrete more acid which lowers extracellular pH (pHe). The tumor extracellular milieu is believed to exert Darwinian selection in favor of cancer cells and against normal cells, based on the cell’s capacity to protect pHi under hypoxia and low pHe. In this chapter, we describe the pathways operating in tumors for removing acid and regulating pHi, with particular emphasis on membrane transporters and carbonic anhydrase (CA) enzymes. We discuss these pathways in terms of survival adaptations and possible targets for anticancer therapy.
Biological Importance of pH The hydrogen atom is very common in the human body, and despite being the lightest of elements, it comprises about a tenth of total body mass. Virtually all hydrogen atoms are bonded by means of electron transfer or sharing with other elements. In many such compounds, the hydrogen nucleus can dissociate reversibly from the remainder of the molecule. In the case of the most common isotope 1 H, the hydrogen nucleus is solely a proton, and therefore the H+ dissociation and
A.L. Harris (*) Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, UK e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_2, © Springer Science+Business Media, LLC 2010
23
24
P. Swietach et al.
association reactions are dubbed deprotonation and protonation, respectively. Water, the biological solvent that contributes towards 60% of the body’s mass, also undergoes reversible deprotonation, and in pure form equilibrates at a “neutral” H+ ion concentration ([H+]) of 1027 M. Acids and bases are defined as molecules that increase and decrease [H+], respectively. To avoid the use of exponential notation, the acidity/basicity of a solution is commonly expressed as the negative logarithm of molar [H+], and given the symbol pH (Boron 2004). Many biologically relevant molecules are weak acids and weak bases. Proteins, for instance, are chains of weak acids/bases. Weak acids/bases exist in dynamic equilibrium between their protonated and unprotonated forms, the concentration ratio of which is very sensitive to pH. Since the H+ ion has very high charge density, pH will have a major impact on the physico-chemical properties of weak acids/ bases. This is particularly relevant to proteins, where charge distribution is linked to structure and function (Boron 2004; Swietach et al. 2007). Indeed, intracellular pH (pHi) is a potent and universal regulator of cellular physiology (Boron 2004; Swietach et al. 2007; Roos and Boron 1981; Vaughan-Jones et al. 2008; Isfort et al. 1993; McConkey and Orrenius 1996). Displacements of pHi by only a fraction of a unit can lead to patho-physiological responses and apoptotic death (Park et al. 1999). Cells must defend their optimal pHi by corrective (homeostatic) mechanisms. A major challenge to these housekeeping mechanisms is metabolic acid production, a process that takes place in all respiring cells throughout their life. To counteract metabolic acid loading, excess intracellular H+ ions must be removed across the cell membrane into the extracellular space and out of the body at the lungs and kidneys. Despite its tiny radius, the highly-polarizing H+ ion is poorly permeant across the lipid bilayer of cell membranes. To allow transmembrane H+ - traffic, cells have evolved transport proteins for H+ ions (e.g. Na+/H+ exchange), or other means of facilitated H+ ion diffusion (e.g. its reaction with HCO3– to form membrane-permeant CO2). The performance of these mechanisms can be compromised by the accumulation of extracellular acid, either as a result of allosteric H+ - inhibition of transport proteins (Vaughan-Jones and Wu 1990; Aronson 1985) or by the collapse diffusion gradients that drive acid-efflux (Swietach et al. 2008, 2009). Through these mechanisms, extracellular pH (pHe) can feedback onto pHi homeostasis. In turn, pHe depends on the diffusive coupling across the extracellular space and with blood. Efficient pHi regulation is central to the survival of metabolically-active tissues, particularly those with relatively poor blood perfusion. Solid tumors are characterized by a high acid production rate (Gatenby and Gillies 2004; Gillies et al. 2008) and inadequate blood supply (Swietach et al. 2007; Vaupel et al. 1989; Kallinowski et al. 1989; Stubbs et al. 2000). Although cancer cells, by definition, harbor a number of mutated gene products, the bulk of cellular protein is no different from normal cells and bears a similar pHi sensitivity, carving a narrow pHi range for survival. The growth of tumors may depend critically on the ability of cancer cells to remove intracellular acid more efficiently than normal cells. The conditions that are characteristic of tumors, notably hypoxia and low pHe (Griffiths et al. 2001; Gatenby et al. 2006), may be tolerated by cancer cells, but not by normal cells, thereby selecting against the latter (Fang et al. 2008). In this chapter, we describe
2 The Tumor Microenvironment
25
the mechanisms for controlling pHi in solid tumors, with particular emphasis on the role of CO2/HCO3– buffer and its enzyme catalyst, carbonic anhydrase (CA).
Sources of Cellular Acid Cellular Respiration A large number of biochemical reactions produce or consume H+ ions, but production of lactic acid by anaerobic respiration and carbon dioxide (CO2) by aerobic respiration are quantitatively the most important acid fluxes that can alter pHi. Glucose, the major respiratory substrate in tumors, produces 2 × H+ plus 2 × lactate (i.e. ionized lactic acid) by the cytosolic O2-independent glycolytic pathway, or 6 × CO2 plus 6 × H2O through O2-dependent mitochondrial pathways. In addition, during periods of nucleic acid synthesis, glucose can yield 1 × CO2 through an additional cytosolic pathway called the pentose phosphate shunt (Helmlinger et al. 2002). Upon hydration, CO2 yields H+ and HCO3−. Assuming equilibrium at pH 7, the molar H+ – yield per aerobically and anaerobically respired glucose is 5.3 and 2.0, respectively (aciddissociation constants for CO2 and lactic acid are 1026.2 and 1024 M, respectively). Tumors demand a particularly high respiratory rate to energize their substantial growth and development. Glucose yields almost 20 times more energy (ATP molecules) when it is respired to CO2 rather than lactic acid. The carbon atoms of lactic acid are less oxidized than those in CO2, and still have considerable energy trapped in their bonds. Indeed, lactic acid can be respired further to CO2. Based on energy efficiency alone, it would be sensible for tumors to prefer aerobic respiration. But to benefit from this higher energy yield, tumors need functional mitochondria and adequate O2 supply. As solid tumors develop, they grow away from their basement membrane and vasculature. This increases the diffusion distance for O2 delivery. Furthermore, the elevated O2 demand in cancer cells that are closer to blood vessels greatly reduces O2 availability in more distal cells, and shortens the distance over which cells are adequately oxygenated. This distance, known as the Krogh radius (Krogh 1919), can be as little as a few cell layers thick in tumors (Dewhirst et al. 1994). Beyond the Krogh radius, tissue becomes hypoxic. In addition to inadequate and highly disorganized vasculature (Thomlinson and Gray 1955), the extent of hypoxia within tumors is increased by variable and discontinuous blood flow (Vaupel et al. 1989; Helmlinger et al. 1997). The size of the hypoxic region can be visualized by pimonidazole staining (Fig. 2.1a). Low O2 tension (<1%) blocks the degradation of hypoxia-inducible factor (HIF), a transcription factor that otherwise has a very short lifetime under normoxia. HIF was discovered as an inducer of erythropoietin expression (Semenza and Wang 1992), and is now an established regulator of genes involved in glucose metabolism (e.g. Glut-1 for glucose uptake, Fig. 2.1b) and pH regulation (e.g. CA9, a carbonic anhydrase isoform, Fig. 2.1c) (Semenza 2003). Hypoxia forces glucose to be respired anaerobically by blocking O2-dependent mitochondrial reactions and
26
P. Swietach et al.
Fig. 2.1 Tumor hypoxia and its correlation with hypoxia-induced proteins, modified from Airley et al. (2003). Serial sections of cervix carcinoma biopsies, immuno-stained for (a) pimonidazole, (b) Glut-1, and (c) CAIX, showing similarities in distribution and pattern. Magnification 200×. Shaded arrows point in the direction of decreasing O2, as assessed by increasing pimonidazole staining
by HIF-induced expression of pyruvate dehydrogenase kinase (PDK) and lactate dehydrogenase (LDH), which divert pyruvate away from mitochondrial reactions (PDK) and towards lactic acid production (LDH) (Semenza et al. 1994).
The Warburg Effect Under uncompromised O2 supply, it is in the interest of cellular energetics to respire aerobically. This phenomenon, called the Pasteur effect, is a coordinated effort by adenosine nucleotides (Ramaiah et al. 1964), redox potentials (Cerdan et al. 2006), and transcription factors (Hardie 2003) to favor the production of CO2 over lactic acid. In an apparent violation of the Pasteur effect, cancer cells typically show constitutive upregulation of lactic acid production even under normoxic conditions. This observation, called the Warburg effect (Gatenby and Gillies 2004; Warburg 1930), is central to cancer biology and is proposed to arise as a result of the stabilization of HIF by lactic acid (Lu et al. 2002), aberrant HIF degradation by mutated von Hippel–Lindau protein (Ivanov et al. 1998), or dysfunctional transcription factors, such as c-myc, which regulate carbohydrate turnover (Liao and Dickson 2000). The persistence of the Warburg effect in cancer cells must provide a benefit for survival that outweighs the lower ATP yield of anaerobic respiration. One advantage of the Warburg effect is its lack of dependence on O2 supply, which is highly unreliable in tumors (Gatenby and Gillies 2004). Fluctuating blood flow has been proposed to promote cancer development by selecting for cells that survive repeated hypoxia-reoxygenation cycles (Gatenby and Gillies 2004; Kimura et al. 1996), i.e. those supporting the Warburg phenomenon. A second plausible benefit of the Warburg effect is the greater acid-yield per ATP molecule generated, seven-fold higher than aerobic respiration. It has been suggested that lactic acid overproduction sets up an acidic microenvironment that is critical for the transition from pre-invasive to malignant carcinoma (Gatenby and Gillies 2004). A positive correlation has been established between glycolytic flux (and hence acid production) and tumor aggressiveness and invasiveness (Gatenby
2 The Tumor Microenvironment
27
and Gillies 2004). Since glucose supply is usually plentiful, it is feasible to upregulate lactic acid production (viz., the Warburg effect) and deposit a greater amount of acid than possible with aerobic respiration, while still catering for cellular energy demands. The near-universal enhancement of glucose utilization by tumors, shown by 18fluorodeoxyglucose positron emission tomography (Gambhir 2002), supports this model of enhanced acid production. According to modern hypotheses of cancer progression, an acidic extracellular milieu (a) encourages cancer cell development and (b) is lethal to normal cells. There is growing evidence for an important role for H+-sensitive G-protein coupled receptors (OGR1 (Ludwig et al. 2003) and G2A (Murakami et al. 2004)) in transducing extracellular acidity into a proliferation signal (Huang et al. 2008). In a neuroblastoma cell line, low pHe activates the inositol-1,4,5-trisphosphate (IP3) signaling pathway, which triggers Ca2+ release from intracellular stores and the activation of the MEK/ERK pathway. In addition, acidic pHe has been shown to favor tumor invasiveness by increasing cell migration, decreasing cell adhesion, and disrupting the extracellular matrix (Gatenby and Gillies 2004; Gatenby and Gawlinski 1996; Kato et al. 1992; Martinez-Zaguilan et al. 1996; Schlappack et al. 1991; Stock and Schwab 2009). Cancer cells are believed to survive better in an acidic extracellular microenvironment by acquiring a more potent acid-extruding phenotype that protects the intracellular compartment from acid buildup (Swietach et al. 2007; Gatenby et al. 2007). Inadequate acid extrusion in normal cells may explain the lethality of low pHe therein (Fig. 2.2).
Fig. 2.2 Cartoon of acid production from a normal cell (smooth outline) and a cancer cell (rigged outline) in an hypoxic region of a tumor, beyond the Krogh radius from a blood vessel (wavy cylinder on right). The cancer cell (bottom cell with jagged outline) produces more acid (gray-filled H+ ions) than the normal cell (top cell with smooth outline, emitting white-filled H+ ions). Extracellular acid (produced mainly by the overactive cancer cell) favors cancer cell growth and development, but has detrimental effects on normal cells due to their lack of sufficient acid-extruding mechanisms to protect the intracellular space from acidification
28
P. Swietach et al.
Transport of Acid Across the Surface Membrane Intracellular and Extracellular pH in Tumors For many decades after Otto Warburg’s seminal finding that tumors overproduce lactic acid, it was assumed that both pHi and pHe are acidic in cancers. The low pH detected using microelectrodes (Kallinowski et al. 1989; Wike-Hooley et al. 1984) was deemed to support this hypothesis, until 31P nuclear magnetic resonance (NMR) revealed alkaline pH in solid tumors (Griffiths et al. 1981). These apparently conflicting reports are easily reconciled by considering that 31P NMR reports mainly pHi, whereas electrodes are sensitive mainly to pHe. Subsequent NMR measurements with extracellular probes such as 3-aminopropylphosphonate confirmed low pHe (Gillies et al. 1994). Therefore, the major difference between cancer and normal tissue is that the former has lower pHe, typically around 6.9 (Vaupel et al. 1990), but as low as 6.0 in some reports (Gillies et al. 2002). Tumors, like normal tissue, require modestly alkaline pHi to support growth, as shown by in vitro (Park et al. 1999; Chiche et al. 2009) and in vivo (Chiche et al. 2009) experiments. The maintenance of high pHi at low pHe requires efficient acid extrusion, a phenotype that is now considered characteristic of cancer cells.
Regulation of Tumor pH by Membrane Transport There are four challenges to efficient pH–i regulation in tumors. Firstly, the demand placed on pHi - regulating mechanisms is considerable. Tumors respire glucose at 0.1–1.0 mM/min (Vaupel et al. 1989) and generate acid equivalents at a rate that could promptly disturb resting free [H+] (~0.06 mM at pHi 7.2). Secondly, the transmembrane efflux of CO2 and lactic acid is limited by their membrane permeability and intracellular dissociation into membrane-impermeant ions (H+, HCO3–, lactate). Of the two acid products, lactic acid is less readily excreted than CO2 because (a) lactic acid is a larger and more polar molecule than CO2, and therefore is less able to cross the membrane’s lipid bilayer, (b) H+ and lactate produced anaerobically stay 99.9% dissociated in cytoplasm because of the high acid dissociation constant of lactic acid (10–4 M), whereas CO2 dissociates less strongly, with a ~90% yield at equilibrium (at pH 7; CO2 dissociation constant of 10–6.2 M). For every molecule of weak acid produced, anaerobic respiration leads to more intracellular H+ ion trapping than aerobic respiration, and therefore places a greater demand for H+ extruding mechanisms. However, intracellular conversion of CO2 into H+ and HCO3– can be catalyzed by intracellular isoforms of CA, a ubiquitously expressed enzyme (Swietach et al. 2007; Maren 1967; Supuran 2008). In a diffusion-reaction steady-state, intracellular hydration of CO2 reduces the capacity of its diffusive flux out of cells.
2 The Tumor Microenvironment
29
Thirdly, the share of cellular ATP for active acid extrusion is limited and cannot impinge on ATP reserves for growth and development. This may be particularly rate limiting in tumors that rely on energy inefficient anaerobic respiration. Finally, acid extruding mechanisms must be adequately active at low pHe. Extracellular H+ ions have been shown to have an inhibitory effect on transporters such as Na+/H+ exchange (Vaughan-Jones and Wu 1990; Aronson 1985). This would significantly reduce the capacity for acid extrusion in tumors with low pHe. To compensate for this, cancer cells may express a higher density of acid/base transporters, or express isoforms that are less susceptible to inhibition by low pHe.
Efflux of Metabolic Acid Figure 2.3 illustrates pathways for pHi regulation in tumor cells. Without specific mechanisms for transporting acid equivalents, cells would have to rely on the passive efflux of their acid products. CO2 and, to a lesser extent, lactic acid can cross the lipid bilayer, but efficient efflux requires a facilitated permeation pathway. Such
Fig. 2.3 The role of membrane transporters in facilitating acid efflux. Aerobic (left) and anaerobic (right) respiration of glucose yield the acid products CO2 and lactic acid, respectively. CO2 and, to a lesser degree, lactic acid are membrane-permeant and can exit across the surface membrane. At near-neutral pH, however, a fraction of CO2 and lactic acid will ionize. To control intracellular pH, cells express several transporters to facilitate transmembrane acid removal: AQP, aquaporins; MCT, monocarboxylic acid transport; HE, H+-ion extrusion; BT, HCO3– transport
30
P. Swietach et al.
facilitated transport can occur through aquaporin gas channels for CO2 (Nakhoul et al. 1998) (Fig. 2.3a) and by monocarboxylic acid transporters (MCT) for H++lactate (equivalent to lactic acid) co-transport (Halestrap and Price 1999) (Fig. 2.3b). Isoforms MCT1 and MCT4 have been identified in cancer. Furthermore, hypoxia induces MCT4 expression to match the HIF-induced rise in lactic acid production (Ullah et al. 2006).
Buffering of H+ Ions Like all weak acids, lactic acid and hydrated CO2 undergo deprotonation in aqueous medium. The magnitude of the intracellular [H+] rise can be reduced by means of pH buffering, for example: Buffer + H + ↔ HBuffer + Cells have high intracellular buffering capacity because of the proteins, peptides, amino acids, and other weak acids/bases that they harbor. On their own, buffers offer limited protection from acid loading as they can minimize, but cannot remove, pHi disturbances. Typically, it takes many mmol/L of acid to reduce pHi by one unit (Swietach et al. 2008, 2009). However, chronic acid loading over the lifetime of a cell would eventually saturate buffer sites and drive pHi into the lethal range. Cells can counteract buffer saturation by keeping the concentration of protonated and unprotonated buffer constant. In a so-called open buffer system, the concentration of either form of buffer can be restored by transport to or from the extracellular space. The major “open” buffer system in cells is CO2/HCO3–. Intracellular H+ ions react with HCO3– forming membrane permeant CO2 that can exit cells freely. Intracellular buffering is then restored by HCO32 uptake, e.g. by means of Na+-dependent Cl–/HCO3– exchange (Lee and Tannock 1998) (Fig. 2.3c). The effectiveness of this mechanism at protecting pHi depends critically on the availability of extracellular HCO3– for cellular uptake and on efficient CO2 venting. The extracellular space of most tissues is often assumed to be an infinite compartment with solutes at well-controlled concentrations. However, in tumors with poor blood flow, the extracellular milieu may not provide adequate HCO3– (particularly at low pHe) to perpetuate pH buffering by CO2/HCO3–. Under those circumstances, excess H+ ions may have to be extruded by HCO3–-independent mechanisms.
Extrusion of H+ Ions Excess H+ ions can be removed from cells by means of membrane-bound transporter proteins. High levels of Na+/H+ exchangers (NHE) (Swietach et al. 2008;
2 The Tumor Microenvironment
31
Lee and Tannock 1998; McLean et al. 2000) and vacuolar-type H+ ATPase (V-ATPase) pumps (Martinez-Zaguilan et al. 1993) have been detected in many types of cancer cell (Fig. 2.3d). Fibroblasts transfected with V-ATPase (Gillies et al. 1990) or NHE (Reshkin et al. 2000) become tumorigenic, suggesting an important role for H+ extruders in developing the cancer phenotype. In breast cancer, expression levels of V-ATPase are high and in excess of NHE, and correlate with metastatic potential (Sennoune et al. 2004). Experimental evidence supports the notion that H+ extruders contribute to extracellular acidification and help to keep pHi in a range that is favorable for growth (Sennoune et al. 2004; Fais et al. 2007). The enhanced capacity for secreting acid into the extracellular space may be a means of autocrine/paracrine signaling, in which cell proliferation is triggered via extracellularly activated G-protein coupled receptors sensitive to H+ (Huang et al. 2008). It is noteworthy that H+ extrusion and buffering do not remove the anionic conjugate base of the metabolic acid (lactate and HCO3–); therefore, additional mechanisms are required to remove or metabolize these. HCO3– efflux in exchange for extracellular Cl– can occur by means of transporters belonging to the SLC4 (Alper 2006) and SLC26 (Mount and Romero 2004) families. Recently described pathways for organic anion transport on SLC26 (Mount and Romero 2004) and SLC21 (Hagenbuch and Meier 2004) carriers may offer non-H+-coupled means of transporting lactate or its catabolic derivatives.
Regulation of pH Using Nonrespiratory Sources of H+ Ions In the discussion so far, the substrate for transmembrane acid flux was the acid generated by cellular respiration. In metabolically active cancer cells, this is the most substantial source of acid. However, the finding that solid tumors with genetically attenuated glycolysis are still able to acidify their extracellular space suggests that cancer cells can excrete acid from intracellular H+ donors other than metabolically generated acid (Newell et al. 1993; Yamagata et al. 1998). Intracellular buffers provide a substantial pool of H+ ions that can be used to fine-tune pHi independently of the cell’s metabolic activity. Without this reserve of H+ ions, the only means of fine-tuning pHi would be to adjust the balance between metabolic acid production and its transmembrane removal. If, for instance, the production and excretion of metabolic acid is perfectly matched, but a rise in pHi is desired, then the cell must extrude its reserve H+ ions. NHE is a major candidate for finetuning pHi, because of the plethora of signaling molecules that target its activity (Vaughan-Jones and Swietach 2008). Experiments have shown that NHE-driven intracellular alkalinization triggers early stages of neoplastic transformation (Reshkin et al. 2000), and is concomitant with cell cycle progression (Cardone et al. 2005).
32
P. Swietach et al.
Role of Carbonic Anhydrase in Acid-Equivalent Transport Intracellular and Extracellular Carbonic Anhydrase Isoforms Several steps in the pathways illustrated in Fig. 2.3 depend on the forward and backward rate constants in the equilibrium: CO2 + H 2 O ↔ HCO3− + H + The kinetics of pH buffering by CO2/HCO3– and CO2 hydration (and the reverse reaction) depend critically on CA expression levels. The first description of CA activity was based on the intracellular compartment of red blood cells (Meldrum and Roughton 1933). The high intracellular CA (CAi) activity in these cells is now considered to be an exception rather than rule, as typical CAi levels in most cells accelerate CO2 hydration by several, rather than several thousand, fold (Swietach et al. 2007, 2008, 2009; Leem and Vaughan-Jones 1998). The moderate CA catalysis inside cells is a compromise that (a) supports adequate intracellular CO2/HCO3– buffering kinetics (e.g. for the reaction between intracellular HCO3– and lactic acid, Fig. 2.3c) and (b) prevents excessive hydration of cell-generated CO2 (e.g. from aerobic production, Fig. 2.3a) that would trap H+ and HCO3– inside cells. Known catalytically-active intracellular CA isoforms include CA1, CA2, CA3, CA7, and CA13 (Maren 1967; Supuran 2008). Recently, a number of membrane-bound CA isoforms with extracellular-facing catalytic sites (CAe) have been described, including CA4, CA9, CA12, and CA14 (Maren 1967; Supuran 2008; Geers and Gros 2000; Pastorek et al. 1994). Two of these, CA9 and CA12, are hypoxically induced (Wykoff et al. 2000; Loncaster et al. 2001; Airley et al. 2003) and correlate positively with cancer aggressiveness and poor prognosis (Haapasalo et al. 2006; Driessen et al. 2006; Beasley et al. 2001; Chia et al. 2001; Koukourakis et al. 2001), although CA12 is also induced by estrogen in breast cancer and is associated then with a good outcome. It has been postulated that CAe activity in tumors accelerates acid extrusion (Swietach et al. 2007, 2008, 2009; Chiche et al. 2009; Svastova et al. 2004). Figure 2.4 illustrates the possible mechanisms by which CAe activity achieves such facilitation.
Facilitated CO2 Diffusion Efficient CO2 efflux from aerobically respiring cells (Fig. 2.3a) can be curtailed by CO2 buildup in poorly perfused extracellular spaces. The outward transmembrane [CO2] gradient can be increased by hydrating extracellular CO2 into HCO3– and H+ (Swietach et al. 2009; Svastova et al. 2004) (Fig. 2.4a). Theoretical modeling predicts that optimal CO2 venting out of cells can be achieved by favoring extracellular over intracellular CO2 hydration (Swietach et al. 2009). This can be implemented by expressing CAe at a higher level than CAi. In multicellular spheroid models,
2 The Tumor Microenvironment
33
expression of CA9 activity has been shown to reduce intracellular acidity (Swietach et al. 2008, 2009) and increase extracellular acidity (Swietach et al. 2009) in a manner that is sensitive to CAe inhibitors. There is evidence, at least from some cell lines, that overexpression of CA9 decreases overall CAi activity (Swietach et al. 2008, 2009), thereby shifting the site of CO2 hydration from the intracellular to the extracellular compartment. This CAe catalyzed pathway is an example of facilitated CO2 diffusion, and results in a fall of pHe. An apparent contradiction may be inferred from the role of an hypoxia-inducible enzyme (CA9, CA12) in facilitating the efflux of aerobically generated CO2 (Fig. 2.4a). However, the CA9 gene is among the most hypoxia sensitive (Wykoff et al. 2000). Along a radial gradient of decreasing oxygen, CA9 levels are likely to rise ahead of the downregulation of aerobic respiration. The mechanism illustrated in Fig. 2.4a may operate in the intermediate zone, where hypoxia is sufficient to induce CAe but inadequate to block aerobic respiration. In more proximal, oxygenated regions, CAe activity becomes redundant due to the small cell-to-capillary distance for CO2 diffusion (Swietach et al. 2009). CAe-facilitated CO2 diffusion can also take in anaerobically respiring cells. The substrate for CAe catalysis could be CO2 generated by the pentose phosphate
Fig. 2.4 The role of extracellular carbonic anhydrase (CAe) in facilitating efflux of aerobic (left) and anaerobic (right) acid-products. (a) Aerobically generated CO2 crosses the membrane passively down a diffusion gradient, maintained in the outward direction by CAe-catalyzed hydration of excreted CO2. (b) Anaerobically generated lactic acid (HLac), buffered by intracellular HCO3–, produces CO2. The CO2 thus generated exits the cells down a diffusion gradient maintained in the outward direction by CAe-catalyzed hydration. HCO3– generated extracellularly is transported into the cell by BT (e.g. Na+–HCO3– cotransport) to complete the cycle. (c) The products of intracellular CO2 hydration, H+ and HCO3–, are transported out of cells by H+ extruders (HE, e.g. Na+/H+ exchange) and bicarbonate transporters (BT, e.g. Cl–/HCO3– exchange). CAe-catalyzed buffering of H+ ions with HCO3– minimizes possible inhibition of HE by low pHe. (d) HLac flux on monocarboxylic acid transporters (MCT) is maintained in the outward direction by CAe-catalyzed titration of HLac and HCO3–. Water omitted for clarity. Pathways in the upper half tend to decrease pHe, and those in the lower half tend to increase pHe. All pathways stimulate acid efflux and raise pHi
34
P. Swietach et al.
shunt. A more important source of CO2 is intracellular buffering of lactic acid by HCO3–, a reaction catalyzed by CAi, if present (Figs. 2.3c and 2.4b). In addition to supporting an outward [CO2] gradient, CAe activity also generates extracellular HCO3– that is then taken up by cells to replenish intracellular CO2/HCO3– buffering capacity.
Facilitated H+ Diffusion A fraction of aerobically generated CO2 will undergo intracellular hydration, particularly in the presence of CAi activity. Extrusion of the resulting H+ ions will then reduce pHe, which may feedback negatively on transport activity, e.g. by means of allosteric auto-inhibition, as shown for NHE (Vaughan-Jones and Wu 1990; Aronson 1985). CAe activity can support H+ - transport by catalyzing the buffering of cell-extruded H+ ions with extracellular HCO3– (Fig. 2.4c). As a consequence of such facilitated H+ diffusion, pHe increases. In anaerobically respiring cells, the yield of intracellular lactic acid titration can be compromised, particularly under conditions of limited HCO3– uptake, e.g. inadequate transport activity or low extracellular substrate. Intracellular lactic acid that does not react with HCO3– can be extruded by MCT as H++lactate (Fig. 2.3b). CAe activity can stimulate this pathway as well, again by titrating the extruded acid with extracellular HCO3–. This converts lactic acid into CO2, a more mobile and less ionizing acid. Consequently, pHe increases and maintains a steeper outward gradient for H+-lactate co-transport (Fig. 2.4d). This pathway is another example of facilitated H+ diffusion.
The Transport Metabolon In the aforementioned pathways, CA activity works in functional association with membrane transporters. This functional coupling has been dubbed the “transport metabolon” and some reports have also proposed a structural basis for the CA-transporter interaction (Sterling et al. 2001; Becker et al. 2005). The transport metabolon was originally proposed for the collaboration between CAi isoforms and Cl−/HCO3− exchange (Sterling et al. 2001), but there is now evidence for a similar interaction between CAe isoforms and HCO3− transporters (Alvarez et al. 2003; Morgan et al. 2007). As membrane transport is a diffusion-reaction process, the transport metabolon ensures that, through the provision and consumption of transport substrate, the membrane-translocation step is not rate-limited by the cis supply and trans removal of solute. The functional significance of the transport metabolon has, however, been questioned (Lu et al. 2006), particularly under conditions of freely available and equilibrated extracellular CO2/HCO3− buffer (Swietach et al. 2008).
2 The Tumor Microenvironment
35
The Dominant Role for Carbonic Anhydrase in Tumors The balance between the four CAe-assisted pHi-regulatory pathways illustrated in Fig. 2.4 will depend on (a) the dominant mode of cellular respiration, (b) the expression and activity of transporter proteins, and (c) the availability of substrate, such as extracellular HCO3– (Swietach et al. 2009). In hypoxic regions, and in cancer cells showing a pronounced Warburg effect, lactic acid production dominates. Elsewhere, in regions of tumors with functional mitochondria and adequate oxygenation, aerobic respiration to CO2 will form the bulk of acid production. However, the transmembrane flux of CO2 versus H+ (lactic acid) may not follow the pattern of aerobic versus anaerobic respiration. In several cancer cell lines, HCO3–dependent transport has been shown to dominate pHi regulation over HCO3–independent fluxes, such as NHE (Swietach et al. 2008, 2009; Lee and Tannock 1998). This provides the transport-protein machinery to support intracellular lactic acid titration with HCO3–, and hence transmembrane CO2 efflux in glycolytic cells. In the corresponding tumors, the source of CO2 for transmembrane efflux would vary with distance from blood vessels, from aerobic CO2 production to titration of lactic acid by HCO3–. A high overall CO2 secretion rate is in agreement with in vivo data showing high extracellular CO2 levels in rodent solid tumors (Gullino et al. 1965) and that 70% of acid output in colon cancers is in the form of CO2 (Griffiths et al. 2001; Holm et al. 1995). CAe-assisted CO2 versus H+ diffusion can be distinguished on the basis of the effect of CAe inhibitors on pHe. In spheroids grown from CA9-transfected cells, CAe inhibitors increase pHe (Swietach et al. 2009). This suggests that the major effect of CAe catalysis in this preparation is to facilitate CO2 diffusion (Fig. 2.4a, b). The balance between CAe-assisted CO2 versus H+ diffusion in cancers in vivo awaits such pharmacological investigation. A dominance of the former would offer an elegant mechanistic link between two well-established correlations, that between tumor aggressiveness and low pHe (Vaupel et al. 1989; Gatenby et al. 2006; Gillies et al. 2002) and between tumor aggressiveness and the expression of CA9 and/or CA12 (Chia et al. 2001; Generali et al. 2006; Giatromanolaki et al. 2001; Koukourakis et al. 2006).
Future Directions and Outlook for Therapy Acidification of the extracellular milieu, in combination with powerful mechanisms to protect pHi, are believed to be a central hallmark of the aggressive cancer phenotype. Restoration of alkaline pHe is predicted to remove the survival advantage that cancer cells have over normal cells and to discourage invasive behavior and progression towards malignant forms of the cancer (Fang et al. 2008). In addition, raising pHe reduces ionization of weak basic drugs used in chemotherapy, such as epirubicin (Generali et al. 2006), and thereby increases drug penetrability to intracellular targets (Raghunand et al. 2001).
36
P. Swietach et al.
The use of bicarbonate salts to alkalinize blood, with the anticipated rise in tumor pHe, has been proposed as a means of tackling cancer (Raghunand et al. 2001). A more selective and specific therapy proposes pH-regulating transporters and enzymes as targets. Inhibition of these proteins has been proposed to be cancer’s Achilles heel (Fang et al. 2008). Recently, three targets for inhibition have been postulated as plausible therapeutic approaches to treating cancer: (a) H+ pumps, (b) monocarboxylic acid (H+-lactate) transporters, and (c) extracellular CA isoforms. Inhibition of V-ATPase activity using interference RNA reduces metastasis (Fais et al. 2007), and its pharmacological inhibition (e.g. with omeprazole) has been shown to improve responses to chemotherapy in solid tumors (Luciani et al. 2004) and promote death of B-cell tumors (De Milito et al. 2007). Fibroblasts transfected with the E7 oncogene failed to undergo intracellular alkalinization and neoplastic transformation when incubated with the NHE inhibitor, 5-(N,N-dimethyl) amiloride (Reshkin et al. 2000). Inhibition of MCT by cinnamate derivatives and, putatively, by lonidamine leads to cellular lactic acid accumulation and intracellular acidification, which are shown to be lethal in neuroblastoma cells (Fang et al. 2006). Although the efficacy of inhibiting V-ATPase, NHE, and MCT has been demonstrated in some in vitro cell lines and in vivo animal tumor models, the use of these drugs in anticancer therapy is not without drawbacks. Cancer cells tend to overexpress isoforms of V-ATPase, NHE, and MCT, but many noncancer cells also rely on these transporters for survival. The lack of a basis for tumor specificity would trigger drug toxicity and uncalibrated effects on whole-body physiology. Before experimental evidence for tumor-associated CAe isoforms was produced, the broad spectrum CA inhibitor acetazolamide has been shown to reduce in vivo tumor growth (Teicher et al. 1993). Following the discovery of CA9, the sulfonamide CA9-inhibitor indisulam was demonstrated to have powerful anticancer effects (Owa et al. 1999). The tumor-associated CAe isoforms, CA9 and CA12, offer an inhibitory target that is almost exclusive to cancer (with the exception of normal gastric mucosa). Membrane-impermeant, CA9- and CA12-selective inhibitors would target tumors, with minimal predicted side effects on other tissues. An impressive range of membrane-impermeant CAe inhibitors has been synthesized, and the effectiveness of these as anticancer drugs is currently being researched (Supuran 2008). Prodrugs activated by the extracellular acid environment would be another selective approach. Other therapeutic strategies based on tumor-specific CAe isoforms may include inhibitory antibodies, vaccines to develop T-cell antiCA9 or anti-CA12 responses, and targeted antibody therapy. Regulation of tumor pHi remains an intensively researched and hotly debated topic. Furthering our knowledge about the special adaptations found in tumors should improve our overall understanding of pH homeostasis, and may reveal more efficacious and safer anticancer therapy. Acknowledgments This work has been supported by the Medical Research Council and Royal Society (PS), Cancer Research UK (ALH) and British Heart Foundation (RDV-J).
2 The Tumor Microenvironment
37
References Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85–91. Alper SL (2006) Molecular physiology of SLC4 anion exchangers. Exp Physiol 91:153–161. Alvarez BV, Loiselle FB, Supuran CT, Schwartz GJ, Casey JR (2003) Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry 42:12321–12329. Aronson PS (1985) Kinetic properties of the plasma membrane Na+-H+ exchanger. Annu Rev Physiol 47:545–560. Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL (2001) Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61:5262–5267. Becker HM, Hirnet DC, Fecher-Trost, Sultemeyer D, Deitmer JW (2005) Transport activity of MCT1 expressed in Xenopus oocytes is increased by interaction with carbonic anhydrase. J Biol Chem 280:39882–39889. Boron WF (2004) Regulation of intracellular pH. Adv Physiol Educ 28:160–179. Cardone RA, Casavola V, Reshkin SJ (2005) The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 5:786–795. Cerdan S, Rodrigues TB, Sierra A, Benito M, Fonseca LL, Fonseca CP, Garcia-Martin ML (2006) The redox switch/redox coupling hypothesis. Neurochem Int 48:523–530. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase ix, in invasive breast carcinoma. J Clin Oncol 19:3660–3668. Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358–368. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S (2007) Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67:5408–5417. Dewhirst MW, Secomb TW, Ong ET, Hsu R, Gross JF (1994) Determination of local oxygen consumption rates in tumors. Cancer Res 54:3333–3336. Driessen, A., Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243:334–340. Fais S, De Milito A, You H, Qin W (2007) Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 67:10627–10630. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 70:2108–2115. Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 18:330–337. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693. Gatenby RA, Gawlinski ET (1996) A reaction-diffusion model of cancer invasion. Cancer Res 56:5745–5753.
38
P. Swietach et al.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66:5216–5223. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ (2007) Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 97:646–653. Geers C, Gros G (2000) Carbon dioxide transport and carbonic anhydrase in blood and muscle. Physiol Rev 80:681–715. Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/ tamoxifen therapy for breast cancer. Endocr Relat Cancer 13:921–930. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61:7992–7998. Gillies RJ, Liu Z, Bhujwalla Z (1994) 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267:C195–203. Gillies RJ, Martinez-Zaguilan R, Martinez GM, Serrano R, Perona R (1990) Tumorigenic 3T3 cells maintain an alkaline intracellular pH under physiological conditions. Proc Natl Acad Sci USA 87:7414–7418. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16:430–450. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49(Suppl 2):24S–42S. Griffiths JR, Stevens AN, Iles RA, Gordon RE, Shaw D (1981) 31P-NMR investigation of solid tumours in the living rat. Biosci Rep 1:319–325. Griffiths JR, McIntyre DJ, Howe FA, Stubbs M (2001) Why are cancers acidic? A carrier-mediated diffusion model for H+ transport in the interstitial fluid. Novartis Found Symp 240:46–62. Gullino PM, Grantham FH, Smith SH, Haggerty AC (1965) Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst 34:857–869. Hagenbuch, B., Meier PJ (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447:653–665. Halestrap AP, Price NT (1999) The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343(Pt 2):281–299. Hardie DG (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144:5179–5183. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177–182. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysisimpaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8:1284–1291. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477. Holm E, Hagmuller E, Staedt U, Schlickeiser G, Gunther HJ, Leweling H, Tokus M, Kollmar HB (1995) Substrate balances across colonic carcinomas in humans. Cancer Res 55:1373–1378. Huang WC, Swietach P, Vaughan-Jones RD, Ansorge O, Glitsch MD (2008) Extracellular acidification elicits spatially and temporally distinct Ca2+ signals. Curr Biol 18:781–785. Isfort RJ, Cody DB, Asquith TN, Ridder GM, Stuard SB, LeBoeuf RA (1993) Induction of protein phosphorylation, protein synthesis, immediate-early-gene expression and cellular proliferation by intracellular pH modulation. Implications for the role of hydrogen ions in signal transduction. Eur J Biochem 213:349–357.
2 The Tumor Microenvironment
39
Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95:12596–12601. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759–3764. Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, Papahadjopoulos D, Hong K, Dewhirst MW (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56:5522–5528. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7:3399–3403. Koukourakis MI, Pitiakoudis M, Giatromanolaki A, Tsarouha A, Polychronidis A, Sivridis E, Simopoulos C (2006) Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci 97: 1056–1060. Krogh A (1919) The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol 52:409–415. Lee AH, Tannock IF (1998) Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 58:1901–1908. Leem CH, Vaughan-Jones RD (1998) Out-of-equilibrium pH transients in the guinea-pig ventricular myocyte. J Physiol 509 (Pt 2):471–485. Liao DJ, Dickson RB (2000) c-Myc in breast cancer. Endocr Relat Cancer 7:143–164. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394–6399. Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111–23115. Lu J, Daly CM, Parker MD, Gill HS, Piermarini PM, Pelletier MF, Boron WF (2006) Effect of human carbonic anhydrase II on the activity of the human electrogenic Na/HCO3 cotransporter NBCe1-A in Xenopus oocytes. J Biol Chem 281:19241–19250. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S (2004) Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 96:1702–1713. Ludwig MG, Vanek M, Guerini D, Gasser JA, Jones CE, Junker U, Hofstetter H, Wolf RM, Seuwen K (2003) Proton-sensing G-protein-coupled receptors. Nature 425:93–98. Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 47:595–781. Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ (1993) Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 265:C1015–1029. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ (1996) Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14:176–186. McConkey DJ, Orrenius S (1996) Signal transduction pathways in apoptosis. Stem Cells 14:619–631. McLean LA, Roscoe J, Jorgensen NK, Gorin FA, Cala PM (2000) Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 278:C676–C688. Meldrum NU, Roughton FJ (1933) Carbonic anhydrase. Its preparation and properties. J Physiol 80:113–142. Morgan PE, Pastorekova S, Stuart-Tilley AK, Alper SL, Casey JR (2007) Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters.. Am J Physiol Cell Physiol. 293:C738–C748.
40
P. Swietach et al.
Mount DB, Romero MF (2004) The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch 447:710–721. Murakami N, Yokomizo T, Okuno T, Shimizu T (2004) G2A is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem 279:42484–42491. Kato Y, Nakayama Y, Umeda M, Miyazaki K (1992) Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 267:11424–11430. Nakhoul NL, Davis BA, Romero MF, Boron WF (1998) Effect of expressing the water channel aquaporin-1 on the CO2 permeability of Xenopus oocytes. Am J Physiol 274:C543–C548. Newell K, Franchi A, Pouyssegur J, Tannock I (1993) Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90:1127–1131. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, Kitoh K (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789–3799. Park HJ, Lyons JC, Ohtsubo T, Song CW (1999) Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 80:1892–1897. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat’ovicova M, Liao S, Portetelle D, Stanbridge EJ et al (1994) Cloning and characterization of MN, a human tumorassociated protein with a domain homologous to carbonic anhydrase and a putative helixloop-helix DNA binding segment. Oncogene 9:2877–2888. Ramaiah A, Hathaway JA, Atkinson DE (1964). Adenylate as a Metabolic Regulator. Effect on Yeast Phosphofructokinase Kinetics. J Biol Chem 239:3619–3622. Raghunand N, Mahoney B, van Sluis R, Baggett B, Gillies RJ (2001) Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone. Neoplasia 3:227–235. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M (2000) Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14:2185–2197. Roos A, Boron WF (1981) Intracellular pH. Physiol Rev 61:296–434. Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells. Br J Cancer 64:663–670. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:5447–5454. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763. Sennoune SR, Bakunts K, Martinez GM, Chua-Tuan JL, Kebir Y, Attaya MN, Martinez-Zaguilan R (2004) Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452. Sterling D, Reithmeier RA, Casey JR (2001) A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J Biol Chem 276:47886–47894. Stock C, Schwab A (2009) Protons make tumor cells move like clockwork. Pflugers Arch 458(2):981–992. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL (2000) Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 6:15–19. Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nature Rev (Drug Discoveries) 7:1–14. Svastova E, Hulikova A, Rafajova M, Zat’ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577:439–445.
2 The Tumor Microenvironment
41
Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26:299–310. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan-Jones RD (2008) Tumorassociated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 283:20473–20483. Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD (2009) The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 284:20299–20310. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS (1993) A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 13:1549–1556. Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539–549. Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281:9030–9037. Vaughan-Jones RD, Swietach P (2008) Pushing and pulling the cardiac sodium/hydrogen exchanger. Circ Res 103:773–775. Vaughan-Jones RD, Wu ML (1990) Extracellular H+ inactivation of Na(+)-H+ exchange in the sheep cardiac Purkinje fibre. J Physiol 428:441–466. Vaughan-Jones RD, Spitzer KW, Swietach P (2008) Intracellular pH regulation in heart. J Mol Cell Cardiol 46(3):318–313. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465. Vaupel P, Kallinowski F, Okunieff P (1990) Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 277:895–905. Warburg O (1930) The metabolism of tumours. Arnold Constable, London. Wike-Hooley JL, Haveman J, Reinhold HS (1984) The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343–366. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083. Yamagata M, Hasuda K, Stamato T, Tannock IF (1998) The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 77:1726–1731.
Chapter 3
Hypoxia, Gene Expression, and Metastasis Olga V. Razorenova and Amato J. Giaccia
Abstract Metastasis is the primary cause of death from cancer due to the spread of disease throughout the body. Increasing evidence suggests that the hypoxic microenvironment serves as a driving force for the metastatic process. Fifty to sixty percent of solid tumors contain hypoxic areas, where the gene expression is reprogrammed by low oxygen microenvironment leading to aggressive invasive cancer cell behavior. Hypoxia upregulates multiple genes involved in different steps of metastatic process, including angiogenesis, proliferation, migration, invasion, motility, adhesion, ECM remodeling, and survival. Moreover, hypoxia confers tumor cells with chemo- and radio-resistance. At the end of this chapter, we discuss the facts linking hypoxia and cancer stem cells (CSC) mainly through the ability of hypoxic microenvironment to shift cells toward the undifferentiated phenotype. Abbreviations AKT ARNT CC-RCC CNS CSC EMT FAK FIH GSC HIF HRE
protein kinase B arylhydrocarbon receptor nuclear translocator clear cell renal cell carcinoma central nervous system cancer stem cell epithelial–mesenchymal transition focal adhesion kinase factor inhibiting HIF glioma stem cell hypoxia-inducible factor hypoxia-responsive element
A.J. Giaccia (*) Division of Radiation and Cancer Biology, Stanford University, Stanford, CA 94305, USA e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_3, © Springer Science+Business Media, LLC 2010
43
44
IDH1 iPS a-KG LOH LOX MAPK NSC PHDs 1–3 PI-3K pVHL VHL WT
O.V. Razorenova and A.J. Giaccia
isocitrate dehydrogenase 1 induced pluripotent stem cell a-ketoglutarate loss of heterozygosity lysyl oxidase mitogen-activated protein kinase neural stem cell prolyl-4-hydroxylases 1–3 phosphoinositide 3 kinase von Hippel–Lindau protein von Hippel–Lindau gene wild-type
The Link Between Hypoxia and Metastasis Metastatic disease is the primary cause of death from cancer due to its spread beyond the primary affected organ to multiple organs in the body (secondary sites). The metastatic process is complex and can be divided into several major steps: (1) invasion and migration of tumor cells, leading to intravasation; (2) survival in the circulation (resistance to anoikis); (3) adhesion and migration, leading to extravasation; (4) survival in the new microenvironment; and (5) proliferation in the secondary site (Fig. 3.1) (Chan and Giaccia 2007; Nguyen et al. 2009). These processes require the involvement of a variety of effector molecules. It has been estimated that 50–60% of solid tumors contain areas of hypoxic and/or anoxic regions (Vaupel and Mayer 2007). Moreover, hypoxia correlates with poor patient outcome and the presence of metastases in multiple tumor types (Hockel et al. 1993, 1996; Brizel et al. 1996; Nordsmark et al. 1996; Fyles et al. 1998). Despite these correlations, it is not clear whether hypoxia provides the appropriate microenvironment promoting metastatic spread or metastasis is a simple consequence of chemo- and radio-resistance of cells in hypoxic regions. Hypoxic cells survive chemotherapy because many chemotherapeutic agents require proliferating cells to induce cytotoxicity and hypoxic cells divide slowly (Shannon et al. 2003). The second cause of failure is the need for vasculature to deliver drugs to cancer cells, which is absent or defective in hypoxic regions (Kizaka-Kondoh et al. 2003). An additional contribution to chemotherapy resistance is through the hypoxic induction of multidrug transporters, leading to the transport of drugs out of the cell (Comerford et al. 2002; Wartenberg et al. 2003). Radiation therapy relies on molecular oxygen to form cytotoxic, double-strand breaks in the cancer cell DNA, which is limited under hypoxic conditions (Kallman and Dorie 1986; Hall 1994). The majority of studies now provide convincing evidence that hypoxia is not only capable to confer cells with chemo- and radio-resistance, but also shifts gene expression to promote the metastatic process (see below).
3 Hypoxia, Gene Expression, and Metastasis
hypoxia
45
intravasation angiogenic factor secretion
adh
esio
n
angiogenesis
extravasation
organ2
surv i
val
organ1
survival, proliferation
Fig. 3.1 Major steps of the metastatic process
Causes and Consequences of Tumor Hypoxia The physiologic range of oxygen for most tissues is between 4 and 8% oxygen (normoxia) in contrast to the 20% level of oxygen used for tissue culture experiments (Gardner and Corn 2008). For each tissue, the range of oxygen tensions can vary accordingly to need; thus, under physiologic conditions it is difficult to establish a universal value to define hypoxia. In this regard, the functional definition of hypoxia is the state when oxygen delivery does not meet the demands of the given tissue. Cellular hypoxia (<1–5% oxygen) is a common stress in normal development (Huang et al. 2004) and numerous pathological conditions, including cancer and ischemia (Giaccia et al. 2003; Semenza 2003). Hypoxic areas in tumors develop as a result of an imbalance between oxygen supply and consumption (Papandreou et al. 2005; Vaupel and Mayer 2007). The expanding tumor mass increases the distance of certain tumor areas from local blood vessels, limiting the oxygen supply. Additionally, at later stages of tumor growth, when a tumor establishes an extensive vasculature to increase oxygen supply, the defects in blood vessel structure contribute to hypoxia reoxygenation of certain tumor areas (Endrich et al. 1979; Grunt et al. 1985; Shah-Yukich and Nelson 1988; Dewhirst et al. 1989). The malformed tumor vasculature is twisted, tortuous with blind ends and can possess arterio-venous shunts. Moreover, tumor vessels are devoid of their normal multilayer complex structure and are leaky and predisposed to dilation and constriction, resulting in transient changes in tissue oxygenation (Carmeliet 2005). The main consequence of hypoxic exposure is the stabilization of hypoxiainducible factors (HIFs), which are critical regulators of gene transcription (Giaccia et al. 2003). The hypoxic microenvironment of the tumor leads to HIF stabilization, which induces gene expression changes in order to adapt to hypoxia (Semenza
46
O.V. Razorenova and A.J. Giaccia
2003; Lee et al. 2004); some of these changes, in turn, allow the acquisition of prometastatic properties of cells (invasiveness, migration, adhesion, and survival) (Giaccia et al. 2003; Semenza 2003). Indeed, HIF stabilization in solid tumors does not simply correlate with poor patient prognosis, but HIFs are active players in the metastatic process (Le et al. 2004; Chan and Giaccia 2007; Rankin and Giaccia 2008; Qing and Simon 2009). There are three known HIF-a molecules (Rankin and Giaccia 2008): HIF-1a, HIF-2a, and HIF-3a, which are all hypoxia inducible with a similar mechanism of regulation by oxygen. HIF-1a is ubiquitously expressed, while HIF-2a expression is restricted to specific cell types: endothelial cells, glial cells, type II pneumocytes, cardiomyocytes, kidney fibroblasts, interstitial cells of the pancreas and duodenum, and hepatocytes (Wiesener et al. 2003). Our knowledge of HIF-3a is currently very limited and some studies suggest that it might act as a dominantnegative regulator of HIF-1a and HIF-2a by generation of an alternatively spliced isoform (Makino et al. 2001). Both HIF-1a and HIF-2a are detected in a variety of human tumors, and elevated HIF-1a expression correlates with poor patient outcome in head and neck cancer, nasopharyngeal carcinoma, colorectal, pancreatic, breast, cervical, osteosarcoma, endometrial, ovarian, bladder, glioblastoma, and gastric carcinomas, while elevated HIF-2a expression correlates with poor patient outcome in hepatocellular, colorectal carcinoma, melanoma, ovarian, and nonsmall cell lung cancers (Rankin and Giaccia 2008). Hypoxic conditions are stress conditions that trigger the cell to make a decision to live or to die. In response to hypoxia, as a pro-survival signal, HIF-a stability and activity increases (Giaccia et al. 2003; Semenza 2003). HIF-mediated gene expression allows cells to respond to a low oxygen environment by increasing oxygen delivery and metabolically to adapt to decreased oxygen availability. HIFs regulate expression of multiple target genes that are involved in glycolysis, angiogenesis, proliferation, migration, etc., by binding to hypoxia-responsive elements (HREs) (5¢RCGTG3¢) in their genomic regulatory regions (Semenza 2003; Le et al. 2004; Chan and Giaccia 2007).
HIF Regulation by Oxygen In untransformed cells, HIF-a activity is oxygen dependent and is tightly regulated (Fig. 3.2). Under normoxia, HIF-1a is hydroxylated on two conserved proline residues, prolines 402 and 564, by prolyl-4-hydroxylases 1–3 (PHDs 1–3) (Ivan et al. 2001; Jaakkola et al. 2001). This hydroxylation reaction requires oxygen and a-ketoglutarate (a-KG) as substrates, and iron and ascorbate as cofactors. When hydroxylated, HIF-1a is recognized by the pVHL protein, which allows the formation of a complex with Elongins B and C, cullin 2, and RING-H2 protein ring-box1. This complex functions as E3 ubiquitin ligase, and ubiquitinated HIF-1a gets degraded in the proteasome (Pause et al. 1999). Under hypoxic conditions, hydroxylation of HIF-1a decreases in an oxygen-dependent manner as oxygen serves as a substrate in the hydroxylation reaction. HIF-1a without proline hydroxyl marks is
3 Hypoxia, Gene Expression, and Metastasis
Normoxia Presence of oxygen Cofactors: ascorbate Fe2+
Hypoxia Absence of oxygen pVHL
pVHL PHDs
HIFα
47
OH
O2 α-KG
OH
Ub Ub Ub
HIFα
HIFα
FIH
p300/ CBP
p300/ CBP
OH
26S
I
F
α
HIFα HIFβ
transcription of HIF target genes
5’RCGTG 3’YGCAC
metabolism angiogenesis invasion migration proliferation
H
Fig. 3.2 Oxygen-dependent HIF regulation. R, purine; Y, pyrimidine
not recognized by pVHL, becomes stabilized, and dimerizes with its constitutively expressed partner HIF-1b (also known as arylhydrocarbon receptor nuclear translocator, ARNT). HIF-a/HIF-1b; heterodimer acts in the nucleus and activates transcription by recruiting the transcriptional co-activators such as p300/CBP (Giaccia et al. 2003; Semenza 2003). The interaction between HIF and p300/CBP is also oxygen dependent and is regulated by factor inhibiting HIF (FIH) (Mahon et al. 2001). Under normoxia, FIH hydroxylates asparagine 803 in HIF-1a transactivation domain and prevents p300/CBP binding. Thus, HIF activation under hypoxia consists of HIF-a stabilization and effective p300/CBP binding.
HIF Regulation by Genetic Alterations of Upstream Regulators Many studies have shown that hypoxia is not the only mechanism of HIF activation. HIF-a stability and activity are tightly controlled in primary cells by multiple signaling pathways. Not surprisingly cancer cells acquire mutations in genes, involved
48
O.V. Razorenova and A.J. Giaccia
into HIF regulation, allowing its activation in tumors under normoxic conditions. As described above, pVHL plays a central role in regulating HIF stability (Fig. 3.2). Genetic inactivation of the VHL gene results in HIF-a stabilization and activation, leading to upregulation of target gene expression under normoxia (Iliopoulos et al. 1996; Maxwell et al. 1999; Giaccia et al. 2003; Kaelin 2008). Germ-line mutations in VHL result in VHL disease, also known as familial Von Hippel–Lindau syndrome (Latif et al. 1993). Affected individuals are born with one wild-type (WT) allele and another mutant allele. In these individuals the remaining, WT VHL allele, is eliminated by a loss of heterozygosity (LOH). Von Hippel–Lindau syndrome is characterized by the high frequency of development of several cancer types, including central nervous system (CNS) and retinal hemangioblastomas, clear-cell renal cell carcinomas (CC-RCCs), and pheochromocytomas. VHL is also inactivated in the majority of sporadic RCCs and hemangioblastomas (up to 80% of cases) (Gnarra et al. 1993; Sprenger et al. 2001; Maynard and Ohh 2004). Families at risk for developing pheochromocytoma almost invariably harbor VHL missense mutations, in contrast to families without pheochromocytomas, which frequently harbor VHL deletions or truncation mutations (Chen et al. 1995; Zbar et al. 1996). Most likely genotype–phenotype correlations in VHL disease reflect the degree of impairment of pVHL function by different mutations (Hoffman et al. 2001; Li et al. 2007). Thus, VHL is a bona fide tumor suppressor gene. One of the best studied functions of HIF-1a is the regulation of glucose metabolism by glycolytic enzymes. Importantly, cell metabolic pathways feedback to HIF to allow tight control of energy generating process. Thus, mutations in isocitrate dehydrogenase 1 (IDH1), which occur in certain types of brain tumors, were found to impair a-KG synthesis. Because a-KG is a substrate in HIF-a hydroxylation reaction (Fig. 3.2), impairment of IDH1 function leads to increased HIF-a stability (Zhao et al. 2009). Importantly, IDH1 acts as a homodimer and mutations in IDH1 not only inactivate the gene product of the mutated allele, but confirm the mutated protein with the dominant-negative activity toward the WT allele (Zhao et al. 2009). This fact explains why the LOH for IDH1 is not observed in tumors. Thus, IDH1 appears to be another tumor suppressor gene involved in HIF-a destabilization. Activation of phosphoinositide 3 kinase/Akt (PI-3K/Akt) and mitogen-activated protein kinase (MAPK) signaling pathways is frequently observed in multiple types of cancer and it was shown that they can induce HIF activity (Berra et al. 2000; Blancher et al. 2001; Jiang et al. 2001; Sodhi et al. 2001). The PI-3K pathway is activated in cancer by enhanced growth factor signaling (Zelzer et al. 1998), activation of oncogenes (positive regulators) or inactivation of PTEN (Zundel et al. 2000), or TSC2 (Brugarolas et al. 2003) (negative regulators). To date, the detailed mechanism of PI-3K/Akt-mediated HIF regulation is unknown, but several studies show it to be mTOR dependent, where mTOR contributes to increased HIF protein synthesis (Hudson et al. 2002; Majumder et al. 2004). On the other hand, MAPK can directly phosphorylate HIF-a and increase its stabilization. In summary, HIF activity can be regulated at multiple levels: oxygen concentration, a-KG synthesis (substrates in hydroxylation reaction), and VHL mutation
3 Hypoxia, Gene Expression, and Metastasis
49
(impairment of HIF-a ubiquitination). One can envision additional ways to stabilize HIF, including mutations in prolines 402 and 564, proteasome inhibition, and treatment with iron chelators. Indeed, these are widely used as artificial means of HIF stabilization; and HIF mutations are rarely found in tumors.
HIF Target Genes Involved in the Metastatic Process Hypoxia promotes metastasis through the regulation of key genes involved in different steps of metastatic process, including angiogenesis, proliferation, migration, invasion, motility, adhesion, ECM remodeling, and survival (list of hypoxia-regulated genes can be found elsewhere) (Giaccia et al. 2003; Semenza 2003; Le et al. 2004; Maynard and Ohh 2007). It is important to note that approximately 1–1.5% of the genome is transcriptionally regulated by hypoxia, and many of these genes have been shown to be HIF regulated (Harris 2002; Semenza 2003, 2007). For some solid tumors, angiogenesis is a critical step in the metastatic process, whereas in other cancers (e.g. ovarian cancer and scirrhous adenocarcinoma), the vasculature is not involved in the metastatic spread. In these tumors, cells from the primary tumor shed to the peritoneal cavity, where they establish secondary lesions. In this case, the group of genes involved in angiogenesis is not relevant for the metastatic spread of these cancer types. The role of individual hypoxia-inducible genes in metastasis has just started to be investigated. This lack of direct in vivo evidence about their role in the metastatic process comes from the fact that many of hypoxia-regulated genes are affecting primary tumor growth, which complicates studies on their roles in metastatic spread. It is believed that the larger the primary tumor, the more cells from that tumor can colonize the secondary organs to form lesions. On the other hand, the establishment of metastasis from one cell requires extensive cell growth. Moreover many hypoxia-inducible genes are multifunctional, involved in several processes, like VEGF, which stimulates cancer cell migration (process not affecting tumor growth) and angiogenesis (affects tumor growth). Furthermore, HIFs activate a diverse array of target genes, which sometimes have opposite functions, like proapoptotic (transcriptional induction of BNIP3, BNIP3L, RTP801 and NIX, and stabilization of p53) and antiapoptotic (transcriptional induction of ADM, IGF2, IGF-BP1, 2, 3, TGF-a, VEGF, Bcl-w like, Pim1, 2). Thus, a shift in the balance of opposing signals as well as the mutation repertoire of a given cancer cell will affect tumor cell behavior under hypoxic conditions. An additional complexity comes from the observation that HIFs not only directly upregulate gene expression, by binding to target promoters, but also indirectly upregulate and downregulate gene expression through downstream signaling. The most significant example of indirect downregulation of gene expression is the E-cadherin (see below). The epithelial–mesenchymal transition (EMT) is one of the primary cellular mechanisms known to be involved in the metastatic process (Berx et al. 2007; Guarino et al. 2007; Tse and Kalluri 2007; Gavert and Ben-Ze’ev 2008). Epithelial
50
O.V. Razorenova and A.J. Giaccia
cells form cell–cell contacts through adherens junctions, whereas the mesenchymal phenotype is characterized by reduced cell–cell contacts, lost cell polarity, and increased interaction with extracellular matrix via integrins and focal adhesion kinase (FAK) (Avizienyte and Frame 2005; McLean et al. 2005). Epithelial cells, which undergo EMT, show a dedifferentiated morphology and become more motile and invasive. Epithelial cells can be reprogrammed to mesenchymal state by hypoxia and HIF that involve suppression of E-cadherin and increased cell motility (Cannito et al. 2008; Sahlgren et al. 2008; Yang et al. 2008). E-cadherin is a cellular adhesion molecule that regulates cell–cell adhesion (for review, see Hanahan and Weinberg 2000). E-cadherin inactivation enhances metastatic potential and its overexpression in cancer inhibits metastasis (Hanahan and Weinberg 2000). HIF has recently been described as a critical factor for the regulation of E-cadherin expression in ovarian carcinoma (Imai et al. 2003) and VHL-deficient CC-RCC (Esteban et al. 2006; Evans et al. 2007). The HIF-mediated upregulation of E-cadherin repressors Twist, Snail, Slug, and SIP1 serves as a mechanism of E-cadherin downregulation (Evans et al. 2007; Vesuna et al. 2008; Yoshida et al. 2009). Twist, a basic helix-loop-helix transcription factor, is a master regulator of gastrulation and mesoderm specification during embryonic development. HIF-1a was shown to regulate the expression of Twist through the HRE located in the Twist proximal promoter (Yang and Wu 2008; Yang et al. 2008). Co-expression of HIF1a, Twist, and Snail in primary tumors of head and neck squamous cell carcinoma patients correlates with the development of metastases and a poor prognosis (Yang et al. 2008). Importantly, the key role of Twist in metastasis was demonstrated by manipulation of Twist expression in highly metastatic mammary carcinoma cells. The downregulation of Twist expression in these cells led to the inhibition of their ability to metastasize from the mammary fat pad to the lung (Yang et al. 2004, 2006). In human breast cancers, high levels of Twist expression are correlated with invasive lobular carcinoma, a highly infiltrating tumor type associated with loss of E-cadherin expression (Yang et al. 2004). Lysyl oxidase (LOX), an amine oxidase involved in extracellular matrix formation, was shown to be regulated by hypoxia and HIFs (Erler et al. 2006; Erler and Giaccia 2006). Expression of LOX is associated with hypoxia in breast cancer as well as head and neck tumors, and correlates with poor patient outcome, including lower metastasis-free and overall survival rates (Erler et al. 2006; Le et al. 2009). Inhibition of LOX pharmacologically, genetically, or using a neutralizing antibody, in an orthotopic breast cancer model suppressed the metastatic potential of the tumor cells without affecting primary tumor growth (Erler et al. 2006). In vitro LOX regulated cell invasion and migration through regulating the activity of FAK. Moreover, LOX is critical for “premetastatic niche” formation in organs, where it relocates after being secreted by hypoxic primary tumors, crosslinks collagen IV in the basement membrane, and promotes CD11b+ myeloid cell recruitment (Erler et al. 2009). CD11b+ cells adhere to crosslinked collagen IV and produce matrix metalloproteinase-2, which cleaves collagen, enhancing the invasion and recruitment of bone marrow derived cells and metastasizing tumor cells.
3 Hypoxia, Gene Expression, and Metastasis
51
Hypoxia, Cancer Stem Cells, and Metastasis In the recent years, our view of cancer has been transformed by the “cancer stem cell” (CSC) theory (Reya et al. 2001; Pardal et al. 2003). Multiple studies have identified CSC subpopulations of cells within leukemias (Lapidot et al. 1994; Bonnet and Dick 1997), gliomas (Singh et al. 2003, 2004), breast (Al-Hajj et al. 2003), colon (Dalerba et al. 2007; O’Brien et al. 2007; Ricci-Vitiani et al. 2007), pancreatic (Li et al. 2007), bladder (Chan et al. 2009), melanoma (Boiko et al. 2010) cancers, head and neck squamous cell carcinoma (Prince et al. 2007), which have high self-renewal capacity, as well as more differentiated cancer cells (nonCSCs), which have very limited proliferative potential, making them incapable to drive tumor growth. The presence of CSC in tumors along with non-CSC makes tumor a complex hierarchically organized tissue. Moreover, it appears that many cancer therapies, while killing the bulk of tumor cells, fail to eliminate CSCs, which are resistant to chemo- and radiation treatment (Bao et al. 2006; Hambardzumyan et al. 2006; Li et al. 2008; Liu et al. 2006; Todaro et al. 2007; Wulf et al. 2001), allowing them to regenerate new tumors. Interestingly, many parallels can be drawn between CSCs and cancer cells residing in the hypoxic microenvironment. There is a striking correlation between chemo- and radiation resistance of CSCs and cancer cells in hypoxic regions. Increasing evidence suggests that hypoxia has the potential to inhibit tumor cell differentiation (Jogi et al. 2002; Helczynska et al. 2003), and thus plays a direct role in the maintenance of CSCs (Keith and Simon 2007; Hill et al. 2009). The role of hypoxia in general and HIFs in particular in maintaining the undifferentiated and pluripotent state of normal stem cells (SCs) is well documented (Cipolleschi et al. 1993, 2000; Lee et al. 2001; Ezashi et al. 2005; Parmar et al. 2007). Embryonic stem cells (ESCs) express the transcription factor Oct4 regulated by hypoxia during development (Covello et al. 2006). Moreover, the activity of Oct4, Sox2, and c-Myc used to reprogram fibroblasts to induced pluripotent stem (iPS) cell state (Takahashi and Yamanaka 2006; Takahashi et al. 2007; Wernig et al. 2007) is modulated by hypoxia. Oct4 is a HIF-2 target gene (Covello et al. 2006), Sox2 is hypoxia inducible in CD133+ neural CSCs and human ES cells (Forristal et al. 2009; McCord et al. 2009), and activity of c-Myc is induced by HIF-2 and inhibited by HIF-1. HIF-2 potentiates c-Myc activity by enhancing its physical association with Sp1, Miz1, and Max, although the precise mechanisms regulating these events are not yet fully understood (Gordan et al. 2007). HIF-1 antagonizes c-Myc activity by competing for binding to the transcription factor Sp1 under hypoxic conditions resulting in inhibition of c-Myc-dependent cell-cycle progression (Koshiji et al. 2004). Hypoxic regulation of Oct4, Sox2, and c-Myc simultaneously in one cell type needs to be investigated, opening the possibility that hypoxic exposure of fibroblasts or forced HIF-2 overexpression might lead to the iPS phenotype. In addition, Notch was shown to maintain a dedifferentiated state in multiple cell types under hypoxia (Gustafsson et al. 2005), where the formation of HIF-1a/Notch ICD domain complex enhanced Notch signaling (Sahlgren et al. 2008).
52
O.V. Razorenova and A.J. Giaccia
Interestingly, PTEN appears to be the negative regulator of SC pool (Groszer et al. 2001; Zheng et al. 2008), because deletion of PTEN results in an increase of neural stem cells (NSCs) numbers along with tumor expansion. Thus, the normal NSCs are finding a way to circumvent PTEN tumor suppressor function in order to become malignant. As discussed above, PTEN is a documented negative regulator of HIF, acting through the PI3K/Akt pathway (Zundel et al. 2000). In recent years, direct links between hypoxia, HIFs, and CSCs have emerged. Growing CD133+ neural CSCs at 7% oxygen compared to 20% reduced their doubling time and increased their self-renewal potential as reflected by clonogenicity (McCord et al. 2009). Growth of neural CSCs at 7% oxygen also resulted in an increase in the expression levels of the NSC markers CD133 and nestin as well as the SC markers Oct4 and Sox2. In addition, HIF-1 activity was not changed in CD133+ CSCs grown at 7%, and HIF-2 was expressed at higher levels (McCord et al. 2009). Another study showed that HIF-2a and multiple HIF-regulated genes are preferentially expressed in glioma stem cells (GSCs) in comparison to nonGSCs and normal neural progenitors (Li et al. 2009). Targeting HIFs in GSCs inhibited self-renewal, proliferation, and survival in vitro, and attenuated tumor initiation potential of GSCs in vivo. The third study showed that hypoxia (1% oxygen) promoted the self-renewal capacity and maintained the undifferentiated phenotype of CD133+ human glioma-derived CSCs, accompanied with expansion of cells bearing CXCR4 (CD184), CD44 (low), and A2B5 surface markers (Soeda et al. 2009). Knockdown of HIF-1a abrogated the hypoxia-mediated CD133-positive CSC expansion. On the other hand, mTOR signal and HIF-1 were shown to negatively regulate CD133 expression in cancer cell lines under 0.1% oxygen (which is close to anoxia) (Matsumoto et al. 2009). In support of the hypothesis that cells might be shifted into the iPS state by forced HIF expression, glioblastoma nonCSCs were unexpectedly found to possess plasticity under hypoxic conditions (2% oxygen), which helped to maintain self-renewal of glioblastoma CSCs and promoted reprogramming of glioblastoma non-CSCs toward a CSC phenotype (Heddleston et al. 2009). Thus, it looks like the oxygen concentration in the normal and CSC niche is very important and it has to be determined whether physiologic oxygen conditions or conditions of hypoxia/anoxia favor CSC and normal SC maintenance. In this case, the apparent discrepancy between the two reports about CD133 expression under hypoxia can be explained by differential effects on HIF-1 and 2 and by different oxygen levels. Because CSCs are capable of self-renewal, and are responsible for the long-term maintenance of tumor growth, it has been predicted that they might be also involved in metastases (Dalerba and Clarke 2007; Hermann et al. 2007). Thus, tumor initiating CD133+ pancreatic CSC population can be subdivided into CXCR4- (nonmetastatic) and CXCR4+ (metastatic) subpopulations. Bulk CD133+ cells (containing a mixture of CD133+/CXCR4+ and CD133+/CXCR4- cells) and individual CD133+/ CXCR4+ and CD133+/CXCR4- populations show similar tumor growth abilities. However, CD133+/CXCR4- tumors do not form spontaneous metastases during the time of experiment. A similar effect was obtained by pharmacological inhibition of
3 Hypoxia, Gene Expression, and Metastasis
53
CXCR4. CXCR4 is the receptor for the CXCL12/SDF-1 chemokine, which is involved in the control of leukocyte trafficking under physiological conditions. In cancer, CXCR4 was shown to regulate migration and metastasis (Muller et al. 2001; Balkwill 2004); notably, its ligand SDF-1 is highly expressed at common sites of metastasis, including the lung, bone marrow, and liver, and might direct CXCR4-expressing tumor cells to secondary metastatic sites (Kucia et al. 2005; Arya et al. 2007). An interesting twist in this story is that CXCR4 (Staller et al. 2003; Phillips et al. 2005; Zagzag et al. 2006) as well as its ligand SDF-1 (Ceradini et al. 2004) are hypoxia-inducible genes and HIF is a potent inducer of CXCR4 in VHL-deficient RCCs, nonsmall cell lung cancer, glioblastomas, and SDF-1 in endothelial cells (Staller et al. 2003; Ceradini et al. 2004; Phillips et al. 2005; Zagzag et al. 2006).
Conclusion The metastatic process is a complex multistep process requiring programming of cancer cells toward mesenchymal undifferentiated phenotype, with dominating promigratory and pro-survival signals. This phenotype is largely achieved through the tumor microenvironment, where cancer cells reside. The growing amount of evidence now shows that hypoxia creates a powerful niche, capable of shifting gene expression in cancer cells through stimulation of HIF activity toward pro-metastatic phenotype and protecting cells from chemo- and radiation treatment. Development of drugs, specifically targeting hypoxic cells, grows rapidly.
References Al-Hajj M, Wicha MS et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988. Arya M, Ahmed H et al (2007) Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 28(3):123–131. Avizienyte E, Frame MC (2005) Src and FAK signalling controls adhesion fate and the epithelialto-mesenchymal transition. Curr Opin Cell Biol 17(5):542–547. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171–179. Bao S, Wu Q et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760. Berra E, Pages G et al (2000) MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19(1–2):139–145. Berx G, Raspe E et al (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24(8):587–597. Blancher C, Moore JW et al (2001) Effects of ras and von Hippel–Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor
54
O.V. Razorenova and A.J. Giaccia
expression and their regulation by the phosphatidylinositol 3’-kinase/Akt signaling pathway. Cancer Res 61(19):7349–7355. Boiko AD, Razorenova OV et al (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133–137. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737. Brizel DM, Scully SP et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943. Brugarolas JB, Vazquez F et al (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2):147–158. Cannito S, Novo E et al (2008) Redox mechanisms switch on hypoxia-dependent epithelial– mesenchymal transition in cancer cells. Carcinogenesis 29(12):2267–2278. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4–10. Ceradini DJ, Kulkarni AR et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10(8):858–864. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 26(2):333–339. Chan KS, Espinosa I et al (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106(33):14016–14021. Chen F, Kishida T et al (1995) Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75. Cipolleschi MG, Dello Sbarba P et al (1993) The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 82(7):2031–2037. Cipolleschi MG, Rovida E et al (2000) The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability. Leukemia 14(4):735–739. Comerford KM, Wallace TJ et al (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62(12):3387–3394. Covello KL, Kehler J et al (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20(5):557–570. Dalerba P, Clarke MF (2007) Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1(3):241–242. Dalerba P, Dylla SJ et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104(24):10158–10163. Dewhirst MW, Tso CY et al (1989) Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys 17(1):91–99. Endrich B, Reinhold HS et al (1979) Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 62(2):387–395. Erler JT, Giaccia AJ (2006) Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res 66(21):10238–10241. Erler JT, Bennewith KL et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226. Erler JT, Bennewith KL et al (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35–44. Esteban MA, Tran MG et al (2006) Regulation of E-cadherin expression by VHL and hypoxiainducible factor. Cancer Res 66(7):3567–3575. Evans AJ, Russell RC et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27(1):157–169. Ezashi T, Das P et al (2005) Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 102(13):4783–4788. Forristal CE, Wright KL et al (2009) Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 139(1):85–97.
3 Hypoxia, Gene Expression, and Metastasis
55
Fyles AW, Milosevic M et al (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48(2):149–156. Gardner LB, Corn PG (2008) Hypoxic regulation of mRNA expression. Cell Cycle 7(13): 1916–1924. Gavert N, Ben-Ze’ev A (2008) Epithelial–mesenchymal transition and the invasive potential of tumors. Trends Mol Med 14(5):199–209. Giaccia A, Siim BG et al (2003) HIF-1 as a target for drug development. Nat Rev Drug Discov 2(10):803–811. Gnarra JR, Glenn GM et al (1993) Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 20(2):207–216. Gordan JD, Bertout JA et al (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11(4):335–347. Groszer M, Erickson R et al (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186–2189. Grunt TW, Lametschwandtner A et al (1985) The vascular pattern of basal cell tumors: light microscopy and scanning electron microscopic study on vascular corrosion casts. Microvasc Res 29(3):371–386. Guarino M, Rubino B et al (2007) The role of epithelial–mesenchymal transition in cancer pathology. Pathology 39(3):305–318. Gustafsson MV, Zheng X et al (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9(5):617–628. Hall EJ (1994) Molecular biology in radiation therapy: the potential impact of recombinant technology on clinical practice. Int J Radiat Oncol Biol Phys 30(5):1019–1028. Hambardzumyan D, Squatrito M et al (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10(6):454–456. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70. Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47. Heddleston JM, Li Z et al (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20): 3274–3284, Helczynska K, Kronblad A et al (2003) Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 63(7):1441–1444. Hermann PC, Huber SL et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313–323. Hill RP, Marie-Egyptienne DT et al (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19(2):106–111. Hockel M, Knoop C et al (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26(1):45–50. Hockel M, Schlenger K et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515. Hoffman MA, Ohh M et al (2001) von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 10(10):1019–1027. Huang ST, Vo KC et al (2004) Developmental response to hypoxia. FASEB J 18(12):1348–1365. Hudson CC, Liu M et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22(20):7004–7014.Iliopoulos O, Levy AP et al (1996) Negative regulation of hypoxia-inducible genes by the von Hippel– Lindau protein. Proc Natl Acad Sci USA 93(20):10595–10599. Imai T, Horiuchi A et al (2003) Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163(4):1437–1447. Ivan M, Kondo K et al (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292(5516):464–468. Jaakkola P, Mole DR et al (2001) Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468–472.
56
O.V. Razorenova and A.J. Giaccia
Jiang BH, Jiang G et al (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxiainducible factor 1. Cell Growth Differ 12(7):363–369. Jogi A, Ora I et al (2002) Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99(10):7021–7026. Kaelin WG Jr (2008) The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865–873. Kallman RF, Dorie MJ (1986) Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 12(4):681–685. Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472. Kizaka-Kondoh S, Inoue M et al (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94(12):1021–1028. Koshiji M, Kageyama Y et al (2004) HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23(9):1949–1956. Kucia M, Reca R et al (2005) Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23(7):879–894. Lapidot T, Sirard C et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645–648. Latif F, Tory K et al (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320. Le QT, Denko NC et al (2004) Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23(3–4):293–310. Le QT, Harris J et al (2009) Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90–03. J Clin Oncol 27(26):4281–4286. Lee YM, Jeong CH et al (2001) Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn 220(2):175–186. Lee JW, Bae SH et al (2004) Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36(1):1–12. Li C, Heidt DG et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037. Li L, Zhang L et al (2007) Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 27(15):5381–5392. Li X, Lewis MT et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679. Li Z, Bao S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513. Liu G, Yuan X et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. Mahon PC, Hirota K et al (2001) FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15(20):2675–2686. Majumder PK, Febbo PG et al (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6):594–601. Makino Y, Cao R et al (2001) Inhibitory PAS domain protein is a negative regulator of hypoxiainducible gene expression. Nature 414(6863):550–554. Matsumoto K, Arao T et al (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69(18):7160–7164. Maxwell PH, Wiesener MS et al (1999) The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. Maynard MA, Ohh M (2004) Von Hippel–Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24(1):1–13. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64(16):2170–2180.
3 Hypoxia, Gene Expression, and Metastasis
57
McCord AM, Jamal M et al (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7(4):489–497. McLean GW, Carragher NO et al (2005) The role of focal-adhesion kinase in cancer – a new therapeutic opportunity. Nat Rev Cancer 5(7):505–515. Muller A, Homey B et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56. Nguyen DX, Bos PD et al (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284. Nordsmark M, Hoyer M et al (1996) The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 35(4):701–708. O’Brien CA, Pollett A et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110. Papandreou I, Powell A et al (2005) Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 569(1–2):87–100. Pardal R, Clarke MF et al (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902. Parmar K, Mauch P et al (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104(13):5431–5436. Pause A, Peterson B et al (1999) Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc Natl Acad Sci USA 96(17): 9533–9538. Phillips RJ, Mestas J et al (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280(23):22473–22481. Prince ME, Sivanandan R et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104(3): 973–978. Qing G, Simon MC (2009) Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 19(1):60–66. Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15(4):678–685. Reya T, Morrison SJ et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111. Ricci-Vitiani L, Lombardi DG et al (2007) Identification and expansion of human colon-cancerinitiating cells. Nature 445(7123):111–115. Sahlgren C, Gustafsson MV et al (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105(17):6392–6397. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. Semenza GL (2007) Hypoxia and cancer. Cancer Metastasis Rev 26(2):223–224. Shah-Yukich AA, Nelson AC (1988) Characterization of solid tumor microvasculature: a threedimensional analysis using the polymer casting technique. Lab Invest 58(2):236–244. Shannon AM, Bouchier-Hayes DJ et al (2003) Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29(4):297–307. Singh SK, Clarke ID et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828. Singh SK, Hawkins C et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401. Sodhi A, Montaner S et al (2001) MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 287(1):292–300. Soeda A, Park M et al (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28(45):3949–3959.
58
O.V. Razorenova and A.J. Giaccia
Sprenger SH, Gijtenbeek JM et al (2001) Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization. J Neurooncol 52(3):241–247. Staller P, Sulitkova J et al (2003) Chemokine receptor CXCR4 downregulated by von Hippel– Lindau tumour suppressor pVHL. Nature 425(6955):307–311. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. Takahashi K, Tanabe K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. Todaro M, Alea MP et al (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1(4):389–402. Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26(2):225–239. Vesuna F, van Diest P et al (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367(2):235–241. Wartenberg M, Ling FC et al (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 17(3):503–505. Wernig M, Meissner A et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151):318–324. Wiesener MS, Jurgensen JS et al (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17(2):271–273. Wulf GG, Wang RY et al (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4):1166–1173. Yang J, Mani SA et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939. Yang J, Mani SA et al (2006) Exploring a new twist on tumor metastasis. Cancer Res 66(9):4549–4552. Yang MH, Wu KJ (2008) TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 7(14):2090–2096. Yang MH, Wu MZ et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305. Yoshida J, Horiuchi A et al (2009) Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol 42(2):82–91. Zagzag D, Lukyanov Y et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12): 1221–1232. Zbar B, Kishida T et al (1996) Germline mutations in the Von Hippel–Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8(4):348–357. Zelzer E, Levy Y et al (1998) Insulin induces transcription of target genes through the hypoxiainducible factor HIF-1alpha/ARNT. EMBO J 17(17):5085–5094. Zhao S, Lin Y et al (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324(5924):261–265. Zheng H, Ying H et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129–1133. Zundel W, Schindler C et al (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14(4):391–396.
Chapter 4
Molecular Mechanisms Regulating Expression and Function of Cancer-Associated Carbonic Anhydrase IX Jaromir Pastorek and Silvia Pastorekova
Abstract Hypoxia and acidosis are typical physiological factors of tumor microenvironment acting in concert to support invasive and metastatic propensity of tumor cells through rearrangement of their gene expression profile and remodeling of their phenotype. Induction of carbonic anhydrase IX (CA IX) has recently been recognized as one of the important molecular events observed in tumor cells exposed to hypoxia. CA IX can serve as a “tag” of hypoxic areas in many tumor types and thereby provides a diagnostic tool as well as a target for selective delivery of anticancer immunotherapy. Moreover, CA IX actively contributes to pH regulation which protects tumor cells from acidosis and thereby provides a target for anticancer therapy based on reduction of tumor cell survival via inhibition of CA IX enzyme activity. Both aspects attract considerable attention but their full appraisal and further development require deeper understanding of the mechanisms behind CA IX expression and functioning. Here, we summarize and discuss the “state of the art” of CA IX field in context of its relevance for tumor microenvironment.
Carbonic Anhydrases Acid–base balance mediated by equilibrium between carbon dioxide and carbonic acid is essential for proper functioning of metabolically active cells, tissues, and organs in virtually all living organisms. Although reversible conversion of carbon dioxide to carbonic acid followed by dissociation of carbonic acid to bicarbonate ion and a proton can proceed spontaneously, turnover of this reaction is not fast enough to satisfactorily supply physiological processes and therefore, it needs to be catalyzed by zinc-binding enzymes traditionally called carbonic anhydrases (CAs).
J. Pastorek (*) Department of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic e-mail:
[email protected] R.G. Bagley (ed.), The Tumor Microenvironment, Cancer Drug Discovery and Development, DOI 10.1007/978-1-4419-6615-5_4, © Springer Science+Business Media, LLC 2010
59
60
J. Pastorek and S. Pastorekova
CAs are present all over the kingdoms of animals, plants, fungi, and bacteria (including archeabacteria), and are encoded by five genetically unrelated families (a–e), each containing diverse isoforms (Supuran 2008). Human CAs belong to a-CA family, which is characterized by a deep and wide active site pocket that contains three histidine residues coordinating catalytic zinc at the bottom of the active site cleft and the fourth histidine residue functioning as a proton shuttle between the active site and solution shifting between inward and outward orientation (Zheng et al. 2008). Twelve out of fifteen human a-CA isoforms are catalytically active (CA I–IV, VA, VB, VI, VII, IX, XII–XIV). In addition to histidine residues, they contain also other conserved amino acids involved in formation of inner and outer layers of the active site cavity. The CA isoezymes differ by their catalytic activity that ranges from extremely high (in case of CA II and CA IX that belong to most efficient enzymes in general) through high/intermediate (CA IV, V, VI, VII, XII, XIV) to very low (CA I, III), as shown in Fig. 4.1. Three acatalytic isoforms (CA VIII, X, XI) lack one of three critical zinc-coordinating histidines. Moreover, there are two CA-related proteins that function as receptor protein tyrosine phosphatases (RPTPb/g). Their incompletely conserved, catalytically silent CA domain pocket serves as a ligand-binding site for neuronal adhesion molecule contactin (Peles et al. 1995).
Fig. 4.1 Schematic illustration of the human CA isoforms, their domain composition, enzyme activity, and subcellular localization. Cytoplasmic and mitochondrial CAs consist only of the CA domain, secreted CA contains a short C-terminal extension, membrane-associated CAs in addition have a transmembrane anchor and, except for CA IV, also the cytoplasmic tail. CA IX is the only isoform containing the N-terminal PG-like domain. Structure of the CA IX isoforms is depicted in more detail on the left side. It includes signal peptide (SP), proteoglycan-like segment (PG), carbonic anhydrase domain (CA), transmembrane anchor (TM), and intracytoplasmic tail (IC). Conserved zinc-binding histidines are indicated by black circles, cysteines are shown as white squares, and intramolecular disulfidic bond is drawn as dotted line. Numbers designate amino acids encompassed within the individual domains
4 Molecular Mechanisms Regulating Expression
61
Evolutionarily oldest human CA isoenzymes contain an extracellular catalytic domain and are either transmembrane (CA IX, XII, XIV), or membrane-associated via GPI anchor (CA IV) or secreted (CA VI). The transmembrane CAs also contain a hydrophobic region and a relatively conserved intracellular tail. In addition, CA IX possesses an N-terminal proteoglycan-like region. The younger CAs (I, II, III, V, VII) are intracellular isoenzymes containing a sole CA domain. Except CA VA and VB that reside in the mitochondrion, all intracellular CAs are located in the cytoplasm. Finally, the evolutionarily youngest cluster includes inactive cytoplasmic isoforms mentioned above. CAs are spread throughout the human body. Some of them are ubiquitous (CA II) or broadly distributed (CA IV, XII, XIII), others are confined to only few tissues/cell types such as muscle and adipocytes (CA III), liver (CA VA), and saliva and milk (CA VI). Cells/organs of the most abundant CA expression include the red blood cells, brain, lung, gut, liver, kidney, and testis, where various concurrently present CA isoforms cooperatively contribute to breathing, synaptic transmission, CSF secretion, production of ocular fluid, bone resorption, secretion of gastric acid, urine acidification, sperm maturation, etc. In metabolically active tissues such as kidney or stomach epithelia, the active CAs located in various subcellular compartments or on the opposite sites of the plasma membrane can interact with bicarbonate transporters or biosynthetic enzymes to form spatially and functionally coordinated protein complexes called metabolons (McMurtrie et al. 2004). In bicarbonate transport metabolon, CAs can improve the transmembrane movement of bicarbonate ion, which is a membrane-impermeable molecule transported by integral membrane bicarbonate transporters and exchangers (Casey 2006). The role of CAs is to increase the local concentration of bicarbonate in order to accelerate its flux across the membrane and thereby regulate intracellular and extracellular pH (McMurtrie et al. 2004). CAs are essential components of physiological processes and disbalance in their expression is associated with several diseases. These include on the one hand osteopetrosis and mental retardation due to CA II deficiency and, on the other hand, glaucoma, diabetic retinopathy, epilepsy, obstructive pulmonary disease, obesity and various neurological diseases linked with abnormally high expression of CA II, III, XII, and other isoforms. Some of these diseases are successfully treated with inhibitors of CA activity used as primary or supplementary therapy, for the others, new derivatives of CA inhibitors are under development as promising drugs (Pastorekova et al. 2004b). Although importance of CAs in cancer has been demonstrated relatively recently, inspections into their expression in tumor cells and tissues have been initiated a long time ago. Several independent studies revealed reduced activity and/or decreased levels of cytosolic isoforms CA I, II, III, XIII in colorectal, hepatocellular, and lung tumors (when compared to their normal counterparts) indicating that these isoforms are predominantly needed for differentiated cells/tissues (Chiang et al. 2002; Kivela et al. 2001; Kummola et al. 2005; Kuo et al. 2003; Mori et al. 1993; Yoshiura et al. 2005). This conclusion has, however, few exceptions, including CA II expression in endothelium of malignant melanomas and meningiomas and a recently discovered
62
J. Pastorek and S. Pastorekova
extremely high expression of CA II in gastrointestinal stromal tumors (Haapasalo et al. 2007; Yoshiura et al. 2005; Parkkila et al. 2010). Relationship of the mitochondrial CA VA and VB isoforms to cancer remains unexplored, although they might be relevant for biosynthesis of metabolic intermediates in proliferating tumor cells. Finally, out of four CA isoforms localized at the cell surface, only CA IX and XII showed consistent link with tumor tissues and are systematically investigated as promising targets for anticancer therapy (Pastorekova et al. 2008). Especially CA IX, which is almost exclusively expressed in tumors, attracts considerable interest with expectation that unraveling its regulation and functional contribution to tumor phenotype will provide clues for development of new anticancer strategies.
Molecular Features of CA IX CA IX (initially named MN antigen) was identified in HeLa cervical carcinoma cells as a density-induced cell surface protein associated with tumor phenotype of human cell lines and tissue specimens (Pastorekova et al. 1992; Zavada et al. 1993). Primary structure of the MN antigen was derived from cDNA and genomic sequences and was found to contain a well-conserved carbonic anhydrase domain located in the large extracellular part of the molecule (Pastorek et al. 1994) (Fig. 4.1). This CA domain shows a significant identity to secreted isozyme CA VI (40.8%) and cytosolic isozyme CA II (35.8%), respectively, and possesses all important amino acids required for the catalytic activity. It is N-glycosylated by 4 kDa high mannose sugar chain attached to N346 and is catalytically active. At the time of MN protein discovery, this was the ninth mammalian CA identified and thus it was renamed to CA IX (Hewett-Emmett and Tashian 1996). In addition to catalytic domain, CA IX (as the only CA isoform) contains an N-terminal PG-like region homologous to keratan sulfate attachment domain of a large proteoglycan aggreccan (Opavsky et al. 1996). According to mass spectrometric analysis, this part of the molecule appears to contain a keratan sulfate glycosaminoglycan chain of about 3.5 kDa that is presumably attached to T115, in the article numbered T78 (without signal peptide) (Hilvo et al. 2008). Presence of such modification might have important biological implications analogous to keratan sulfate chain of CD44 metastasis-related protein, which mediates interactions with constituents of extracellular matrix. However, experimental proof of this concept has not been given for CA IX so far. The PG-like region has also another important feature – it predominantly contains negatively charged acidic amino acids that are mostly arranged within four identical and three imperfect GEEDLP repeats. This results in remarkably acidic character of the PG-like region that seems to have a significant impact on the catalytic activity of CA IX as an intrinsic buffer optimizing CO2 hydration at acidic pH values characteristic for solid tumors (Innocenti et al. 2009). Thus, activity of the entire extracellular portion of CA IX (including PG and CA domains) expressed in baculovirus system exceeds that of CA II
4 Molecular Mechanisms Regulating Expression
63
(the best known catalyst) and reaches maximum at pH values around 6.5 in contrast to other CA isoforms which have optimum catalytic efficiency around pH 7. C-terminal part of the catalytic domain is extended with a little juxtamembrane fragment, followed by a hydrophobic transmembrane (TM) region and a short intracellular tail (IC). The IC tail is well conserved among the transmembrane CA isoforms (CA IX, XII, XIV) and its removal leads to loss of cell surface location of CA IX despite preserved TM region suggesting that IC mediates protein–protein interactions that maintain CA IX at its proper position (Hulikova et al. 2009). In vitro mutagenesis of the submembrane cluster of basic amino acids revealed that IC tail participates in inside-out signaling that affects functions of the extracellular CA IX portion (Hulikova et al. 2009). In addition, the IC tail contains three potential phosphorylation sites (T443, S448, andY449). While Y449 participates in EGFRinduced signal transduction to Akt kinase (Dorai et al. 2005), phosphorylated T443 is critical for modulation of the pH regulatory function of CA IX (manuscript in preparation). Molecular weight of CA IX analyzed under reducing conditions and visualized on Western blot corresponds to 58/54 kDa. Existence of two forms of the protein remains unexplained and the data attributing the double band to different parts of CA IX molecule are still controversial. Interestingly, in non-reducing conditions, CA IX is capable to form oligomers that were initially considered for trimers (or tetramers). This supposition was based on the molecular weight of about 153 kDa and on other indices including the capability of CA IX to fit into envelope of the vesicular stomatitis virus and form the virus pseudotypes (Pastorekova et al. 1992; Zavada et al. 1993). The latter aspect was shown to require trimerization or tetramerization (Kreis and Lodish 1986). In fact, CA IX molecule contains four cysteine residues, three of them located in the catalytic domain and one in the region just above the plasma membrane. While C156 and C336 are placed at the positions analogous to intra-molecular S–S bond-forming cysteines in other CAs, the additional two residues C174 and C409 might be theoretically available for intermolecular S–S bonds. Biochemical and crystallographic studies confirmed the proposed intramolecular S–S bond, but they also suggested that CA domain of CA IX forms dimer stabilized by homologous S–S bridge between C174 corresponding to C41 according to CA I numbering (Alterio et al. 2009). Although results of the biochemical and crystallographic analyses do not support the concept of CA IX trimerization, it is still possible that the discrepancy results from the absence of the regions flanking the catalytic domain, as it was observed also in other cases, such as with Fas receptor or TRAF6 (Scott et al. 2009; Yin et al. 2009). Crystallographic analysis brought very important structural data on the CA IX catalytic domain that is similar to other a-CAs (Alterio et al. 2009). It has a compact globular appearance with a large conical cavity containing zinc ion at the bottom. The entrance to the active site is occupied by three arginine residues R95, R97, and R167, which are not conserved in other CA isoforms and have been proposed to mediate crosstalk of CA domain with acidic PG-like region presumably implicated in steric control of the substrate accession or the proton-transfer reaction. The active site and the N-terminus of the catalytic domain face the extracellular space, whereas
64
J. Pastorek and S. Pastorekova
its C-terminus is oriented toward the plasma membrane. This arrangement is fully compatible with the role of CA IX in extracellular acidification of tumor microenvironment.
CA IX Tissue Distribution CA IX protein expression has been studied in a broad range of human tissues. Most of these studies were performed using the monoclonal antibody M75 that recognizes a repetitive linear epitope in the PG-like domain of both native and denatured CA IX (Zavada et al. 2000) and is therefore suitable for virtually all immunodetection methods including immunohistochemistry on both paraffinembedded and frozen sections (even those archived for years), immunoblotting, immunoprecipitation, flow cytometry, etc. Additional antibodies produced by our team (Zat’ovicova et al. 2003) are mostly directed to CA domain and bind to conformational epitopes (thus they do not work in immunoblotting) similarly to well-known monoclonal antibody G250 that was generated even before the discovery of CA IX against a renal cell carcinoma antigen later shown to be identical to CA IX (Oosterwijk 2008a, b). New human monoclonal antibodies described recently display excellent CA IX binding properties (Ahlskog et al. 2009b). Some of these antibodies have a great potential as diagnostic and therapeutic tools. Noteworthy, a commercial antibody NB100 was advertised to give the same staining pattern as M75, but later demonstration of its significant non-specific reactivity against tubulin considerably reduces its value for detection of CA IX (Li et al. 2009). Overall expression pattern of CA IX is characterized by limited expression in normal tissues and broad distribution in different tumors. Physiological expression of CA IX is linked with epithelial tissues of the gastrointestinal tract with the highest CA IX level in all principal cell types of the glandular gastric mucosa and in the gallbladder epithelium. CA IX is also present in the small intestine and proximal colon, but its level decreases toward rectum (Pastorekova et al. 1997). Intestinal CA IX is expressed in the cryptal epithelial cells that possess the greatest proliferative activity (Saarnio et al. 1998). CA IX is also abundant in the gallbladder mucosa, while the pancreatic ducts show only weak expression. In all gastrointestinal epithelia, CA IX is present in the basolateral membranes, suggesting its possible involvement in intercellular communication, maintenance of tissue integrity, and regulation of basolateral ion transport (Pastorekova et al. 1997). Based on gastric phenotype of CA IX-deficient mice that includes hyperplasia, numerous cysts, and abnormal lineage development but no change in gastric pH, CA IX plays a role in gastric morphogenesis and control of cell proliferation and/or differentiation (Gut et al. 2002). CA IX is also expressed in some other healthy tissues, albeit at much lower levels compared to alimentary tract. These include linings of the body cavity, reproductive tract, ventricular linings of CNS, and choroid plexus (Ivanov et al. 2001). The other normal human tissues are CA IX negative.
4 Molecular Mechanisms Regulating Expression
65
In contrast, CA IX expression is readily detected at significant levels in diverse tumors, including carcinomas of the uterine cervix, kidney, brain, head and neck, esophagus and lung, colon, breast, ovaria, endometrium, vulva, bladder, etc. (Bartosova et al. 2002; Haapasalo et al. 2006; Ivanov et al. 2001; Jarvela et al. 2008; Kowalewska et al. 2005; Liao et al. 1994, 1997; McKiernan et al. 1997; Niemela et al. 2007; Saarnio et al. 1998; Turner et al. 1997; Vermylen et al. 1999). From an unknown reason, CA IX is only occasionally expressed in the prostate carcinomas (Smyth et al. 2009).
Regulation of CA IX Expression Presence of CA IX in cancerous tissues of different origin suggests that it represents a phenomenon common to all solid tumors. In accord with this supposition, it has been proven that transcription of CA IX is principally driven by hypoxia that occurs in variable extent in virtually all tumor tissues. Hypoxia often develops in growing tumors due to insufficient supply of oxygen by irregular and functionally inadequate vasculature. This creates a selective pressure favoring those tumor cells that are capable to induce adaptative responses including shift to anaerobic glycolysis, angiogenesis, reduced proliferation and cell adhesion, increased pH regulation, etc. Consequently, hypoxic cells gain oncogenic metabolism, resistance to conventional anticancer treatment, and more aggressive phenotype with metastatic potential (Harris 2002). At the molecular level, hypoxia leads to reprogramming of the cell’s transcriptional profile, which is principally governed by a master transcription factor HIF, i.e. hypoxia inducible factor (Coleman and Ratcliffe 2007), illustrated in Fig. 4.2. HIF is a heterodimer consisting of an oxygen-regulated a subunit (existing in three isoforms) and a constitutive b subunit. In normoxia, HIF-a is modified by oxygendependent prolyl hydroxylases (PHDs) and an asparaginyl hydroxylase (factor inhibiting HIF, named FIH), enzymes that belong to the Fe(II) and 2-oxoglutarate dioxygenase superfamily. FIH hydroxylates N803 in the C-terminal activation domain of human HIF-1a and thereby prevents its interaction with transcriptional coactivators. Prolyl hydroxylases hydoxylate P564 and P402 in the oxygen-dependent degradation domain, thus leading to HIF-a recognition by pVHL tumor suppressor protein, followed by its rapid ubiquitilation and proteasome degradation (Hirota and Semenza 2005). In hypoxia and/or following oncogenic activation or loss of VHL function, HIF-a escapes modifications by PHDs and FIH, enters the nucleus, dimerizes with the constitutive b subunit of HIF, interacts with coactivators, and forms an active transcriptional complex (Ruas and Poellinger 2005). This complex binds DNA at sites containing the hypoxia-response element (HRE; 5¢-RCGTG-3¢), which is present in the promoters of a wide spectrum of target genes encoding functionally diverse proteins involved in angiogenesis (VEGF, VEGF receptor, transforming growth factor TGF-b), vascular tonus (nitric oxide synthase), erythropoiesis (erythropoietin-1),
66
J. Pastorek and S. Pastorekova
Fig. 4.2 Hypoxia-induced HIF-1-mediated transcriptional activation of CA9 gene. The left side shows the situation in normoxia. When oxygen supply is sufficient, prolyl hydroxylases (PHD) and factor inhibiting HIF (FIH) modify a-subunit of hypoxia-inducible factor 1 (HIF-a). Hydroxylation of conserved prolines in HIF-a molecule leads to its recognition by von Hippel– Lindau tumor suppressor protein (VHL), which triggers HIF-a ubiquitilation and degradation. Hydroxylaion of N-terminal asparagine blocks binding of co-activators. This principally results in the absence of active HIF-a from normoxic cells. The right part shows the situation in hypoxia. Lack of oxygen keeps hydroxylases inactive, HIF-a is not modified and remains protected from recognition by VHL. This results in stabilization and accumulation of HIF-a, translocation to nucleus, dimerization with HIF-b, interaction with co-activators, and formation of active transcription complex, which induces expression of target genes, including CA9. This induction can be modified by additional pathways not shown in the figure and leads to exposure of CA IX protein on the surface of hypoxic cells
glycolysis (glucose transporters GLUT-1,3, lactate dehydrogenase LDH-A, pyruvate dehydrogenase kinase PDK1), ion transport and pH regulation (natrium-proton exchanger NHE1, monocarboxylate transporter MCT4), remodeling of extracellular matrix (matrix metalloproteinase MMP-2, cathepsin D), adhesion and migration (hepatocyte growth factor receptor c-Met, transcription factors Snail/Slug), cell proliferation and survival (insulin growth factor-binding protein), drug resistance (P glycoprotein), and additional cellular phenomena linked with tolerance of tumor cells to hypoxia. Genomic position of HRE differs among the transcriptional targets of HIF, in some cases representing enhancer rather than promoter element (Camenisch et al. 2001). In case of the CA9 gene, HRE is an important component of the core promoter and its position adjacent to transcription initiation site (–3/–10) makes it a key regulatory element principally determining CA9 gene expression (Wykoff et al. 2000). This HRE element binds HIF-1 (rather than HIF-2) and cooperates with a neighboring consensus sequence binding SP1 transcription factor (Kaluz et al. 2002). The HRE-SP1 module is critical for transcriptional activation of the CA9 gene both in hypoxia and in high cell density (creating pericellular hypoxia) and its mutagenesis leads to reduction or complete loss of the promoter activity (Kopacek et al. 2005). Additional regulatory elements present within the CA9 promoter, including AP-1 binding site and position/orientation-independent
4 Molecular Mechanisms Regulating Expression
67
silencer, play secondary roles as they just modulate the outcome of the transcriptional activation triggered by HIF-1-SP1 (Kaluz et al. 1999). As recently discussed, CA9 transcription profile primarily reflects the transcriptional activity (not the level) of HIF-1 (Kaluz et al. 2009). In accord, different pathways that affect HIF-1 can also increase the expression of CA9 gene, such as MAPK and PI3 kinase pathways, Notch pathway, HBx oncoprotein of hepatitis B virus, and v-Src and c-Src oncoproteins (Holotnakova et al. 2010; Kopacek et al. 2005; Sansone et al. 2007; Takacova et al. 2010). Moreover, hypoxia-induced CA9 gene expression requires an intact unfolded protein response (UPR) pathway, which operates via ATF4 transcription factor that binds to CA9 promoter (van den Beucken et al. 2009a, b). Under normoxic conditions, expression of CA9 gene is down-regulated by pVHL tumor suppressor protein, which negatively regulates HIF-1a. However, CA9 expression is not suppressed by the mutated variants of pVHL lacking the elongin binding domain which is required for the interaction of pVHL with elongins B/C and integration of pVHL within a ubiquitin ligase complex (Ivanov et al. 1998). This explains why CA IX protein is overexpressed in a high percentage of renal cell carcinomas (RCC) that frequently carry an inactivating mutation in the VHL gene (Mandriota et al. 2002). Extracellular acidosis, which frequently occurs in tumor microenvironment, contributes to CA9 transcription at least in some tumor cell types, such as those derived from glioblastoma (Ihnatko et al. 2006). CA9 induction by acidosis can be observed in both absence and presence of hypoxia. Promoter analysis revealed involvement of SP1 and HRE promoter elements and showed that acidosis can modulate CA9 expression only when basic CA9 activation through MAPK and/or PI3K pathways is preserved. However, inconsistent effects of acidosis on CA9 expression were obtained in other cell types possibly due to their differential sensitivity to acidosis-associated stress (Willam et al. 2006). Finally, transcription of CA9 gene can be negatively controlled by methylation of CA9 promoter and by treatment with xenobiotics (Ashida et al. 2002; Cho et al. 2000; Jakubickova et al. 2005; Takacova et al. 2009). CA9 is also a subject of post-transcriptional regulation via alternative splicing that produces two types of transcripts – a full-length transcript encoding a plasma membrane-localized and functionally competent CA IX protein, and a truncated mRNA lacking exons 8/9 and producing a cytoplasmic/secreted form of CA IX protein with decreased enzyme activity (Barathova et al. 2008). The longer transcript is regulated by hypoxia and linked to tumor phenotype, whereas the shorter one is expressed at low level independently of hypoxia and is therefore detectable also under normoxia and in the normal tissues. This is very important for the correct design of primers used in the clinical studies of cancer- and/or hypoxia-related expression of CA9, where the alternatively spliced variant can provide a falsepositive signal. As recently demonstrated in non-small cell lung carcinoma, fulllength CA9 transcript is the most accurate surrogate of hypoxic stress and represents the only variant with a prognostic role (Malentacchi et al. 2009). These data indicate the importance of a separate measurement of the two isoforms in cancer and
68
J. Pastorek and S. Pastorekova
the need of an accurate re-evaluation of most studies on the clinical role of CA9 mRNA in cancer diagnosis. At the posttranslational level, CA IX protein shows high stability, with the halflife of about 38 h (as determined in reoxygenated HeLa cells), and therefore represents a marker of both present and past hypoxia (Rafajova et al. 2004). The final amount of CA IX protein is regulated by shedding of its ectodomain (ECD) to culture medium and to body fluids of tumor patients (Zatovicova et al. 2005; Zavada et al. 2003). Constitutive shedding of CA IX ECD releases approximately 10% of the cell-associated protein and is sensitive to metalloproteinase-inhibitor batimastat. Hypoxia maintains the normal rate of the basal ECD release, thus leading to a concomitant increase in cell-associated and extracellular levels of CA IX. The CA IX ECD shedding can be several fold induced by treatment with phorbol12-myristate-13-acetate and pervanadate. This activated shedding is mediated by TNF-a-converting enzyme (TACE/ADAM17). Thus, cleavage of CA IX ectodomain appears to be a regulated process that responds to signal transduction-related stimuli and may contribute to adaptive changes in the protein composition of tumor cells and of their microenvironment. In this context, it is noteworthy that the extracellular domain of CA IX shed to body fluids is a promising circulating cancer marker for patient selection, and monitoring of treatment outcome (Carney 2007). Finally, posttranslational modifications, such as phosphorylation, regulate the CA IX-mediated signal transduction (Dorai et al. 2005) as well as the functional status of CA IX (the latter aspect has just been experimentally proven). Taken all data together, it can be concluded that control of CA9 gene expression is a complex process, which affects biogenesis of CA IX protein at several levels, including the functional activation (as discussed in the text below). It is also evident that hypoxic pathway is a major regulator of CA IX.
Role of CA IX in Cancer Hypoxic regulation of CA9 gene indicates that it is a part of the adaptive mechanisms of tumor cells exposed to hypoxia (and associated acidosis) and that the cells need the CA IX protein to survive these stresses typical for tumor microenvironment. In accord with this supposition, it has been demonstrated that CA IX protein is functionally involved in pH regulation and in cell adhesion–migration–invasion, which are important phenomena contributing to tumor progression. The need for increased pH regulation is related to metabolic changes triggered by hypoxia. Insufficient oxygen delivery to hypoxic tumor areas restricts energy production by oxidative phosphorylation and induces metabolic shift of hypoxic cells to glycolysis, which can produce ATP in the absence of oxygen. For this purpose, HIF-1 coordinates up-regulation of virtually all glycolytic enzymes and glucose transporters, as well as lactate dehydrogenase isoforms LDH-A and LHD5, which convert pyruvate to lactate, and also pyruvate dehydrogenase kinase 1, which prevents entry of pyruvate into the Krebs cycle and reinforces the glycolytic
4 Molecular Mechanisms Regulating Expression
69
metabolism (Brahimi-Horn and Pouyssegur 2007). Although glycolysis is less efficient in energy production than respiration, its metabolic intermediates can be utilized for biosynthetic reactions and this makes it useful for proliferating tumor cells in both anaerobic and aerobic conditions, in accord with the classical Warburg’s observation (Gatenby and Gillies 2004). For that reason, tumor cells depend on oncogenic metabolism, in which glycolysis predominates over respiration to extent depending on oxygen availability and activation of different oncogenic pathways. Glycolysis generates lactate as an end-product, but the oncogenic metabolism produces also excess of protons and CO2 (Helmlinger et al. 2002). These acidic products have to be eliminated from tumor cells to maintain neutral intracellular pH and preserve proliferation and survival. The acidic waste then accumulates in the extracellular space because of its insufficient removal by inadequate tumor vasculature and causes extracellular acidosis (Stubbs et al. 2000). Acidosis develops especially in tumor regions that suffer from hypoxia. This is supported by correlation between the mean profiles of partial oxygen pressure and intratumoral pH values (Helmlinger et al. 1997), as well as by VHL/HIF pathway controlled expression of several pH regulating molecules (Karumanchi et al. 2001). Importantly, acidic extracellular pH (pHe) has been associated with tumor progression via multiple effects including up-regulation of angiogenic factors and proteases, increased invasion, and impaired immune functions (Fukumura and Jain 2007; Raghunand et al. 2003). In addition, it can influence the uptake of anticancer drugs and modulate the response of tumor cells to conventional therapy (Teicher 2009). Tumor cells utilize two main mechanisms to regulate their pH – lactate/proton extrusion and bicarbonate uptake (Fig. 4.3). Lactic acid and protons are extruded mostly by the H+/monocarboxylate transporters (MCT4 and MCT1) and the Na+/H+ exchanger (NHE1). Bicarbonate ions are imported by anion exchangers (e.g. AE2) or Na+/bicarbonate co-transporters (NBC1) and react with intracellular protons, thereby increasing the intracellular production of CO2, which diffuses across the plasma membrane to extracellular space. However, origin of the extracellular bicarbonate ions in an acidic pericellular milieu was unclear until CA IX was described as a component of hypoxic tumor phenotype (Stubbs et al. 2000). CA IX seems to be “designed” for this purpose, because its high catalytic activity is insensitive to lactate and reaches maximum at pH 6.5 typical for acidic tumor microenvironment (both aspects contrasting with other CA isoforms) (Innocenti et al. 2005, 2009). In addition, the catalytic domain of CA IX is localized on the cell surface and its entrance is exposed to extracellular space in the position suitable for accommodating CO2 substrate (Alterio et al. 2009). Moreover, CA IX activity is inhibited by bicarbonate suggesting that it operates mainly in catalysis of CO2 hydration to produce bicarbonate rather than to utilize it (Innocenti et al. 2005). Finally, CA IX spatially and functionally cooperates with bicarbonate exchangers/ transporters in bicarbonate transport metabolon (Morgan et al. 2007). According to a recent concept, bicarbonate locally produced by CA IX from extracellular CO2 is directly consumed for transport and neutralization of intracellular pH in tumor cells, whereas proton produced in the same reaction remains
70
J. Pastorek and S. Pastorekova
Fig. 4.3 Role of CA IX as a component of pH regulatory machinery in cancer cell. Hypoxia induces expression of many proteins involved in metabolism and pH regulation including GLUT-1 and glycolytic enzymes. This causes shift to glycolysis that produces excess of lactate and protons. To preserve neutral intracellular pH, these acidic products are extruded by HIF-1-regulated monocarboxylate transporter (MCT4) and the Na+/H+-exchanger (NHE1) and acidify the extracellular microenvironment. Tumor cells also produce CO2 that diffuses across the plasma membrane. Extracellular CO2 is hydrated in a reaction catalyzed by CA IX, which produces protons and bicarbonate ions. Protons remain outside of cell and further enhance acidosis. Bicarbonate ions are delivered directly to bicarbonate transporters (BT) for accelerated inward transport to cytoplasm where they buffer protons and contribute to intracellular pH neutralization. This produces CO2 that leaves the cell by diffusion and may enter new round of hydration
outside of cells and increases extracellular acidosis (Fig. 4.3). In accord with this concept, CA IX role in pH regulation was demonstrated using different cellular models either with constitutive overexpression of CA IX or with suppression of CA IX by RNA interference. The first proof was obtained using MDCK cells grown in monolayer, in which CA IX could acidify the culture medium in hypoxia but not in normoxia, suggesting that hypoxia activates the catalytic performance of CA IX (Svastova et al. 2004). Additional evidence was obtained in three-dimensional multicellular spheroids generated from transfected HCT116 cells (Swietach et al. 2008, 2009). There, the ectopic expression of CA IX resulted in less prominent core intracellular acidity and in enhanced core extracellular acidity. The data obtained in spheroids and interpreted in the framework
4 Molecular Mechanisms Regulating Expression
71
of tumor microenvironment indicate that CA IX facilitates CO2 excretion from cells and that this effect depends on the cellular CO2/lactic acid emission ratio set by local oxygenation and bicarbonate uptake (Swietach et al. 2009). Finally, in hypoxic LS174Tr tumor cells, CA IX was shown to contribute to extracellular acidification in response to a CO2 load and to maintenance of a neutral-alkaline intracellular pH (Chiche et al. 2009b). This latest study also demonstrated that CA IX preserves tumor cell survival in a range of acidic extracellular pH (6.0– 6.8). Moreover, CA IX silencing led to a 40% reduction in xenograft tumor volume supporting the view that hypoxia-induced CA IX is a significant tumor pro-survival pH-regulating enzyme. Interestingly, parallel suppression of CA IX and XII caused dramatic 85% reduction in tumor growth, suggesting cooperation/ compensation of these transmembrane CA isoforms (although suppression of CA XII alone had no effect). The second function of CA IX is linked to cell adhesion and related processes, such as motility, migration, and invasion, which facilitate tumor progression. Again, the insight into this role of CA IX was obtained in the study of E-cadherin-mediated cell–cell adhesion in CA IX-transfected MDCK cells (Svastova et al. 2003). Ectopic expression of CA IX resulted in decreased intercellular contacts, reduced aggregation, and increased dissociation. Similarly to some oncoproteins, such as EFGR and Muc-1, CA IX acts via competitive interaction with b-catenin, thereby disconnecting E-cadherin from adhesion contacts with actin cytoskeleton. The capability of CA IX to interfere with the function of E-cadherin in those tumors that express both proteins might contribute to acquisition of more aggressive phenotype. Since decreased cell adhesion is a prerequisite of motile/migratory phenotype, it was tempting to examine possible involvement of CA IX. Recent experiments using various cell models have shown that expression of CA IX leads to increased scattering, better wound healing, and improved transwell migration both with and without HGF stimulation (manuscript in preparation). On the other hand, the suppression of CA IX by RNA interference decreases the wound healing capacity of tumor cells (Chiche et al. 2010). In this context, it is important to note that motility and migration require not only coordinated formation and release of cell adhesion contacts, digestion and reorganization of the extracellular matrix, but also intense local ion and water transport across the plasma membrane. All of these operations depend on intracellular and extracellular pH regulation. Thus, cell migration is significantly affected by mechanisms that protect tumor cells from hypoxia and acidosis (Stock and Schwab 2009). This knowledge is integrated into a model, in which protruding edge of migrating cell is occupied and driven by different components of ion transport and pH regulating machinery (including CA IX). On this basis, it is conceivable that the catalytic activity plays a considerable role in CA IX-induced de-adhesion, motility, and migration and that the PG domain, implicated in these processes, requires a cooperation with the CA domain (and possibly also with intracellular tail) of CA IX. Initial experimental data favor this idea (unpublished data).
72
J. Pastorek and S. Pastorekova
Clinical Value of CA IX Association with different solid tumors and up-regulation by hypoxia predisposes CA IX to serve as an intrinsic marker of hypoxia and prognostic indicator (Potter and Harris 2004). Moreover, expression pattern and functional involvement of CA IX in hypoxic tumor phenotype make it a suitable target for anticancer treatment (Pastorekova et al. 2006). Both aspects already found a considerable support in clinical studies, in vivo models, and even in the clinical trials. When considering CA IX as a marker of hypoxia, it is important to take into account temporal parameters of its induction and stability. Based on cell culture data, CA IX protein appears on the cell surface several hours after exposure of cell culture to hypoxia, reaching maximum level at around 16 h (Rafajova et al. 2004). Due to its high stability, CA IX remains detectable for several days also in reoxygenated cells. Moreover, CA9 gene is responsive to a broad range of oxygen concentrations representing severe to moderate hypoxia, with optimum between 1 and 2% atmospheric O2 in culture conditions. These parameters differ from those of HIF-1a, which is both quickly induced and short-lived protein as well as from metabolic labels, such as pimonidazole, which accumulates only in severely hypoxic cells (as indicated by narrow perinecrotic incorporation pattern). Furthermore, HIF-1a staining only detects protein levels, but not the transactivation status, which actually determines induction of transcriptional targets. All these facts can explain why there is incomplete overlap between HIF-1a staining and CA IX staining in tumor tissue specimens, and why there are areas with presence of CA IX in absence of HIF-1a and vice versa. From the similar reasons, partial discrepancy exists also between CA IX and other HIF-1 targets, such as VEGF (which is secreted and considerably regulated by non-hypoxic pathways), GLUT-1 (which shows the highest response at 0.1% O2), and surely also other HIF-regulated molecules that all differ with respect to time and magnitude of induction, stability, and other characteristics (Lendahl et al. 2009). Such enormous variability suggests that there is no ideal intrinsic hypoxia marker, since each hypoxia-induced molecule or metabolic label represents only certain facet of the hypoxic response. Indeed, this can be taken as an advantage – for example, comparison of the spatial distribution of CA IX and pimonidazole allows for the discrimination between hypoxic and reoxygenated areas, which might have different clinical impact (Shin et al. 2007). Nevertheless, based on numerous studies it appears that CA IX is the best available indicator of chronic hypoxia and as such, it also seems to have prognostic and/or predictive value in certain tumor types, particularly derived from brain, lung, breast, colon, cervix, ovaria, etc. Although some groups reported absence of significant association with cancer prognosis, most of the published papers state that CA IX expression can be utilized as an independent predictor of poor outcome after therapy and indicator of worse cancer development (summarized in Table 4.1). In this respect, renal cell carcinomas (particularly of clear cell type) represent a special category of tumors, in which CA IX expression is frequent and high due to genetic defect in VHL gene, and absent or non-functional pVHL protein.
Independent prognostic factor for both progression-free survival and overall survival in high-risk early-stage cervical cancer Elevated expression associated with more frequent distant metastases in early-stage cervical cancer Strong correlation to metastasis, important indicator for more aggressive systemic therapy Up-regulated in hypoxic human cervical tumors and ssociated with poor prognosis
Associated with aggressive phenotype and chemo-resistance of basal-like breast tumors Independent prognostic factor with respect to relapse-free survival Correlates with poor prognosis in invasive breast carcinoma In both univariate and multivariate analysis, survival is significantly inferior in patients with invasive breast tumors expressing CA IX Independent prognostic marker in premenopausal patients with one to three positive lymph nodes and a putative marker of radiation resistance Negative predictor of treatment efficacy in ER-positive patients on the adjuvant tamoxifen after primary chemo-endocrine therapy Associated with a significantly shorter disease-free survival in patients with HIF-a-negative breast tumors Perinecrotic HIF-a overexpression with strong expression of CA IX and GLUT-1 associated with poor prognosis in invasive breast cancer Associated with worse relapse-free and overall survival in an unselected cohort of patients with invasive breast cancer
Cervical carcinoma
Breast carcinoma
Chia et al. (2001) (continued)
Vleugel et al. (2005)
Generali et al. (2006a)
Generali et al. (2006b)
Brennan et al. (2006)
Tan et al. (2009) Crabb et al. (2008) Trastour et al. (2007) Hussain et al. (2007)
Kim et al. (2006) Loncaster et al. (2001)
Kirkpatrick et al. (2008)
Liao et al. (2010)
Table 4.1 Overview of clinical studies on relationship of CA IX to cancer progression, prognosis, and/or treatment outcome (non-RCC tumors) Tumor type Proposed clinical value of CA IX Reference
4 Molecular Mechanisms Regulating Expression 73
Proposed clinical value of CA IX
Co-expression of CA IX and HIF-a associated with poor prognosis in oral squamous cell carcinoma patients Combined CA IX and HIF-a significantly predictive of overall survival in patients with advanced head-and-neck cancer Better local control in radiotherapy-treated laryngeal carcinoma patients having tumors with non-hypoxic profile (low CA IX, low HIF-a) Significant association with postoperative recurrence and poor overall survival in surgically treated oral squamous cell carcinoma High CA IX and Ki-67 expression associated with poorer overall survival and shorter diseasefree survival in patients with squamous cell carcinoma of the tongue Independent correlation with prognosis when combined with GLUT-1
Poorer outcome in patients with oligodendroglial tumors Significant parameter for the survival of patients with grades II/III astrocytic gliomas Poor prognosis in astrocytic tumor patients
Expression by cancer-associated fibroblasts predicts lower survival rate in patients with lung adenocarcinoma Full-length CA IX transcript associated with lymph node involvement, tumor stage, and poor prognosis Indicates poor prognosis for patients with stages I+II lung adenocarcinoma The most reliable hypoxia marker for predicting tumor aggressiveness Indicator for poor disease-free survival in early-stage non-small-cell lung cancer Associated with a poor prognosis in non-small-cell lung cancer
Intensity predicts disease-free survival and disease-specific survival in patients with rectal cancer
Correlates with extremely poor prognosis in esophageal and gastric adenocarcinomas Has a tripartite role as a diagnostic, prognostic, and therapeutic molecular marker in urothelial carcinoma of the bladder Correlates with clinical outcome in transitional cell carcinoma of the bladder Predicts for poor prognosis in patients with deep, large, and high-grade soft tissue sarcoma
Head-and-neck cancer
Brain tumors
Lung carcinoma
Colorectal carcinoma
Other tumors
Table 4.1 (continued)
Tumor type
Hussain et al. (2004) Maseide et al. (2004)
Driessen et al. (2006) Klatte et al. (2009)
Korkeila et al. (2009)
Kon-no et al. (2006) Kim et al. (2005) Kim et al. (2004) Swinson et al. (2003)
Malentacchi et al. (2009)
Nakao et al. (2009)
Jarvela et al. (2008) Korkolopoulou et al. (2007) Haapasalo et al. (2006)
De Schutter et al. (2005)
Kim et al. (2007)
Choi et al. 2008)
Schrijvers et al. (2008)
Kappler et al. (2008)
Eckert et al. (2010)
Reference
74 J. Pastorek and S. Pastorekova
4 Molecular Mechanisms Regulating Expression
75
Resulting activation of HIF pathway leads to constitutive up-regulation of HIF targets including CA IX independently of physiological hypoxia (Mandriota et al. 2002). In contrast to other tumor types, CA IX expression in RCC decreases with increasing tumor grade and stage. This is apparently because CA IX is a target of HIF-1a that predominates early in VHL disease but is later displaced by tumor growth-promoting isoform HIF-2a (Raval et al. 2005). Correspondingly, decreased CA IX levels are independently associated with poor prognosis in advanced RCC (Bui et al. 2003). However, levels of CA IX can be upregulated by interferons (IFN-a and IFN-g), which can increase the therapeutic responses in 5–25% of patients with metastatic RCC (Brouwers et al. 2003b). Furthermore, high CA IX expression was suggested as an important predictor of better outcome in RCC patients receiving interleukin-2-based therapy (Atkins et al. 2005). In several recent reviews, CA IX has been proposed to be the most significant molecular marker described in kidney cancer (Pantuck et al. 2008; Signoretti et al. 2008). Assessment of CA IX expression in biopsies offers a new means for stratification of cancer patients and rational selection of appropriate treatment strategy – an approach highly desirable in recent clinical oncology. However, in certain phases of cancer management, the patients would benefit from non-invasive monitoring of CA IX shed to blood circulation. Data published so far suggest that serum CA IX levels in RCC patients correlate with tumor size and stage of the disease, and support the use of soluble CA IX as a biomarker of progression and postoperative recurrence (Zhou et al. 2009). Furthermore, in vivo imaging of CA IX is recently coming to the scene as a very promising approach for pre-surgical diagnosis of RCC (Divgi et al. 2007; Zhang 2008). The imaging tool called REDECTANE® developed by WILEX AG company is based on radioactively labeled monoclonal antibody G250 originally generated by Oosterwijk and coworkers (Lam et al. 2005). The radiolabeled antibody WX-G250 targets clear cell renal cell carcinoma and accumulates in the tumor tissue via binding to CA IX followed by receptor-mediated internalization (Durrbach et al. 1999). The G250 accumulation can be visualized by means of positron emission tomography (PET) (Divgi et al. 2007). A proof-of-concept study showed that REDECTANE® could predict clear cell RCC with a specificity of 100% and a sensitivity of 94%. Moreover, Phase II clinical study demonstrated that the combination of REDECTANE® with PET and computer tomography (CT) versus the standard use of CT alone could improve the diagnosis of renal masses (http://www.wilex.com).
CA IX Targeting Strategies CA IX usefulness as therapeutic target stems from the following facts: (a) strong association with different tumors and low or absent expression in normal tissues, (b) induction by hypoxia and correlation with aggressive phenotype, (c) localization
76
J. Pastorek and S. Pastorekova
on the cell surface allowing interaction with antibodies or drugs, and (d) direct functional involvement in hypoxic tumor phenotype. These facts create a basis for two principal strategies of targeting CA IX-expressing tumor cells – immunotherapy with specific antibodies inducing cytotoxicity and functional inhibition of the CA IX catalytic activity leading to disruption of pH control. The first approach has been consistently studied in pre-clinical and clinical experiments in patients with renal cell carcinomas. Although advanced RCC show reduced CA IX expression, the cut-off was set to 85% (i.e. the expression is considered low when less than 85% of cells display CA IX) and this is still a very high proportion of targetable cells. Again, the major tool here is the monoclonal antibody G250 (Brouwers et al. 2003a; Mulders et al. 2004). Chimeric G250 (composed of variable regions of murine G250 and constant regions derived from human IgG) is recently produced by WILEX AG under commercial name RENCAREX®. Its effector mechanism is ADCC (antibody-dependent cell cytotoxicity). In Phase I and II studies, RENCAREX® has shown good safety and tolerability and a promising efficacy profile. The purpose of the ongoing Phase III study (called ARISER) is to assess the effect of adjuvant treatment with RENCAREX® on disease-free survival and overall survival in RCC patients with a high risk of recurrence following surgery (nephrectomy). Additional monoclonal antibodies potentially suitable for immunotherapeutic purposes are under development. Some of them display similar binding properties and capacity to internalize as G250 and exhibit anticancer effects in animal models (Zatovicova et al. in press). The second approach – functional inhibition of cancer-related carbonic anhydrases – is only at early stage of investigation and is based on carbonic anhydrase inhibitors (sulfonamides and their derivatives) that are mostly produced and characterized by Supuran and coworkers, who were the first to introduce the concept of their use as anticancer drugs (Supuran 2007). Sulfonamides and related compounds generally show non-selective inhibitory activity toward different CA isoenzymes including CA IX, which can be inhibited by a broad range of compounds (see Table 4.2). Interestingly, efficient CA IX inhibition was observed also with celecoxib and valdecoxib, sulfonamide inhibitors of cyclooxygense 2 (COX-2, a key enzyme of arachidonic acid metabolism involved in colorectal carcinoma), and with inhibitors of steroid sulfatase (implicated in production of active steroids in breast cancer) (Weber et al. 2004; Winum et al. 2003a). This may suggest that the mode of action of these drugs could involve targeting of CAs. As demonstrated by several recent papers, increased selectivity toward CA IX can be successfully achieved by modulating the physical and chemical properties of the compounds via attachment of different side chains and other modifications. Certain alterations can introduce or improve the membrane impermeability so that the inhibitor can bind only or predominantly to extracellularly exposed CAs. The other changes can modify the size or surface topology that fits better into active site cavity of CA IX than into other isoforms. Some types of modifications increase the efficiency of inhibition so that they work even at subnanomolar concentrations. This approach was used for development of several
Acetazolamide Aromatic and heterocyclic sulfonamides Halogenated sulfonamides Aliphatic sulfamates Sulfamates or bis-sulfamates (+ steroid sulfatase inhibitors) E7070 (indisulam) anticancer drug in clinical development Non-steroidal anti-inflammatory inhibitors of COX-2 Positively-charged pyridinium derivatives of sulfanilamides Polyfluorinated sulfonamides Sulfonamides incorporating 1,2,4-triazine moieties Sulfonamides derived from 4-isothiocyanato-benzolamide Carboxylates Bis-sulfamates Sulfonamides incorporating hydrazino moieties Boron-containing sulfamides, sulfonamides, and sulfamates
Abbate et al. (2004) Weber et al. (2004)
Potent inhibition of CA I, II, IX in the range of 15–31 nM Unexpected nanomolar inhibition of CA I, II, IV, IX by celecoxib and valdecoxib First selective, membrane-impermeant inhibitors targeting CA IX
Effective inhibitors of CA IX suitable for boron neutron capture therapy targeting hypoxic tumors
The first subnanomolar and selective CA IX inhibitor CA IX-selective inhibitors with selectivity ratios for CA IX over CA II inhibition in the range of 166–706 Excellent inhibitory properties against CA IX with inhibition constants in the range of 3.2–23 nM Lactate insensitivity of CA IX Low nanomolar CA IX inhibitors with good selectivity ratio Several low nanomolar CA IX inhibitors
Ilies et al. (2003) Winum et al. (2003b) Winum et al. (2003a)
CA IX inhibition profile different from CA I, II, IV Efficient CA IX inhibition in the range of 9–23 nM Efficient CA IX inhibition in the range of 18–63 nM
(continued)
Winum et al. (2005a)
Innocenti et al. (2005) Winum et al. (2005c) Winum et al. (2005b)
Cecchi et al. (2004)
Vullo et al. (2004) Garaj et al. (2004)
Pastorekova et al. (2004a)
Parkkila et al. (2000) Vullo et al. (2003)
Inhibition of in vitro migration of renal carcinoma cells Several nanomolar CA IX inhibitors
Table 4.2 Summary of sulfonamide inhibitors, their derivatives, and other compounds tested against different CA isoforms including CA IX Inhibitor type Inhibition properties Reference
4 Molecular Mechanisms Regulating Expression 77
Imatinib (Glivec/Gleevec) and nilotinib (Tasigna)
Inhibitor-coated gold nanoparticles Coumarin derivatives
Bioreductive nitro-containing sulfonamides Biphenylsulfonamides
Mercaptans increase the inhibitory power (52.8- to 243-fold) over the corresponding oxidized derivatives Several potent and selective inhibitors of CA IX
Aromatic sulfonamides activatable in hypoxic tumors Glycoconjugate benzene sulfonamides Antiepileptic drug sulthiame Glycosyl-thioureido-sulfonamides Potent inhibitor of CA II, VII, IX, XII (6–56 nM) Low nM binding to CA IX and XII, high selectivity ratios in the range of 107–955 Some CA IX inhibitors with excellent selectivity ratios (in the range of 10–1395) Inhibitors of CA IX with cytotoxic activity against human colon, lung, and breast cancer cell lines Selective inhibition of CA IX (membrane impermeant) Bind at the entrance of the active site cavity, one of them highly selective for CA IX Inhibited all 13 catalytically active CA isoforms in the range of 4.1 nM–20.2 mM
Inhibition properties
Table 4.2 (continued)
Inhibitor type
Parkkila et al. (2009)
Stiti et al. (2008) Maresca et al. (2010)
Morsy et al. (2009)
D’Ambrosio et al. (2008)
Temperini et al. (2007) Smaine et al. (2007)
Wilkinson et al. (2006)
Saczewski et al. (2006)
Reference
78 J. Pastorek and S. Pastorekova
4 Molecular Mechanisms Regulating Expression
79
compounds with a reasonable selectivity ratio favoring inhibition activities against CA IX compared to other isoforms, in particular CA II (Table 4.2). Another strategy was used to generate hypoxia-activated inhibitors. Different 2-mercapto-substituted-benzenesulfonamides and their disulfides/sulfones showed consistently increased inhibitory power (52.8- to 243-fold) over the corresponding oxidized (S–S type) derivatives (Saczewski et al. 2006). The best representatives out of these differentially acting derivatives can serve as lead compounds for further development of CA IX -specific inhibitors with therapeutic potential against cancer. Since the inhibition data were obtained using the purified recombinant catalytic domain of CA IX, experiments with native protein in cellular context are needed to determine their effective concentrations and consequences of their application. Noteworthy, fluorescein-conjugated carbonic anhydrase inhibitor thioureidohomosulfanilamide (FITC-CAI) was found to bind only to hypoxic cells expressing CA IX, but neither to CA IX-positive normoxic cells nor the CA IX-negative controls (Cecchi et al. 2005; Svastova et al. 2004). Moreover, the FITC-CAI binding was perturbed by reoxygenation (Dubois et al. 2007). This interesting finding suggests that CA IX active site is accessible to sulfonamide only under hypoxic conditions. Results of in vivo imaging confirm previous in vitro data demonstrating that CAI binding and retention requires exposure to hypoxia (Dubois et al. 2009). Thus, labeled sulfonamides may provide a powerful tool to visualize hypoxic tumors. This may represent a promising approach to patient selection for CA IX-directed therapies based on the functional inhibition of CA IX. CA inhibitors can be used as anticancer drugs to compromise the survival of tumor cells due to perturbed pH control, or in combination with conventional chemotherapeutics to improve their uptake and efficacy due to modulated pH gradient. The first option is based on significance of the proper pH control in tumor cells, particularly in those that suffer from hypoxia. It is well established that extracellular acidosis supports cancer progression, whereas neutral intracellular pH is required for survival of hypoxic cancer cells (Stubbs et al. 2000). Inhibition or reduction of extracellular acidosis by carbonic anhydrase inhibitors thus offers a possible therapeutic approach to retardation of tumor progression (Pouyssegur et al. 2006). On the other hand, inhibition of CA activity can lead to inability of tumor cells to neutralize their intracellular pH and adapt to metabolic stress. In fact, several sulfonamide derivatives were capable of reducing an extracellular acidification and intracellular neutralization mediated by CA IX, suggesting that these compounds interfere with the activity of CA IX in cell culture model (Svastova et al. 2004; Swietach et al. 2009). In addition, changes in extracellular pH can affect therapeutic outcome of conventional chemotherapy by influencing the uptake of weakly electrolytic anticancer drugs (Kozin et al. 2001; Vukovic and Tannock 1997). In particular, reduction of extracellular acidosis can increase the uptake and cytotoxic effects of weakly basic drugs, including doxorubicin. Interestingly, chronic ingestion of sodium bicarbonate solution was shown to enhance the capacity of doxorubicin to decrease the tumor size (Raghunand et al. 2003).
80
J. Pastorek and S. Pastorekova
In line with these suppositions, older but forward-looking study showed that acetazolamide, a classical CA inhibitor, reduced in vivo growth of tumor when given alone and produced additive tumor growth delays when administered in combination with various chemotherapeutic compounds (Teicher et al. 1993). This was recently supported using more sophisticated approach, based on two acetazolamide derivatives containing either a charged fluorophore or an albumin-binding moiety, which restrict binding to carbonic anhydrase IX and XII present on tumor cells (Ahlskog et al. 2009a). In vivo studies showed the preferential targeting of tumor cells by the fluorescent acetazolamide derivative and the ability of the albuminbinding acetazolamide derivative to cause tumor retardation in a SK-RC-52 (RCC) xenograft model of cancer. Additional in vivo experiments with promising preliminary results are underway.
Conclusion Our present knowledge on CA IX clearly suggests that this hypoxia-induced molecule is an important component of the tumor microenvironment and that many tumors need CA IX to survive microenvironmental stresses. This addiction of tumor cells to CA IX makes it a useful marker of hypoxia, prognostic indicator, and therapeutic target. Although main strategies of diagnostic and therapeutic exploitation of CA IX have been rationally designed, their concepts were experimentally proven, practically evaluated (in part), and several specific tools are available; further preclinical and clinical studies are necessary to translate all proposed applications to the benefit of cancer patients.
References Abbate F, Casini A, Owa T, Scozzafava A, Supuran CT (2004) Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 14:217–223 Ahlskog JK, Dumelin CE, Trussel S, Marlind J, Neri D (2009a) In vivo targeting of tumorassociated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 19:4851–4856 Ahlskog JK, Schliemann C, Marlind J, Qureshi U, Ammar A, Pedley RB, Neri D (2009b) Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 101:645–657 Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, Scozzafava A, Monti SM, De Simone G (2009) Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 106:16233–16238 Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T (2002) Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 128:561–568
4 Molecular Mechanisms Regulating Expression
81
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714–3721 Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, Hulikova A, Kopacek J, Parkkila S, Supuran CT, Pastorekova S, Pastorek J (2008) Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br J Cancer 98:129–136 Bartosova M, Parkkila S, Pohlodek K, Karttunen TJ, Galbavy S, Mucha V, Harris AL, Pastorek J, Pastorekova S (2002) Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 197:314–321 Brahimi-Horn MC, Pouyssegur J (2007) Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem 43:165–178 Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O’Brien SL (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12:6421–6431 Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ (2003a) Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 9:3953S–3960S Brouwers H, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC (2003b) Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm 18:539–547 Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802–811 Camenisch G, Stroka DM, Gassmann M, Wenger RH (2001) Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflugers Arch 443:240–249 Carney WP (2007) Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn 7:309–319 Casey JR (2006) Why bicarbonate? Biochem Cell Biol 84:930–939 Cecchi A, Hulikova A, Pastorek J, Pastorekova S, Scozzafava A, Winum JY, Montero JL, Supuran CT (2005) Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 48:4834–4841 Cecchi A, Winum JY, Innocenti A, Vullo D, Montero JL, Scozzafava A, Supuran CT (2004) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanatobenzolamide. Bioorg Med Chem Lett 14:5775–5780 Coleman ML, Ratcliffe PJ (2007) Oxygen sensing and hypoxia-induced responses. Essays Biochem 43:1–15 Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, Huntsman DG, Gelmon KA (2008) Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res 10:R6 D’Ambrosio K, Vitale RM, Dogne JM, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT (2008) Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J Med Chem 51: 3230–3237 De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S (2005) The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/– chemotherapy. BMC Cancer 5:42
82
J. Pastorek and S. Pastorekova
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8:304–310 Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 41:2935–2947 Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243:334–340 Dubois L, Douma K, Supuran CT, Chiu RK, van Zandvoort MA, Pastorekova S, Scozzafava A, Wouters BG, Lambin P (2007) Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 83:367–373 Dubois L, Lieuwes NG, Maresca A, Thiry A, Supuran CT, Scozzafava A, Wouters BG, Lambin P (2009) Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother Oncol 92:423–428 Durrbach A, Angevin E, Poncet P, Rouleau M, Chavanel G, Chapel A, Thierry D, Gorter A, Hirsch R, Charpentier B, Senik A, Hirsch F (1999) Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 6:564–571 Eckert AW, Lautner MH, Schutze A, Bolte K, Bache M, Kappler M, Schubert J, Taubert H, Bilkenroth U (2010) Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 39:313–317 Fukumura D, Jain RK (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101:937–949 Garaj V, Puccetti L, Fasolis G, Winum JY, Montero JL, Scozzafava A, Vullo D, Innocenti A, Supuran CT (2004) Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 14:5427–5433 Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899 Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB (2006a) Hypoxiainducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 12: 4562–4568 Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL (2006b) Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/ tamoxifen therapy for breast cancer. Endocr Relat Cancer 13:921–930 Gut MO, Parkkila S, Vernerova Z, Rohde E, Zavada J, Hocker M, Pastorek J, Karttunen T, Gibadulinova A, Zavadova Z, Knobeloch KP, Wiedenmann B, Svoboda J, Horak I, Pastorekova S (2002) Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 123:1889–1903 Haapasalo J, Nordfors K, Jarvela S, Bragge H, Rantala I, Parkkila AK, Haapasalo H, Parkkila S (2007) Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol 9:308–313 Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477 Harris AL (2002) Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2:38–47
4 Molecular Mechanisms Regulating Expression
83
Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK (2002) Acid production in glycolysisimpaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8: 1284–1291 Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177–182 Hewett-Emmett D, Tashian RE (1996) Functional diversity, conservation, and convergence in the evolution of the alpha-, beta-, and gamma-carbonic anhydrase gene families. Mol Phylogenet Evol 5:50–77 Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, Lindfors M, Janis J, Valjakka J, Pastorekova S, Pastorek J, Kulomaa MS, Nordlund HR, Supuran CT, Parkkila S (2008) Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 283:27799–27809 Hirota K, Semenza GL (2005) Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338:610–616 Holotnakova T, Tylkova L, Takacova M, Kopacek J, Petrik J, Pastorekova S, Pastorek, J (2010) Role of the HBx oncoprotein in carbonic anhydrase 9 induction. J Med Virol 82:32–40 Hulikova A, Zatovicova M, Svastova E, Ditte P, Brasseur R, Kettmann R, Supuran CT, Kopacek J, Pastorek J, Pastorekova S (2009) Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett 583:3563–3568 Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH (2007) Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 96:104–109 Hussain SA, Palmer DH, Ganesan R, Hiller L, Gregory J, Murray PG, Pastorek J, Young L, James ND (2004) Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11:1005–1010 Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19:3660–3668 Chiang WL, Chu SC, Yang SS, Li MC, Lai JC, Yang SF, Chiou HL, Hsieh YS (2002) The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett 188:199–205 Chiche J, Ilc K, Brahimi-Horn MC, Pouyssegur J (2010) Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv Enzyme Regul 50:20–33 Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009b) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69:358–368 Cho M, Grabmaier K, Kitahori Y, Hiasa Y, Nakagawa Y, Uemura H, Hirao Y, Ohnishi T, Yoshikawa K, Ooesterwijk E (2000) Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol Carcinog 27:184–189 Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S (2008) Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 39:1317–1322 Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, Kopacek J, Pastorekova S (2006) Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 29:1025–1033 Ilies MA, Vullo D, Pastorek J, Scozzafava A, Ilies M, Caproiu MT, Pastorekova S, Supuran CT (2003) Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J Med Chem 46:2187–2196 Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT (2009) The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic
84
J. Pastorek and S. Pastorekova
buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett 19:5825–5828 Innocenti A, Vullo D, Scozzafava A, Casey JR, Supuran C (2005) Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett 15:573–578 Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919 Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI (1998) Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95:12596–12601 Jakubickova L, Biesova Z, Pastorekova S, Kettmann R, Pastorek J (2005) Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol 26:1121–1127 Jarvela S, Parkkila S, Bragge H, Kahkonen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H (2008) Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 8:1 Kaluz S, Kaluzova M, Chrastina A, Olive PL, Pastorekova S, Pastorek J, Lerman MI, Stanbridge EJ (2002) Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3¢-kinase. Cancer Res 62:4469–4477 Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795:162–172 Kaluz S, Kaluzova M, Opavsky R, Pastorekova S, Gibadulinova A, Dequiedt F, Kettmann R, Pastorek J (1999) Transcriptional regulation of the MN/CA 9 gene coding for the tumorassociated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem 274:32588–32595 Kappler M, Taubert H, Holzhausen HJ, Reddemann R, Rot S, Becker A, Kuhnt T, Dellas K, Dunst J, Vordermark D, Hansgen G, Bache M (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther Onkol 184:393–399 Karumanchi SA, Jiang L, Knebelmann B, Stuart-Tilley AK, Alper SL, Sukhatme VP (2001) VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol Genomics 5:119–128 Kim JY, Shin HJ, Kim TH, Cho KH, Shin KH, Kim BK, Roh JW, Lee S, Park SY, Hwang YJ, Han IO (2006) Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer. J Cancer Res Clin Oncol 132:302–308 Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, Oosterwijk E, Kelley MJ (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335 Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ (2004) Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10:7925–7933 Kim SJ, Shin HJ, Jung KY, Baek SK, Shin BK, Choi J, Kim BS, Shin SW, Kim YH, Kim JS, Oosterwijk E (2007) Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 37:812–819 Kirkpatrick JP, Rabbani ZN, Bentley RC, Hardee ME, Karol S, Meyer J, Oosterwijk E, Havrilesky L, Secord AA, Vujaskovic Z, Dewhirst MW, Jones EL (2008) Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomark Insights 3:45–55 Kivela AJ, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila TS, Rajaniemi H (2001) Differential expression of cytoplasmic carbonic
4 Molecular Mechanisms Regulating Expression
85
anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 46:2179–2186 Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ (2009) Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer 115:1448–1458 Kon-no H, Ishii G, Nagai K, Yoshida J, Nishimura M, Nara M, Fujii T, Murata Y, Miyamoto H, Ochiai A (2006) Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. Lung Cancer 54:409–418 Kopacek J, Barathova M, Dequiedt F, Sepelakova J, Kettmann R, Pastorek J, Pastorekova S (2005) MAPK pathway contributes to density- and hypoxia-induced expression of the tumorassociated carbonic anhydrase IX. Biochim Biophys Acta 1729:41–49 Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjanen K, Sundstrom J, Pyrhonen S (2009) Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100:874–880 Korkolopoulou P, Perdiki M, Thymara I, Boviatsis E, Agrogiannis G, Kotsiakis X, Angelidakis D, Rologis D, Diamantopoulou K, Thomas-Tsagli E, Kaklamanis L, Gatter K, Patsouris E (2007) Expression of hypoxia-related tissue factors in astrocytic gliomas. A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 38:629–638 Kowalewska M, Radziszewski J, Kulik J, Barathova M, Nasierowska-Guttmajer A, Bidzinski M, Pastorek J, Pastorekova S, Siedlecki JA (2005) Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. Int J Cancer 116:957–962 Kozin SV, Shkarin P, Gerweck LE (2001) The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61:4740–4743 Kreis TE, Lodish HF (1986) Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell 46:929–937 Kummola L, Hamalainen JM, Kivela J, Kivela AJ, Saarnio J, Karttunen T, Parkkila S (2005) Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 5:41 Kuo WH, Chiang WL, Yang SF, Yeh KT, Yeh CM, Hsieh YS, Chu SC (2003) The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 73:2211–2223 Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA